<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004416.pub2" GROUP_ID="SKIN" ID="750602041911475569" MERGED_FROM="" MODIFIED="2015-02-26 10:27:54 +0000" MODIFIED_BY="Laura Prescott" REVIEW_NO="#53" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.0">
<COVER_SHEET MODIFIED="2015-02-26 10:27:54 +0000" MODIFIED_BY="Laura Prescott">
<TITLE MODIFIED="2013-04-01 21:34:49 +0100" MODIFIED_BY="[Empty name]">Oral evening primrose oil and borage oil for eczema</TITLE>
<CONTACT MODIFIED="2015-02-26 10:27:54 +0000" MODIFIED_BY="Laura Prescott"><PERSON ID="D86F2ABF82E26AA20080535FA172C66D" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Joel</FIRST_NAME><MIDDLE_INITIALS>TM</MIDDLE_INITIALS><LAST_NAME>Bamford</LAST_NAME><POSITION>Dermatologist</POSITION><EMAIL_1>JoelTMBamford@icloud.com</EMAIL_1><MOBILE_PHONE>218 390 9025</MOBILE_PHONE><ADDRESS><ORGANISATION/><ADDRESS_1>PO 3247</ADDRESS_1><CITY>Duluth</CITY><ZIP>55803-3247</ZIP><REGION>Minnesota</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 218 390 9025</PHONE_1><PHONE_2>+1 218 848 2412</PHONE_2><FAX_1>+1 218 848 2412</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2015-02-26 10:27:54 +0000" MODIFIED_BY="Laura Prescott"><PERSON ID="D86F2ABF82E26AA20080535FA172C66D" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Joel</FIRST_NAME><MIDDLE_INITIALS>TM</MIDDLE_INITIALS><LAST_NAME>Bamford</LAST_NAME><POSITION>Adjunct Clinical Professor</POSITION><EMAIL_1>JoelTMBamford@icloud.com</EMAIL_1><MOBILE_PHONE>218 390 9025</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Family Medicine and Community Health</DEPARTMENT><ORGANISATION>University of Minnesota Medical School</ORGANISATION><ADDRESS_1>1035 University Drive</ADDRESS_1><CITY>Duluth</CITY><ZIP>55812</ZIP><REGION>Minnesota</REGION><COUNTRY CODE="US">USA</COUNTRY></ADDRESS></PERSON><PERSON ID="57134380935593446211100204155024" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Sujoy</FIRST_NAME><LAST_NAME>Ray</LAST_NAME><SUFFIX>MBBS</SUFFIX><POSITION>Junior Resident</POSITION><EMAIL_1>raysujoy8@gmail.com</EMAIL_1><EMAIL_2>sujoyray@rediffmail.com</EMAIL_2><MOBILE_PHONE>91-9916-821-079</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Psychiatry</DEPARTMENT><ORGANISATION>St. John's Medical College and Hospital</ORGANISATION><ADDRESS_1>Sarjapur Road</ADDRESS_1><CITY>Bangalore</CITY><ZIP>560008</ZIP><REGION>Karnataka</REGION><COUNTRY CODE="IN">India</COUNTRY><PHONE_1>+91 9916821079</PHONE_1><PHONE_2>+91 9916934563</PHONE_2></ADDRESS></PERSON><PERSON ID="8B0BF7C782E26AA20026894812FC1FDD" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Alfred</FIRST_NAME><LAST_NAME>Musekiwa</LAST_NAME><POSITION>Biostatistician</POSITION><EMAIL_1>alfred.musekiwa@gmail.com</EMAIL_1><MOBILE_PHONE>072 503 7613</MOBILE_PHONE><ADDRESS><DEPARTMENT>Wits Reproductive Health and HIV Institute (WRHI), Faculty of Health Sciences</DEPARTMENT><ORGANISATION>University of the Witwatersrand</ORGANISATION><CITY>Johannesburg</CITY><COUNTRY CODE="ZA">South Africa</COUNTRY><PHONE_1>+27 11 358 5338</PHONE_1><FAX_1>+27 11 358 5400</FAX_1></ADDRESS></PERSON><PERSON ID="5647" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Christel</FIRST_NAME><LAST_NAME>van Gool</LAST_NAME><POSITION>Researcher</POSITION><EMAIL_1>c.vangool@maastrichtuniversity.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Epidemiology, CAPHRI</DEPARTMENT><ORGANISATION>Maastricht University</ORGANISATION><ADDRESS_2>PO Box 626</ADDRESS_2><CITY>Maastricht</CITY><ZIP>NL-6200MD</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 433 882372</PHONE_1></ADDRESS></PERSON><PERSON ID="9217" ROLE="AUTHOR"><PREFIX>Mrs</PREFIX><FIRST_NAME>Rosemary</FIRST_NAME><LAST_NAME>Humphreys</LAST_NAME><EMAIL_1>RNHumphreys@aol.com</EMAIL_1><ADDRESS><DEPARTMENT>c/o Cochrane Skin Group</DEPARTMENT><ORGANISATION>The University of Nottingham</ORGANISATION><ADDRESS_1>A103, King's Meadow Campus</ADDRESS_1><ADDRESS_2>Lenton Lane</ADDRESS_2><CITY>Nottingham</CITY><ZIP>NG7 2NR</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="7423" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Edzard</FIRST_NAME><LAST_NAME>Ernst</LAST_NAME><SUFFIX>MD, PhD</SUFFIX><EMAIL_1>E.Ernst@exeter.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Complementary Medicine Department</DEPARTMENT><ORGANISATION>Peninsula Medical School, University of Exeter</ORGANISATION><CITY>Exeter</CITY><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2013-06-25 16:47:38 +0100" MODIFIED_BY="Laura Prescott">
<UP_TO_DATE>
<DATE DAY="29" MONTH="8" YEAR="2012"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="29" MONTH="8" YEAR="2012"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="29" MONTH="8" YEAR="2014"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2003"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2013"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2013"/>
</DATES>
<WHATS_NEW MODIFIED="2015-02-20 11:49:37 +0000" MODIFIED_BY="Laura E Prescott">
<WHATS_NEW_ENTRY EVENT="STABLE" MODIFIED="2015-02-20 11:49:37 +0000" MODIFIED_BY="Laura E Prescott">
<DATE DAY="15" MONTH="5" YEAR="2014"/>
<DESCRIPTION>
<P>The conclusion is so certain that the addition of new information will not change it, and there is unlikely to be any more research done on this topic. There were no ongoing studies or studies awaiting classification listed in the last published review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2015-02-20 11:44:18 +0000" MODIFIED_BY="Laura E Prescott">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2015-02-20 11:44:18 +0000" MODIFIED_BY="Laura E Prescott">
<DATE DAY="13" MONTH="11" YEAR="2013"/>
<DESCRIPTION>
<P>Author information (affiliation) updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-11-13 16:18:50 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="25" MONTH="6" YEAR="2013"/>
<DESCRIPTION>
<P>Contact author's out-of-date email address removed and current email address added</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2011-12-09 20:45:47 +0000" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2011-12-09 20:45:47 +0000" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2011-12-09 20:45:47 +0000" MODIFIED_BY="[Empty name]">
<NAME>Cathy Bennett</NAME>
<COUNTRY CODE="NONE">Other</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2015-02-26 10:26:50 +0000" MODIFIED_BY="Laura E Prescott">
<SUMMARY MODIFIED="2013-04-02 00:18:04 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2012-02-12 10:12:55 +0000" MODIFIED_BY="[Empty name]">Oral evening primrose oil and borage oil for eczema</TITLE>
<SUMMARY_BODY MODIFIED="2013-04-02 00:18:04 +0100" MODIFIED_BY="[Empty name]">
<P>Eczema is an itchy and red skin condition, which may affect 20% of people world wide at some time in their life. Though it may improve with age, there is no cure. Many children outgrow this disorder as they reach secondary school age. Constant itch makes life uncomfortable for those with this condition, no matter what age they are.</P>
<P>Conventional medical treatments make life better for people; however, some people who do not see an adequate improvement in their eczema or fear side-effects of conventional medical products, turn to complementary alternatives to conventional medical treatment. This review is of two such products: evening primrose oil (EPO) and borage oil (BO) taken orally (by mouth), which have been thought to have benefits for eczema.</P>
<P>We included 27 studies, with 1596 adults and children from 12 countries. Of these, 19 studies compared EPO with a placebo (dummy) treatment, and 8 used BO compared with placebo. We looked for evidence of overall improvement in eczema and in quality of life. All 27 studies evaluated overall improvement of eczema, but only 2 studies of EPO measured improvement in quality of life. There was no statistically significant advantage demonstrated for either EPO or BO compared to placebo. In summary, we did not find evidence that eczema improved by taking these products any more than it did by taking placebo.</P>
<P>There was some evidence of mild and temporary side-effects for participants with either product or placebo, which were mainly mild, and included temporary headache and upset stomach or diarrhoea. With EPO there is an anticoagulant (blood-thinning) effect when taking these products. There is a warning with the blood thinner warfarin (Coumadin®) that taking EPO can increase bleeding. One report warns that if EPO is taken for a prolonged period of time (more than one year), there is a potential risk of inflammation, thrombosis, and immunosuppression due to slow accumulation of EPO in the tissues. Another reports a single case in which EPO was thought to have produced harms. We found no clinical evidence of such harm in these short-term trials.</P>
<P>This systematic review found no evidence that either BO or EPO are effective in treatment of eczema. Both of these products and the placebos used in the studies had similar mild, temporary side-effects, which were mainly gastrointestinal.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-04-02 00:14:15 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2013-03-23 01:40:37 +0000" MODIFIED_BY="Joel Bamford">
<P>Eczema is a chronic inflammatory skin condition, which usually develops in early childhood. Many children outgrow this disorder as they reach secondary school age, and although It may improve with age, there is no cure. Constant itch makes life uncomfortable for those with this condition, no matter what age they are, so it may have a significant effect on a person's quality of life. Its prevalence seems to be increasing as populations move from rural locations to cities. Some people, who do not see an adequate improvement or fear side-effects of conventional medical products, try complementary alternatives to conventional treatment. This is a review of evening primrose oil (EPO) and borage oil (BO) taken orally (by mouth); these have been thought to be beneficial because of their gamma-linolenic acid content.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2013-02-18 11:52:36 +0000" MODIFIED_BY="Joel Bamford">
<P>To assess the effects of oral evening primrose oil or borage oil for treating the symptoms of atopic eczema.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-03-18 12:31:19 +0000" MODIFIED_BY="Liz Doney">
<P>We searched the following databases up to August 2012: Cochrane Skin Group Specialised Register, CENTRAL in <I>The Cochrane Library</I>, MEDLINE (from 1946), EMBASE (from 1974), AMED (from 1985), and LILACS (from 1982). We also searched online trials registers and checked the bibliographies of included studies for further references to relevant trials. We corresponded with trial investigators and pharmaceutical companies to try to identify unpublished and ongoing trials. We performed a separate search for adverse effects of evening primrose oil and borage oil in November 2011.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2013-03-18 12:31:52 +0000" MODIFIED_BY="Joel Bamford">
<P>All randomised controlled, parallel, or cross-over trials investigating oral intake of evening primrose oil or borage oil for eczema.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2013-04-01 23:55:35 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors independently applied eligibility criteria, assessed risk of bias, and extracted data. We pooled dichotomous outcomes using risk ratios (RR), and continuous outcomes using the mean difference (MD). Where possible, we pooled study results using random-effects meta-analysis and tested statistical heterogeneity using both the Chi² test and the I² statistic test. We presented results using forest plots with 95% confidence intervals (CI).</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2013-04-02 00:10:42 +0100" MODIFIED_BY="[Empty name]">
<P>A total of 27 studies (1596 participants) met the inclusion criteria: 19 studies assessed evening primrose oil, and 8 studies assessed borage oil. For EPO, a meta-analysis of results from 7 studies showed that EPO failed to significantly increase improvement in global eczema symptoms as reported by participants on a visual analogue scale of 0 to 100 (MD -2.22, 95% CI -10.48 to 6.04, 176 participants, 7 trials) and a visual analogue scale of 0 to 100 for medical doctors (MD -3.26, 95% CI -6.96 to 0.45, 289 participants, 8 trials) compared to the placebo group.</P>
<P>Treatment with BO also failed to significantly improve global eczema symptoms compared to placebo treatment as reported by both participants and medical doctors, although we could not conduct a meta-analysis as studies reported results in different ways. With regard to the risk of bias, the majority of studies were of low risk of bias; we judged 67% of the included studies as having low risk of bias for random sequence generation; 44%, for allocation concealment; 59%, for blinding; and 37%, for other biases.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-04-02 00:14:15 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Implications for practice  </B>
</P>
<P>Oral borage oil and evening primrose oil lack effect on eczema; improvement was similar to respective placebos used in trials. Oral BO and EPO are not effective treatments for eczema.</P>
<P>In these studies, along with the placebos, EPO and BO have the same, fairly common, mild, transient adverse effects, which are mainly gastrointestinal.</P>
<P>The short-term studies included here do not examine possible adverse effects of long-term use of EPO or BO. A case report warned that if EPO is taken for a prolonged period of time (more than one year), there is a potential risk of inflammation, thrombosis, and immunosuppression; another study found that EPO may increase bleeding for people on Coumadin® (warfarin) medication.</P>
<P>
<B>Implications for research </B>
</P>
<P>Noting that the confidence intervals between active and placebo treatment are narrow, to exclude the possibility of any clinically useful difference, we concluded that further studies on EPO or BO for eczema would be hard to justify.</P>
<P>This review does not provide information about long-term use of these products.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-04-02 01:37:40 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2013-04-02 00:36:25 +0100" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2013-04-02 00:28:25 +0100" MODIFIED_BY="[Empty name]">
<P>Eczema is a chronic inflammatory skin condition, which usually develops in early childhood, often in the first three months of life. There is often a fluctuating course, but most cases clear up or improve by adulthood, the majority within the first five years of life.</P>
<P>Eczema can appear on all areas of the skin. In infants it often affects the face, forearms, knees, and ankles, and in older children mainly the flexures of the elbows and knees. Adults who suffer from eczema are often affected on their face and flexural areas of the neck, elbows, knees, and ankles. There is a frequent association of eczema with other atopic disorders, such as asthma and hay fever (<LINK REF="REF-Williams-2000" TYPE="REFERENCE">Williams 2000</LINK>), and environmental factors play an important role (<LINK REF="REF-Wang-2007" TYPE="REFERENCE">Wang 2007</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Definition</HEADING>
<P>After international discussions regarding the word 'atopic', a task force has suggested the term 'atopic eczema/dermatitis syndrome' (AEDS) to summarise all forms of eczema that have previously been called 'prurigo Besnier' or 'atopic dermatitis' (<LINK REF="REF-Johansson-2001" TYPE="REFERENCE">Johansson 2001</LINK>). We used the term 'eczema' throughout this review.</P>
<P>The diagnosis of eczema is made clinically. In 1980, Hanifin and Rajka published a list of all the possible signs and symptoms of eczema, divided into major and minor features (<LINK REF="REF-Hanifin-1980" TYPE="REFERENCE">Hanifin 1980</LINK>). They include pruritus or itch, a chronic relapsing course, typical morphology and distribution of lesions, and familial or personal history of other atopic disorders.</P>
<P>Sampson defined "three major criteria for atopic dermatitis: family history of atopic disease; typical facial, or extensor, eczematous or lichenified dermatitis; and evidence of pruritus (itching)" (<LINK REF="REF-Sampson-1992" TYPE="REFERENCE">Sampson 1992</LINK>).</P>
<P>The most recent form of diagnosis was developed by a UK working group (<LINK REF="REF-Williams-1994" TYPE="REFERENCE">Williams 1994</LINK>). It is based on a range of sensitive and specific symptoms and signs and depends on a person having an itchy skin condition, plus three or more of the following:<BR/>
</P>
<UL>
<LI>history of involvement of skin creases;</LI>
<LI>personal history of asthma or allergic rhinitis, or history of atopic disease in a first-degree relative of children;</LI>
<LI>history of general dry skin in past year;</LI>
<LI>visible flexural eczema or eczema on cheeks, forehead, or outer limbs; or</LI>
<LI>onset before two years of age.</LI>
</UL>
<P>A variety of criteria have been proposed that allow a diagnosis to be made (<LINK REF="REF-Bos-2010" TYPE="REFERENCE">Bos 2010</LINK>; <LINK REF="REF-Tofte-2001" TYPE="REFERENCE">Tofte 2001</LINK>). In this review, we use a clinician's diagnosis of eczema (<LINK REF="REF-Nankervis-2010" TYPE="REFERENCE">Nankervis 2010</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Causes</HEADING>
<P>The causes of eczema remain unclear, but it is likely to be of a multi-factorial nature. Genetic (<LINK REF="REF-Friedmann-2002" TYPE="REFERENCE">Friedmann 2002</LINK>), environmental (<LINK REF="REF-McNally-2001" TYPE="REFERENCE">McNally 2001</LINK>), and socioeconomic (<LINK REF="REF-McNally-2001" TYPE="REFERENCE">McNally 2001</LINK>) factors may all be important. Twin studies have shown a concordance rate of 72% in monozygotic twins and 23% in dizygotic twins (<LINK REF="REF-Schultz_x002d_Larsen-1993" TYPE="REFERENCE">Schultz-Larsen 1993</LINK>). Eczema is possibly "inherited more often from the mother than from the father and tends to run true to type within each family" (<LINK REF="REF-Weller-2009" TYPE="REFERENCE">Weller 2009</LINK>). It is more prevalent in higher social classes in industrialised societies (<LINK REF="REF-McNally-1998" TYPE="REFERENCE">McNally 1998</LINK>). Low birth order and small family size also appear to be risk factors for atopic disorders. "A cross-sectional parental postal survey in the UK showed statistically significant associations between eczema symptoms and dampness in the home, the use of a radiator to heat the child's bedroom and the use of synthetic pillows. Frequent vacuuming in the home was associated with a decreased prevalence of eczema" (<LINK REF="REF-McNally-2001" TYPE="REFERENCE">McNally 2001</LINK>). The perception that eczema is caused by house dust mites and food allergies often dominates the lives of people it affects (<LINK REF="REF-Barnetson-2002" TYPE="REFERENCE">Barnetson 2002</LINK>).</P>
<P>"A model for the immune pathogenesis proposes a predominant Th2 cytokine milieu in the initiating stages of acute atopic dermatitis lesions, and a mixed Th1 and Th2 pattern in chronic lesions" (<LINK REF="REF-Pastar-2005" TYPE="REFERENCE">Pastar 2005</LINK>).</P>
<P>A defective skin barrier function may be of major importance (<LINK REF="REF-Gfesser-1997" TYPE="REFERENCE">Gfesser 1997</LINK>), although other studies have contradicted the finding of a disturbed skin barrier (<LINK REF="REF-Matsumoto-2000" TYPE="REFERENCE">Matsumoto 2000</LINK>). Molecules, called structural lipids, which are located between stratum corneum cells, are also thought to "play a considerable role in the water-holding potential of the stratum corneum" (<LINK REF="REF-Imokawa-1991" TYPE="REFERENCE">Imokawa 1991</LINK>). "One of the major structural lipids is ceramide. Natural ceramides are too expensive at present to be made commercially available; however, several pseudo-ceramides have been synthesised and shown to be clinically effective in preventing and improving dry skin" (<LINK REF="REF-Draelos-2008" TYPE="REFERENCE">Draelos 2008</LINK>). Epidermal barrier dysfunction has been suggested as a primary event in the development of this disease (<LINK REF="REF-Cork-2009" TYPE="REFERENCE">Cork 2009</LINK>).</P>
<P>Breastfeeding had been believed to help prevent or delay the development of atopic conditions such as eczema (<LINK REF="REF-van-Odijk-2003" TYPE="REFERENCE">van Odijk 2003</LINK>). One systematic review found "no strong evidence of a protective effect of exclusive breastfeeding for at least 3 months against eczema, even in those with a positive family history of atopy" (<LINK REF="REF-Batchelor-2010" TYPE="REFERENCE">Batchelor 2010</LINK>). A recent systematic review found no conclusive evidence that breastfeeding lessens established eczema in infants (<LINK REF="REF-Kramer-2012" TYPE="REFERENCE">Kramer 2012</LINK>).</P>
<P>A deficiency in essential fatty acids of the skin has been suspected as having a role in the cause of eczema (<LINK REF="REF-Horrobin-2000" TYPE="REFERENCE">Horrobin 2000</LINK>; <LINK REF="REF-Melnik-1992" TYPE="REFERENCE">Melnik 1992</LINK>). It has been suggested that eczema could be caused by a (possibly inherited) defect or deficiency of the enzyme delta-6-desaturase and possibly also the enzyme delta-5-desaturase (<LINK REF="REF-Manku-1982" TYPE="REFERENCE">Manku 1982</LINK>; <LINK REF="REF-Melnik-1992" TYPE="REFERENCE">Melnik 1992</LINK>). These enzymes are responsible for converting linoleic acid to gamma-linolenic acid, a substance with anti-inflammatory properties (<LINK REF="REF-Diezel-1993" TYPE="REFERENCE">Diezel 1993</LINK>). Reduced conversion may result in a relative skin deficiency of gamma-linolenic acid, alpha-linolenic acid, and stearidonic acid.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Epidemiology</HEADING>
<P>Eczema is a common problem "affecting 10 to 20% of school age children in developed countries" (<LINK REF="REF-Johnson-1984" TYPE="REFERENCE">Johnson 1984</LINK>; <LINK REF="REF-Rajka-1989" TYPE="REFERENCE">Rajka 1989</LINK>) and 1% to 3% of the general adult population (<LINK REF="REF-Larsen-2002" TYPE="REFERENCE">Larsen 2002</LINK>). The prevalence of the disease has increased by two- to three-fold in the developed world during the last three decades (<LINK REF="REF-Saito-2005" TYPE="REFERENCE">Saito 2005</LINK>). "Its prevalence in the United States alone has nearly tripled in the past thirty to forty years" (<LINK REF="REF-Schram-2010" TYPE="REFERENCE">Schram 2010</LINK>). "However, it remains much lower in agricultural regions, such as China, Eastern Europe and rural Africa" (<LINK REF="REF-Leung-2003" TYPE="REFERENCE">Leung 2003</LINK>). The reasons for the rising prevalence are not clear; however, prevalence seems to be increasing as populations become increasingly urbanised (<LINK REF="REF-Leung-2008" TYPE="REFERENCE">Leung 2008</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Impact</HEADING>
<P>At a personal level, eczema has a significant effect on life quality and affects sleep (<LINK REF="REF-Reid-1995" TYPE="REFERENCE">Reid 1995</LINK>; <LINK REF="REF-Terreehorst-2002" TYPE="REFERENCE">Terreehorst 2002</LINK>), school (<LINK REF="REF-Lewis-Jones-1995" TYPE="REFERENCE">Lewis Jones 1995</LINK>), employment, relationships, and family life (<LINK REF="REF-Lewis-Jones-1995" TYPE="REFERENCE">Lewis Jones 1995</LINK>; <LINK REF="REF-Su-1997" TYPE="REFERENCE">Su 1997</LINK>).</P>
<P>For people of all ages, there is the physical impact of eczema - the constant itch and the unbearable need to scratch, even though this exacerbates the condition. Chronic scratching causes the skin to take on a leathery texture because the skin has thickened (lichenification). The skin becomes hot, tight, and sore, and it is often worse at night, resulting in sleepless nights for those with eczema and their families.</P>
<P>The skin can become cracked, weeping, or even infected, making it painful to wash, swim, or perform everyday tasks. Psychologically, the red, damaged skin is embarrassing and difficult to hide. Promotion at work may be blocked for people who do not "look good". Children are taunted at school. They often have low self-esteem. Their relationships can be difficult to initiate and sustain.</P>
<P>The extra time needed for bathing and skin-care makes dealing with work, studies, and social life more stressful. Cracked skin makes routine everyday tasks, such as housework, gardening, childcare, and food preparation, difficult. Careers such as catering, nursing, hairdressing, horticulture, and many manual trades are unsuitable.</P>
<P>There are additional financial costs incurred in the purchase of items designed for sensitive skin, such as special clothing, bedding, detergents, and make-up, etc. In 1996, a British study reported that the annual costs to the National Health Service (NHS) exceeded £125 million, and personal costs, including lost salary, were around £300 million (<LINK REF="REF-Herd-1996" TYPE="REFERENCE">Herd 1996</LINK>). Economic data in the USA have shown that the cost of illness from atopic dermatitis and eczema ranged from $0.9 billion to $3.8 billion per year in people younger than 65 years (<LINK REF="REF-Ellis-2002" TYPE="REFERENCE">Ellis 2002</LINK>).</P>
</SUBSECTION>
</CONDITION>
<INTERVENTION MODIFIED="2013-04-02 00:35:26 +0100" MODIFIED_BY="[Empty name]">
<P>There are at least 47 different types of interventions for eczema, which can be classified according to 10 major groupings (<LINK REF="REF-Hoare-2000" TYPE="REFERENCE">Hoare 2000</LINK>). The management of eczema requires adequate time allocation for doctors and nurses to explain to the person with it how to deal with the disease. Management involves a discussion of the avoidance of soaps and detergents, extremes of temperatures, and clothing that may irritate, such as wool. In one trial "patients attending the eczema workshop had a greater improvement in eczema severity than patients attending a dermatologist-led clinic", supporting collaborative models of service provision (<LINK REF="REF-Moore-2009" TYPE="REFERENCE">Moore 2009</LINK>).</P>
<P>The mainstays of the management of eczema are the use of emollients (creams, ointments, and bath additives). Recently, manufactured "pseudo-ceramides" (<LINK REF="REF-Draelos-2011" TYPE="REFERENCE">Draelos 2011</LINK>) have joined topical corticosteroids and immune modulators (<LINK REF="REF-Thestrup_x002d_Pedersen-2003" TYPE="REFERENCE">Thestrup-Pedersen 2003</LINK>; <LINK REF="REF-Williams-2008" TYPE="REFERENCE">Williams 2008</LINK>) as treatments for eczema. There is no evidence that probiotics have an effect on established eczema (<LINK REF="REF-Williams-2008" TYPE="REFERENCE">Williams 2008</LINK>).</P>
<P>Severe eczema, as well as nummular or hand forms, are often resistant to topical treatment and a variety of oral treatments are used. Sedating antihistamines are widely used to reduce itching and sleep disturbance. Other systemic treatments (<LINK REF="REF-Pl_x00f6_tz-2010" TYPE="REFERENCE">Plötz 2010</LINK>) have included cyclosporin, azathioprine (<LINK REF="REF-Poyner-2001" TYPE="REFERENCE">Poyner 2001</LINK>), methotrexate (<LINK REF="REF-Roberts-2010" TYPE="REFERENCE">Roberts 2010</LINK>), alitretinoin (<LINK REF="REF-Kubica-2011" TYPE="REFERENCE">Kubica 2011</LINK>), adalimumab (<LINK REF="REF-Beswick-2011" TYPE="REFERENCE">Beswick 2011</LINK>), cyclosporin A, or mycophenolate mofetil (<LINK REF="REF-Belch-2000" TYPE="REFERENCE">Belch 2000</LINK>). Phototherapy and photochemotherapy have also been used. When first- and second-line therapies, i.e. topical steroids and ultraviolet light treatments, prove inadequate, Schmit suggested that until there are more adequate randomised controlled trials comparing systemic treatments for severe eczema (<LINK REF="REF-Schmitt-2007" TYPE="REFERENCE">Schmitt 2007</LINK>), it might be better to consider short-term systemic steroids and avoid cyclosporin A because of its renal toxicity. He suggested: "Lefluonomide might be such a therapeutic alternative, but much larger trials are required."</P>
<P>In the USA in 2007, 38% of adults and 11% of children used some form of complementary or alternative medicine (CAM) (<LINK REF="REF-NHIS-2007" TYPE="REFERENCE">NHIS 2007</LINK>). Some individuals use complementary therapies, including evening primrose oil supplements, borage oil, homeopathy, and Chinese herbal medicine (<LINK REF="REF-Ernst-2000" TYPE="REFERENCE">Ernst 2000</LINK>; <LINK REF="REF-Sheehan-1992" TYPE="REFERENCE">Sheehan 1992</LINK>), in the treatment of eczema.</P>
<P>Natural sources of gamma-linolenic acid (GLA) include the following: borage seed oil, blackcurrant seed oil, evening primrose seed oil, and human milk (0.6%). Evening primrose (<I>Oenothera biennis</I>) is a tall plant with pretty yellow flowers blooming in the evening. Evening primrose oil, which contains 8% to 10% gamma-linolenic acid, has been widely used for treating eczema, both as a prescription item and an over-the-counter remedy. Borage (<I>Borago officinalis</I>) oil contains at least 23% gamma-linolenic acid.</P>
<SUBSECTION>
<HEADING LEVEL="3">Adverse effects</HEADING>
<P>An earlier concern that evening primrose oil (EPO) might cause epilepsy or seizures has been shown to be incorrect. In fact, the "EPO-derived omega-6 fatty acid arachidonic acid inhibits sodium ion currents and synaptic transmission, while the EPO-derived eicosanoid prostaglandin E(1) appears to have anticonvulsant activity. In light of these findings, formularies should now remove seizures or epilepsy as a side-effect of EPO, and should remove a history of seizures or epilepsy as a contraindication to taking EPO" (<LINK REF="REF-Puri-2007" TYPE="REFERENCE">Puri 2007</LINK>).</P>
<P>There has been one case report of lipoid pneumonia secondary to long-term use of EPO in a person with gastroesophageal reflux disease (GERD) (<LINK REF="REF-Rabahi-2010" TYPE="REFERENCE">Rabahi 2010</LINK>).</P>
<P>Another case report warns that if EPO is taken for a prolonged period of time (more than one year), there is a potential risk of inflammation, thrombosis, and immunosuppression due to slow accumulation of EPO in the tissues (<LINK REF="REF-Phinney-1994" TYPE="REFERENCE">Phinney 1994</LINK>).</P>
<P>Animal research suggests that EPO has important anticoagulant and antiplatelet activity, which may last 60 days (<LINK REF="REF-Riaz-2009" TYPE="REFERENCE">Riaz 2009</LINK>). Anticoagulant drugs warn of interaction with EPO (<LINK REF="REF-Jellin-2005" TYPE="REFERENCE">Jellin 2005</LINK>). Although suggested as helping heart attacks, essential fatty acids (EFAs) cause increased bleeding, which was documented in a study that showed no benefit to rheumatoid arthritis (<LINK REF="REF-Nordstrom-1995" TYPE="REFERENCE">Nordstrom 1995</LINK>).</P>
<P>Ingesting EPO during pregnancy "may be associated with an increase in the incidence of prolonged rupture of membranes, oxytocin augmentation, arrest of descent, and vacuum extraction" (<LINK REF="REF-Dove-1999" TYPE="REFERENCE">Dove 1999</LINK>).</P>
<P>Borage oil (BO) has a similar profile of headache and minor gastrointestinal adverse effects. A recent single case report (<LINK REF="REF-Al_x002d_Khamees-2011" TYPE="REFERENCE">Al-Khamees 2011</LINK>) brings up the same concern for seizures with BO, which was shown to be a spurious concern for EPO.</P>
</SUBSECTION>
</INTERVENTION>
<THEORY MODIFIED="2013-04-02 00:35:50 +0100" MODIFIED_BY="[Empty name]">
<P>"The possible mechanisms by which EFAs might improve inflammatory skin disease include modification of eicosanoid metabolism so as to favour synthesis of relatively non-inflammatory prostaglandins and leukotrienes (n6, n7). Since both n6 and n3 essential fatty acids may possess this property, it is possible that giving both together will have a synergistic effect" (<LINK REF="STD-Berth_x002d_Jones-1993" TYPE="STUDY">Berth-Jones 1993</LINK>). Antioxidant properties have been studied in EPO (<LINK REF="REF-Shahidi-1997" TYPE="REFERENCE">Shahidi 1997</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2013-04-02 00:36:25 +0100" MODIFIED_BY="Joel TM Bamford">
<P>Many people with eczema are reluctant to use the most commonly recommended treatments, i.e. topical corticosteroids, because of fear of local side-effects, such as allergies, skin thinning, and fear of other long-term health effects, such as growth retardation and adrenal gland suppression (<LINK REF="REF-Charman-2000" TYPE="REFERENCE">Charman 2000</LINK>). People with eczema often use complementary medicine (<LINK REF="REF-Eisenberg-1998" TYPE="REFERENCE">Eisenberg 1998</LINK>). Some evidence suggests that people with eczema seek treatment with complementary medicine because they are highly satisfied with complementary medicine (<LINK REF="REF-Augustin-1999" TYPE="REFERENCE">Augustin 1999</LINK>; <LINK REF="REF-Jensen-1990" TYPE="REFERENCE">Jensen 1990</LINK>; <LINK REF="REF-Triebskorn-1989" TYPE="REFERENCE">Triebskorn 1989</LINK>). Another study showed that "(68%) of patients expressed a positive difference in the relationship they had with their practitioner at the Center compared to their own GP" (<LINK REF="REF-Finnigan-1991" TYPE="REFERENCE">Finnigan 1991</LINK>).</P>
<P>There is a lay perception that complementary treatments, such as EPO and BO, treat the skin 'from within' and are 'gentler' when compared to physician-prescribed topicals.</P>
<P>Previous studies of supplementation of gamma-linolenic acid for eczema have shown conflicting results. Thus, there is uncertainty whether EPO and BO are effective and whether it is safe to prescribe these oils. This systematic review aims to address these questions.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2013-02-18 11:53:12 +0000" MODIFIED_BY="Joel TM Bamford">
<P>To assess the effects of oral evening primrose oil or borage oil for treating the symptoms of atopic eczema.</P>
</OBJECTIVES>
<METHODS MODIFIED="2013-04-02 00:56:41 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2013-03-18 15:53:39 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2013-03-18 15:50:49 +0000" MODIFIED_BY="Joel Bamford">
<P>All randomised controlled trials (RCTs) with parallel or cross-over design, investigating oral intake of EPO or BO for eczema or synonyms including <B>a</B>topic <B>e</B>czema (AE), <B>a</B>topic <B>d</B>ermatitis (AD), <B>a</B>topic <B>e</B>czema/<B>d</B>ermatitis <B>s</B>yndrome (AEDS), and atopiform dermatitis.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2013-03-18 15:52:56 +0000" MODIFIED_BY="[Empty name]">
<P>We included adults and children diagnosed with eczema by a medical practitioner. We accepted diagnostic criteria such as the Hanifin and Rajka definition (<LINK REF="REF-Hanifin-1980" TYPE="REFERENCE">Hanifin 1980</LINK>) or the UK modification (<LINK REF="REF-Williams-1994" TYPE="REFERENCE">Williams 1994</LINK>), as well as atopic eczema diagnosed by a dermatologist using the terms 'atopic eczema' or 'atopic dermatitis'<I>.</I>
</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2013-03-18 15:53:14 +0000" MODIFIED_BY="[Empty name]">
<P>Oral intake of EPO or BO compared against placebo (usually liquid paraffin, olive oil, or sunflower oil) or other active eczema therapies.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2013-03-18 15:53:39 +0000" MODIFIED_BY="Joel TM Bamford">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2013-02-25 14:14:47 +0000" MODIFIED_BY="Diane A  Horsley">
<UL>
<LI>Global degree of improvement in symptoms and signs as rated by participant or medical doctor.</LI>
<LI>Improvement in quality of life.</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2013-03-18 15:53:39 +0000" MODIFIED_BY="Joel TM Bamford">
<UL>
<LI>Severe adverse events (caused by EPO or caused by BO) requiring withdrawal from the trial, including severe skin irritation.</LI>
<LI>Minor participant-reported adverse events, including mild skin irritation not sufficient to require cessation of treatment.</LI>
<LI>Systemic or topical treatments taken concurrently with EPO or BO.</LI>
<LI>Skin irritation (such as redness, itch, scaling).</LI>
<LI>Change of score of any validated scoring system for atopic eczema.</LI>
<LI>Time off school/work.</LI>
<LI>Need for topical steroids and emollients.</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-04-02 00:45:05 +0100" MODIFIED_BY="[Empty name]">
<P>We aimed to identify all relevant randomised controlled trials (RCTs) regardless of language or publication status (published, unpublished, in press, or in progress).</P>
<ELECTRONIC_SEARCHES MODIFIED="2013-04-02 00:39:29 +0100" MODIFIED_BY="Liz Doney">
<P>We searched the following databases up to 29 August 2012.</P>
<UL>
<LI>the Cochrane Skin Group Specialised Register using the following terms: (((atopic or infantile or childhood) and eczema) or ((atopic and eczema and dermatitis and syndrome) or AEDS) or ((atopic or atopiform) and dermatitis) or (neurodermatitis or neurodermitis) and (primrose or herb* or plant* or efamol or epogam or epo or borag*));</LI>
<LI>the Cochrane Central Register of Controlled Trials (CENTRAL) in <I>The Cochrane Library </I>using the search strategy in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>;</LI>
<LI>MEDLINE via OVID (from 1946) using the strategy in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>;</LI>
<LI>EMBASE via OVID (from 1974) using the strategy in <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>;</LI>
<LI>AMED via OVID (Allied and Complementary Medicine, from 1985) using the strategy in <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>; and</LI>
<LI>LILACS (Latin American and Caribbean Health Science Information database, from 1982) using the strategy in <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>.</LI>
</UL>
<SUBSECTION>
<HEADING LEVEL="4">Trials registers</HEADING>
<P>We searched for reports of trials in the following trials databases up to 29 August 2012 using the terms "eczema", "primrose", and "borage" or "borago":</P>
<UL>
<LI>The metaRegister of Controlled Trials (<A HREF="http://www.controlled-trials.com/">www.controlled-trials.com</A>).</LI>
<LI>The US National Institutes of Health Ongoing Trials Register (<A HREF="http://www.clinicaltrials.gov/">www.clinicaltrials.gov</A>).</LI>
<LI>The Australian New Zealand Clinical Trials Registry (<A HREF="http://www.anzctr.org.au/">www.anzctr.org.au</A>).</LI>
<LI>The World Health Organization International Clinical Trials Registry platform (<A HREF="http://www.who.int/trialsearch">www.who.int/trialsearch</A>).</LI>
<LI>The Ongoing Skin Trials Register (<A HREF="http://www.nottingham.ac.uk/ongoingskintrials">www.nottingham.ac.uk/ongoingskintrials</A>).</LI>
</UL>
</SUBSECTION>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2013-04-02 00:45:05 +0100" MODIFIED_BY="Liz Doney">
<SUBSECTION>
<HEADING LEVEL="4">Reference lists</HEADING>
<P>We checked the bibliographies of included studies for further references to relevant trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Grey literature</HEADING>
<P>We identified unpublished and ongoing trials by correspondence with trial authors. We contacted pharmaceutical companies such as Nutricia, Canada (former Epogam® producer Scotia Holdings) who produce relevant products.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Correspondence</HEADING>
<P>We (KS in a past version of the authoring team, and JB in the present team) sent emails and letters to investigators to ask for more information about their trials where there were insufficient documentation within reports of the studies (<LINK REF="STD-Bahmer-1992" TYPE="STUDY">Bahmer 1992</LINK>; <LINK REF="STD-Bamford-1985" TYPE="STUDY">Bamford 1985</LINK>; <LINK REF="STD-Biagi-1994" TYPE="STUDY">Biagi 1994</LINK>; <LINK REF="STD-Don-2003" TYPE="STUDY">Don 2003</LINK>; <LINK REF="STD-Lovell-1981" TYPE="STUDY">Lovell 1981</LINK>; <LINK REF="STD-Wright-1982" TYPE="STUDY">Wright 1982</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse effects</HEADING>
<P>Safety data were as reported in the RCTs (Data and analyses). Additionally, we contacted manufacturers for long-term surveillance data on EPO and BO safety. We made additional searches (4 November 2011) for non-randomised EPO and BO studies, revealing more adverse events. We searched the following:</P>
<UL>
<LI>the World Health Organization;</LI>
<LI>the Medicines and Healthcare products Regulatory Agency's (MHRA's) Yellow Card reporting Scheme for adverse drug reactions;</LI>
<LI>the WHO database for adverse events; and</LI>
<LI>the German database '<A HREF="http://medcertain.org">medcertain.org</A>', a collection of published and unpublished cases of adverse events.</LI>
</UL>
</SUBSECTION>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2013-04-02 00:56:41 +0100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2013-03-18 16:07:19 +0000" MODIFIED_BY="[Empty name]">
<P>Two review authors (JB and SR) independently screened title/abstract results of the searches. Where title/abstract did not provide clear direction, we used full-text articles and a predesigned eligibility form based on the inclusion criteria to complete the selection of included articles. If details were unclear, we sought clarification from the trial authors, and we reassessed the corresponding articles. We resolved any difference between the eligibility results by consensus. We excluded studies that did not meet the inclusion criteria and stated the reasons in the 'Characteristics of excluded studies' section of the review.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2013-03-18 16:08:11 +0000" MODIFIED_BY="[Empty name]">
<P>Two review authors (JB and SR) independently extracted data on methods, participants, interventions, and outcomes from each included trial, using a specially designed prepiloted data extraction form. One review author (AM) also independently extracted data on outcomes for the purpose of data analysis. For each dichotomous outcome, we extracted the number of participants experiencing the event and the number randomised in each treatment group. For each continuous outcome, we extracted the mean, standard deviation (or information to estimate the standard deviation), and the number randomised in each treatment group. We contacted the trial authors in the case of unclear or missing data. We resolved any disagreements by consensus.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2013-04-02 00:56:41 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors (JB and SR) independently assessed the risk of bias of the included studies using the guidelines provided in the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We followed guidance given in the <I>handbook</I> when assessing whether adequate steps were taken to reduce the risk of bias across six components:<BR/>(a) sequence generation;<BR/>(b) allocation concealment;<BR/>(c) blinding (of participants, personnel, and outcome assessors);<BR/>(d) incomplete outcome data;<BR/>(e) selective outcome reporting; and<BR/>(f) other sources of bias.</P>
<P>We categorised judgements in order to indicate a low, high, or unclear risk of bias. The results were summarised using the 'Risk of bias' graph (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>) and the 'Risk of bias' summary (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>), in addition to the 'Risk of bias' table for each included study. Where necessary, we contacted trial authors for clarification. We resolved any disagreements by consensus with CvG.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2012-05-01 17:42:00 +0100" MODIFIED_BY="Finola M Delamere">
<P>We calculated risk ratios (RR) for dichotomous outcomes and mean differences (MD) for continuous outcomes. We presented these results with 95% confidence intervals (CI).</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2013-03-18 16:10:27 +0000" MODIFIED_BY="Cathy Bennett">
<P>We noted the unit of analysis at the level of randomisation (individual or group) and analysed accordingly.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2013-03-18 17:32:30 +0000" MODIFIED_BY="Cathy Bennett">
<P>We contacted original authors of studies for clarification of study methodology and results. When we required further information to assess risk of bias, we contacted trial investigators of studies to obtain clarifications. We were unable to obtain information from many trial investigators because of the age of the study (the information was unavailable or the trial investigator could not be contacted). We carried out analyses according to the intention-to-treat (ITT) principle where there was no missing data. In the case of missing data, we carried out an available case analysis.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2013-03-18 16:13:04 +0000" MODIFIED_BY="Finola M Delamere">
<P>We assessed statistical heterogeneity by applying the Chi² test (P value &lt; 0.10 considered statistically significant) and the I² statistic (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>), where an I² statistic of greater than 50% represented substantial heterogeneity. The Chi² test (also called the Cochran's Q test) is a test of significance of heterogeneity, and the I² statistic describes the percentage of the variability in effect estimates that is due to heterogeneity rather than chance (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2013-03-18 16:14:29 +0000" MODIFIED_BY="Finola M Delamere">
<P>We did not construct a funnel plot to assess the possibility of publication bias because there were few trials per meta-analysis (less than 10). The <I>Cochrane Handbook of Systematic Reviews</I> recommends at least 10 studies in a meta-analysis in order to construct a funnel plot. However, we employed the following criteria to assess reporting bias:</P>
<OL>
<LI>authors and institutions involved;</LI>
<LI>publication of articles;</LI>
<LI>funding;</LI>
<LI>sponsorship of commercially available supplements; and</LI>
<LI>affiliation of the authors with the manufacturer.</LI>
</OL>
<P>We recorded this information in the 'Risk of bias' tables.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2013-04-02 00:51:44 +0100" MODIFIED_BY="Cathy Bennett">
<P>We analysed data separately for EPO and BO using Review Manager 5 (RevMan 5). We examined the data from included studies for descriptive synthesis and pooled data where trials were sufficiently homogeneous in design, methodology, and outcomes. When we pooled data, we used the DerSimonian and Laird random-effects model because of anticipated heterogeneity between the included studies.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2013-04-02 00:52:27 +0100" MODIFIED_BY="Cathy Bennett">
<P>The original authors of the protocol did not refer to an intention to carry out subgroup analyses, but if they found statistical heterogeneity, they did plan to explore further - using the Chi² test (P &lt; 0.1) - possible reasons, such as participants, study design, and intervention. We anticipated we would investigate potentially influential study characteristics by conducting subgroup analysis with respect to the following (where sufficient studies existed):</P>
<UL>
<LI>RCTs reporting the use of oral placebo capsules with vitamin E versus oral placebo capsules without vitamin E.</LI>
<LI>Results in infected atopic dermatitis (bacterial, viral, and fungal) versus results in non-infected atopic dermatitis.</LI>
<LI>Immunoglobulin E (IgE)-associated atopic eczema versus non-IgE-associated atopic eczema.</LI>
<LI>Results in infants/children versus results in other (adults only or adults and children).</LI>
</UL>
<P>However, we only managed to carry out subgroup analyses with respect to the last comparison.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2013-04-02 00:55:19 +0100" MODIFIED_BY="Joel Bamford">
<P>The protocol prespecified the following sensitivity analyses:</P>
<UL>
<LI>IgE-associated atopic eczema versus non-IgE-associated atopic eczema;</LI>
<LI>protein deficiency versus no protein deficiency;</LI>
<LI>participants who continued with conventional treatment versus participants who stopped with conventional treatment;</LI>
<LI>studies of different levels of gamma-linolenic acid - borage seed oil 60 to 120 mg GLA, evening primrose oil 40 to 68 mg GL;</LI>
<LI>studies with parallel design versus studies with cross-over design;</LI>
<LI>studies with oral intake of EPO or borage oil versus studies with oral intake of EPO plus vitamin E or oral intake of borage oil plus vitamin E;</LI>
<LI>results in infants/children versus results in adults; and</LI>
<LI>RCTs reporting the use of oral placebo capsules that additionally contain vitamin E or other substances "will initially be included and a sensitivity analysis will be carried out to see whether Vitamin E on its own could have had an effect on the improvement of eczema symptoms".</LI>
</UL>
<P>We could not perform sensitivity analyses with respect to any of the above factors because of the non-availability of the relevant data from the trial reports, although the review considered the following two subgroups:</P>
<UL>
<LI>participants who continued with conventional treatment versus participants who stopped with conventional treatment; and</LI>
<LI>studies with parallel design versus studies with cross-over design.</LI>
</UL>
<P>Most studies failed to report on whether conventional treatment was continued or stopped during the study; therefore, we could not factor this information in sensitivity analysis, and we did not include any cross-over studies in the meta-analyses.</P>
<P>We did carry out some sensitivity analysis for one meta-analysis where there was significant heterogeneity by excluding an outlying study and simultaneously examining the effect that this had on both the treatment effect and heterogeneity.</P>
<P>We did not look at heterogeneity related to presence or absence of vitamin E in placebo capsules.</P>
<SUBSECTION>
<HEADING LEVEL="3">Other</HEADING>
<P>The systematic review team included a consumer (RM) to ensure readability and clarity of the terminology of the final review.</P>
<P>Three studies had a third arm, which was not relevant to this review; therefore, we excluded the irrelevant arm from analysis.</P>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-04-02 01:27:46 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2013-04-02 01:06:57 +0100" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2013-04-02 00:56:41 +0100" MODIFIED_BY="[Empty name]">
<P>The study flow diagram is displayed in <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>. The search yielded a total of 179 citations, of which 167 came from electronic databases, 11 were unpublished 'in house' studies, and 1 was referenced in <A HREF="http://www.clinicaltrials.gov/">www.clinicaltrials.gov</A>. A total of 3 duplicate records were removed, leaving 176 citations, which we assessed for eligibility. After reading titles and abstracts, we excluded a total of 142 studies. We obtained full texts for the remaining 34 citations and included 27 studies in the review. We excluded seven studies after reading the full-texts, as well as one further study (<LINK REF="STD-NCT00878670" TYPE="STUDY">NCT00878670</LINK>), which was ongoing at the time we were preparing this review, when <A HREF="http://www.clinicaltrials.gov/">www.clinicaltrials.gov</A> reported it was an open trial. No other ongoing trials were registered as of 16 December 2012.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2013-04-02 01:06:57 +0100" MODIFIED_BY="[Empty name]">
<P>A total of 27 studies (1596 participants) met the inclusion criteria. The characteristics and risk of bias have been presented figuratively and descriptively in the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' tables.</P>
<SUBSECTION>
<HEADING LEVEL="4">Design</HEADING>
<P>Of the 27 included studies, 21 were single centre (<LINK REF="STD-Bahmer-1992" TYPE="STUDY">Bahmer 1992</LINK>; <LINK REF="STD-Bamford-1985" TYPE="STUDY">Bamford 1985</LINK>; <LINK REF="STD-Berth_x002d_Jones-1993" TYPE="STUDY">Berth-Jones 1993</LINK>; <LINK REF="STD-Biagi-1994" TYPE="STUDY">Biagi 1994</LINK>; <LINK REF="STD-Borrek-1997" TYPE="STUDY">Borrek 1997</LINK>; <LINK REF="STD-Buslau-1996" TYPE="STUDY">Buslau 1996</LINK>; <LINK REF="STD-Don-2003" TYPE="STUDY">Don 2003</LINK>; <LINK REF="STD-Harper-1990" TYPE="STUDY">Harper 1990</LINK>; <LINK REF="STD-Heddle-1990" TYPE="STUDY">Heddle 1990</LINK>; <LINK REF="STD-Kenicer-2001" TYPE="STUDY">Kenicer 2001</LINK>; <LINK REF="STD-Kiehl-1994" TYPE="STUDY">Kiehl 1994</LINK>; <LINK REF="STD-Kovar-1992" TYPE="STUDY">Kovar 1992</LINK>; <LINK REF="STD-Lovell-1981" TYPE="STUDY">Lovell 1981</LINK>; <LINK REF="STD-MacKie-Adult-1990" TYPE="STUDY">MacKie Adult 1990</LINK>; <LINK REF="STD-MacKie-Child-1990" TYPE="STUDY">MacKie Child 1990</LINK>; <LINK REF="STD-MacLeod-2001" TYPE="STUDY">MacLeod 2001</LINK>; <LINK REF="STD-Schalin_x002d_Karrila-1987" TYPE="STUDY">Schalin-Karrila 1987</LINK>; <LINK REF="STD-Senapati-2008" TYPE="STUDY">Senapati 2008</LINK>; <LINK REF="STD-Takwale-2003" TYPE="STUDY">Takwale 2003</LINK>; <LINK REF="STD-Valsecchi-2006" TYPE="STUDY">Valsecchi 2006</LINK>; <LINK REF="STD-Wright-1982" TYPE="STUDY">Wright 1982</LINK>), and 6 were multicentre with 2 to 12 sites (<LINK REF="STD-Finlay-2001" TYPE="STUDY">Finlay 2001</LINK>; <LINK REF="STD-France-1988" TYPE="STUDY">France 1988</LINK>; <LINK REF="STD-Fraser-2001" TYPE="STUDY">Fraser 2001</LINK>; <LINK REF="STD-Hederos-1996" TYPE="STUDY">Hederos 1996</LINK>; <LINK REF="STD-Henz-1999" TYPE="STUDY">Henz 1999</LINK>; <LINK REF="STD-Wishart-1992" TYPE="STUDY">Wishart 1992</LINK>).</P>
<P>Five studies were cross-over (<LINK REF="STD-Bamford-1985" TYPE="STUDY">Bamford 1985</LINK>; <LINK REF="STD-Borrek-1997" TYPE="STUDY">Borrek 1997</LINK>; <LINK REF="STD-Heddle-1990" TYPE="STUDY">Heddle 1990</LINK>; <LINK REF="STD-Lovell-1981" TYPE="STUDY">Lovell 1981</LINK>; <LINK REF="STD-Wright-1982" TYPE="STUDY">Wright 1982</LINK>), and the remaining 22 were parallel in design (<LINK REF="STD-Bahmer-1992" TYPE="STUDY">Bahmer 1992</LINK>; <LINK REF="STD-Berth_x002d_Jones-1993" TYPE="STUDY">Berth-Jones 1993</LINK>; <LINK REF="STD-Biagi-1994" TYPE="STUDY">Biagi 1994</LINK>; <LINK REF="STD-Buslau-1996" TYPE="STUDY">Buslau 1996</LINK>; <LINK REF="STD-Don-2003" TYPE="STUDY">Don 2003</LINK>; <LINK REF="STD-Finlay-2001" TYPE="STUDY">Finlay 2001</LINK>; <LINK REF="STD-France-1988" TYPE="STUDY">France 1988</LINK>; <LINK REF="STD-Fraser-2001" TYPE="STUDY">Fraser 2001</LINK>; <LINK REF="STD-Harper-1990" TYPE="STUDY">Harper 1990</LINK>; <LINK REF="STD-Hederos-1996" TYPE="STUDY">Hederos 1996</LINK>; <LINK REF="STD-Henz-1999" TYPE="STUDY">Henz 1999</LINK>; <LINK REF="STD-Kenicer-2001" TYPE="STUDY">Kenicer 2001</LINK>; <LINK REF="STD-Kiehl-1994" TYPE="STUDY">Kiehl 1994</LINK>; <LINK REF="STD-Kovar-1992" TYPE="STUDY">Kovar 1992</LINK>; <LINK REF="STD-MacKie-Adult-1990" TYPE="STUDY">MacKie Adult 1990</LINK>; <LINK REF="STD-MacKie-Child-1990" TYPE="STUDY">MacKie Child 1990</LINK>; <LINK REF="STD-MacLeod-2001" TYPE="STUDY">MacLeod 2001</LINK>; <LINK REF="STD-Schalin_x002d_Karrila-1987" TYPE="STUDY">Schalin-Karrila 1987</LINK>; <LINK REF="STD-Senapati-2008" TYPE="STUDY">Senapati 2008</LINK>; <LINK REF="STD-Takwale-2003" TYPE="STUDY">Takwale 2003</LINK>; <LINK REF="STD-Valsecchi-2006" TYPE="STUDY">Valsecchi 2006</LINK>; <LINK REF="STD-Wishart-1992" TYPE="STUDY">Wishart 1992</LINK>).</P>
<P>Three studies had a third arm that was not relevant to this review (<LINK REF="STD-Berth_x002d_Jones-1993" TYPE="STUDY">Berth-Jones 1993</LINK>; <LINK REF="STD-Biagi-1994" TYPE="STUDY">Biagi 1994</LINK>; <LINK REF="STD-MacLeod-2001" TYPE="STUDY">MacLeod 2001</LINK>).</P>
<P>In all articles, the whole person was the unit of analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Sample sizes in studies</HEADING>
<P>We included 27 studies, with a total of 1596 randomised participants (65 are not counted here as they were on other trial arms in 3 studies not fitting this review criteria). Details of all the studies are included in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>. Sample sizes ranged from 12 (<LINK REF="STD-Bahmer-1992" TYPE="STUDY">Bahmer 1992</LINK>) to 160 (<LINK REF="STD-Henz-1999" TYPE="STUDY">Henz 1999</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Setting</HEADING>
<P>The included studies were carried out in 10 countries: UK (13), Germany (5), Italy (3), India (1), Finland (1), New Zealand (1), Sweden (1), USA (1), and Switzerland (1).</P>
<P>The 11 house studies (<LINK REF="STD-Finlay-2001" TYPE="STUDY">Finlay 2001</LINK>; <LINK REF="STD-France-1988" TYPE="STUDY">France 1988</LINK>; <LINK REF="STD-Fraser-2001" TYPE="STUDY">Fraser 2001</LINK>; <LINK REF="STD-Harper-1990" TYPE="STUDY">Harper 1990</LINK>; <LINK REF="STD-Heddle-1990" TYPE="STUDY">Heddle 1990</LINK>; <LINK REF="STD-Kenicer-2001" TYPE="STUDY">Kenicer 2001</LINK>; <LINK REF="STD-Kovar-1992" TYPE="STUDY">Kovar 1992</LINK>; <LINK REF="STD-MacKie-Adult-1990" TYPE="STUDY">MacKie Adult 1990</LINK>; <LINK REF="STD-MacKie-Child-1990" TYPE="STUDY">MacKie Child 1990</LINK>; <LINK REF="STD-MacLeod-2001" TYPE="STUDY">MacLeod 2001</LINK>; <LINK REF="STD-Wishart-1992" TYPE="STUDY">Wishart 1992</LINK>) were never published outside the pharmaceutical company, and we use the term "house studies" to designate those studies.</P>
<P>Peer-reviewed journals published 16 included studies, which had lead authors outside the pharmaceutical industry.</P>
<P>All the studies were carried out in a secondary care setting (referral or dermatology clinic).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Participants</HEADING>
<P>The majority of articles described recruitment from those who were attending dermatology or paediatric clinics, but no article described advertising or stipends paid to participants. One article (<LINK REF="STD-Bamford-1985" TYPE="STUDY">Bamford 1985</LINK>) detailed the method of participant recruitment.</P>
<P>Nine studies had participants who were mixed groups of adults and children (<LINK REF="STD-Bamford-1985" TYPE="STUDY">Bamford 1985</LINK>; <LINK REF="STD-Berth_x002d_Jones-1993" TYPE="STUDY">Berth-Jones 1993</LINK>; <LINK REF="STD-Fraser-2001" TYPE="STUDY">Fraser 2001</LINK>; <LINK REF="STD-Kiehl-1994" TYPE="STUDY">Kiehl 1994</LINK>; <LINK REF="STD-Lovell-1981" TYPE="STUDY">Lovell 1981</LINK>; <LINK REF="STD-Senapati-2008" TYPE="STUDY">Senapati 2008</LINK>; <LINK REF="STD-Takwale-2003" TYPE="STUDY">Takwale 2003</LINK>; <LINK REF="STD-Valsecchi-2006" TYPE="STUDY">Valsecchi 2006</LINK>; <LINK REF="STD-Wright-1982" TYPE="STUDY">Wright 1982</LINK>). There were nine trials with only children enrolled (<LINK REF="STD-Biagi-1994" TYPE="STUDY">Biagi 1994</LINK>; <LINK REF="STD-Borrek-1997" TYPE="STUDY">Borrek 1997</LINK>; <LINK REF="STD-Don-2003" TYPE="STUDY">Don 2003</LINK>; <LINK REF="STD-Finlay-2001" TYPE="STUDY">Finlay 2001</LINK>; <LINK REF="STD-Harper-1990" TYPE="STUDY">Harper 1990</LINK>; <LINK REF="STD-Heddle-1990" TYPE="STUDY">Heddle 1990</LINK>; <LINK REF="STD-Hederos-1996" TYPE="STUDY">Hederos 1996</LINK>; <LINK REF="STD-Kovar-1992" TYPE="STUDY">Kovar 1992</LINK>; <LINK REF="STD-MacKie-Child-1990" TYPE="STUDY">MacKie Child 1990</LINK>). The remaining nine studies had only adult participants (<LINK REF="STD-Bahmer-1992" TYPE="STUDY">Bahmer 1992</LINK>; <LINK REF="STD-Buslau-1996" TYPE="STUDY">Buslau 1996</LINK>; <LINK REF="STD-France-1988" TYPE="STUDY">France 1988</LINK>; <LINK REF="STD-Henz-1999" TYPE="STUDY">Henz 1999</LINK>; <LINK REF="STD-Kenicer-2001" TYPE="STUDY">Kenicer 2001</LINK>; <LINK REF="STD-MacKie-Adult-1990" TYPE="STUDY">MacKie Adult 1990</LINK>; <LINK REF="STD-MacLeod-2001" TYPE="STUDY">MacLeod 2001</LINK>; <LINK REF="STD-Schalin_x002d_Karrila-1987" TYPE="STUDY">Schalin-Karrila 1987</LINK>; <LINK REF="STD-Wishart-1992" TYPE="STUDY">Wishart 1992</LINK>).</P>
<P>In the (16) studies that stated the sex of the individuals, there were 344 men or boys and 384 women or girls (<LINK REF="STD-Biagi-1994" TYPE="STUDY">Biagi 1994</LINK>; <LINK REF="STD-Borrek-1997" TYPE="STUDY">Borrek 1997</LINK>; <LINK REF="STD-Buslau-1996" TYPE="STUDY">Buslau 1996</LINK>; <LINK REF="STD-Don-2003" TYPE="STUDY">Don 2003</LINK>; <LINK REF="STD-Fraser-2001" TYPE="STUDY">Fraser 2001</LINK>; <LINK REF="STD-Harper-1990" TYPE="STUDY">Harper 1990</LINK>; <LINK REF="STD-Hederos-1996" TYPE="STUDY">Hederos 1996</LINK>; <LINK REF="STD-Henz-1999" TYPE="STUDY">Henz 1999</LINK>; <LINK REF="STD-Kovar-1992" TYPE="STUDY">Kovar 1992</LINK>; <LINK REF="STD-MacKie-Adult-1990" TYPE="STUDY">MacKie Adult 1990</LINK>; <LINK REF="STD-MacKie-Child-1990" TYPE="STUDY">MacKie Child 1990</LINK>; <LINK REF="STD-MacLeod-2001" TYPE="STUDY">MacLeod 2001</LINK>; <LINK REF="STD-MacLeod-2001" TYPE="STUDY">MacLeod 2001</LINK>; <LINK REF="STD-Schalin_x002d_Karrila-1987" TYPE="STUDY">Schalin-Karrila 1987</LINK>; <LINK REF="STD-Senapati-2008" TYPE="STUDY">Senapati 2008</LINK>; <LINK REF="STD-Wishart-1992" TYPE="STUDY">Wishart 1992</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Interventions</HEADING>
<P>The included trials fell into two broad therapeutic categories (EPO or BO). Further information about interventions, results, and outcomes can be found in the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' tables.</P>
<UL>
<LI>Evening primrose oil was used in 19 studies (<LINK REF="STD-Bamford-1985" TYPE="STUDY">Bamford 1985</LINK>; <LINK REF="STD-Berth_x002d_Jones-1993" TYPE="STUDY">Berth-Jones 1993</LINK>; <LINK REF="STD-Biagi-1994" TYPE="STUDY">Biagi 1994</LINK>; <LINK REF="STD-Finlay-2001" TYPE="STUDY">Finlay 2001</LINK>; <LINK REF="STD-France-1988" TYPE="STUDY">France 1988</LINK>; <LINK REF="STD-Fraser-2001" TYPE="STUDY">Fraser 2001</LINK>; <LINK REF="STD-Harper-1990" TYPE="STUDY">Harper 1990</LINK>; <LINK REF="STD-Heddle-1990" TYPE="STUDY">Heddle 1990</LINK>; <LINK REF="STD-Hederos-1996" TYPE="STUDY">Hederos 1996</LINK>; <LINK REF="STD-Kenicer-2001" TYPE="STUDY">Kenicer 2001</LINK>; <LINK REF="STD-Kovar-1992" TYPE="STUDY">Kovar 1992</LINK>; <LINK REF="STD-Lovell-1981" TYPE="STUDY">Lovell 1981</LINK>; <LINK REF="STD-MacKie-Adult-1990" TYPE="STUDY">MacKie Adult 1990</LINK>; <LINK REF="STD-MacKie-Child-1990" TYPE="STUDY">MacKie Child 1990</LINK>; <LINK REF="STD-MacLeod-2001" TYPE="STUDY">MacLeod 2001</LINK>; <LINK REF="STD-Schalin_x002d_Karrila-1987" TYPE="STUDY">Schalin-Karrila 1987</LINK>; <LINK REF="STD-Senapati-2008" TYPE="STUDY">Senapati 2008</LINK>; <LINK REF="STD-Wishart-1992" TYPE="STUDY">Wishart 1992</LINK>; <LINK REF="STD-Wright-1982" TYPE="STUDY">Wright 1982</LINK>).</LI>
</UL>
<UL>
<LI>Borage oil was used in 8 studies (<LINK REF="STD-Bahmer-1992" TYPE="STUDY">Bahmer 1992</LINK>; <LINK REF="STD-Borrek-1997" TYPE="STUDY">Borrek 1997</LINK>; <LINK REF="STD-Buslau-1996" TYPE="STUDY">Buslau 1996</LINK>; <LINK REF="STD-Don-2003" TYPE="STUDY">Don 2003</LINK>; <LINK REF="STD-Henz-1999" TYPE="STUDY">Henz 1999</LINK>; <LINK REF="STD-Kiehl-1994" TYPE="STUDY">Kiehl 1994</LINK>; <LINK REF="STD-Takwale-2003" TYPE="STUDY">Takwale 2003</LINK>; <LINK REF="STD-Valsecchi-2006" TYPE="STUDY">Valsecchi 2006</LINK>).</LI>
</UL>
<UL>
<LI>Duration of treatment (intervention) varied from 3 weeks (<LINK REF="STD-Lovell-1981" TYPE="STUDY">Lovell 1981</LINK>) to 24 weeks (<LINK REF="STD-Henz-1999" TYPE="STUDY">Henz 1999</LINK>); 2 studies were 8 weeks (<LINK REF="STD-Biagi-1994" TYPE="STUDY">Biagi 1994</LINK>; <LINK REF="STD-Heddle-1990" TYPE="STUDY">Heddle 1990</LINK>); 10, 12 weeks (<LINK REF="STD-Bahmer-1992" TYPE="STUDY">Bahmer 1992</LINK>; <LINK REF="STD-Borrek-1997" TYPE="STUDY">Borrek 1997</LINK>; <LINK REF="STD-Buslau-1996" TYPE="STUDY">Buslau 1996</LINK>; <LINK REF="STD-Don-2003" TYPE="STUDY">Don 2003</LINK>; <LINK REF="STD-Finlay-2001" TYPE="STUDY">Finlay 2001</LINK>; <LINK REF="STD-Fraser-2001" TYPE="STUDY">Fraser 2001</LINK>; <LINK REF="STD-Kiehl-1994" TYPE="STUDY">Kiehl 1994</LINK>; <LINK REF="STD-Schalin_x002d_Karrila-1987" TYPE="STUDY">Schalin-Karrila 1987</LINK>; <LINK REF="STD-Takwale-2003" TYPE="STUDY">Takwale 2003</LINK>; <LINK REF="STD-Wright-1982" TYPE="STUDY">Wright 1982</LINK>); 1, 14 weeks (<LINK REF="STD-Valsecchi-2006" TYPE="STUDY">Valsecchi 2006</LINK>); 10, 16 weeks (<LINK REF="STD-Berth_x002d_Jones-1993" TYPE="STUDY">Berth-Jones 1993</LINK>; <LINK REF="STD-France-1988" TYPE="STUDY">France 1988</LINK>; <LINK REF="STD-Harper-1990" TYPE="STUDY">Harper 1990</LINK>; <LINK REF="STD-Hederos-1996" TYPE="STUDY">Hederos 1996</LINK>; <LINK REF="STD-Kenicer-2001" TYPE="STUDY">Kenicer 2001</LINK>; <LINK REF="STD-Kovar-1992" TYPE="STUDY">Kovar 1992</LINK>; <LINK REF="STD-MacKie-Adult-1990" TYPE="STUDY">MacKie Adult 1990</LINK>; <LINK REF="STD-MacKie-Child-1990" TYPE="STUDY">MacKie Child 1990</LINK>; <LINK REF="STD-MacLeod-2001" TYPE="STUDY">MacLeod 2001</LINK>; <LINK REF="STD-Wishart-1992" TYPE="STUDY">Wishart 1992</LINK>); 1, 3 months (<LINK REF="STD-Bamford-1985" TYPE="STUDY">Bamford 1985</LINK>); and 1, 20 weeks (<LINK REF="STD-Senapati-2008" TYPE="STUDY">Senapati 2008</LINK>).</LI>
</UL>
<UL>
<LI>Only one study had a four-week no-treatment run (<LINK REF="STD-Kenicer-2001" TYPE="STUDY">Kenicer 2001</LINK>). Three studies had post-intervention assessment at eight weeks (<LINK REF="STD-Berth_x002d_Jones-1993" TYPE="STUDY">Berth-Jones 1993</LINK>; <LINK REF="STD-MacKie-Adult-1990" TYPE="STUDY">MacKie Adult 1990</LINK>; <LINK REF="STD-MacKie-Child-1990" TYPE="STUDY">MacKie Child 1990</LINK>; <LINK REF="STD-Wishart-1992" TYPE="STUDY">Wishart 1992</LINK>). One cross-over study had a four-week wash-out period before the second treatment started (<LINK REF="STD-Heddle-1990" TYPE="STUDY">Heddle 1990</LINK>).</LI>
</UL>
<UL>
<LI>The studies used several placebos: paraffin, sunflower, coconut, palm, olive, corn, glandol, and miglyol. Nine studies used olive oil (<LINK REF="STD-Biagi-1994" TYPE="STUDY">Biagi 1994</LINK>; <LINK REF="STD-Don-2003" TYPE="STUDY">Don 2003</LINK>; <LINK REF="STD-Fraser-2001" TYPE="STUDY">Fraser 2001</LINK>; <LINK REF="STD-Harper-1990" TYPE="STUDY">Harper 1990</LINK>; <LINK REF="STD-Heddle-1990" TYPE="STUDY">Heddle 1990</LINK>; <LINK REF="STD-Kenicer-2001" TYPE="STUDY">Kenicer 2001</LINK>; <LINK REF="STD-Kovar-1992" TYPE="STUDY">Kovar 1992</LINK>; <LINK REF="STD-MacKie-Adult-1990" TYPE="STUDY">MacKie Adult 1990</LINK>; <LINK REF="STD-MacKie-Child-1990" TYPE="STUDY">MacKie Child 1990</LINK>); nine, paraffin (<LINK REF="STD-Bamford-1985" TYPE="STUDY">Bamford 1985</LINK>; <LINK REF="STD-Berth_x002d_Jones-1993" TYPE="STUDY">Berth-Jones 1993</LINK>; <LINK REF="STD-France-1988" TYPE="STUDY">France 1988</LINK>; <LINK REF="STD-Lovell-1981" TYPE="STUDY">Lovell 1981</LINK>; <LINK REF="STD-MacLeod-2001" TYPE="STUDY">MacLeod 2001</LINK>; <LINK REF="STD-Schalin_x002d_Karrila-1987" TYPE="STUDY">Schalin-Karrila 1987</LINK>; <LINK REF="STD-Takwale-2003" TYPE="STUDY">Takwale 2003</LINK>; <LINK REF="STD-Valsecchi-2006" TYPE="STUDY">Valsecchi 2006</LINK>; <LINK REF="STD-Wright-1982" TYPE="STUDY">Wright 1982</LINK>); two, palm kernel oil (<LINK REF="STD-Bahmer-1992" TYPE="STUDY">Bahmer 1992</LINK>; <LINK REF="STD-Buslau-1996" TYPE="STUDY">Buslau 1996</LINK>); three, sunflower oil (<LINK REF="STD-Hederos-1996" TYPE="STUDY">Hederos 1996</LINK>; <LINK REF="STD-Senapati-2008" TYPE="STUDY">Senapati 2008</LINK>; <LINK REF="STD-Wishart-1992" TYPE="STUDY">Wishart 1992</LINK>); one, coconut oil (<LINK REF="STD-Finlay-2001" TYPE="STUDY">Finlay 2001</LINK>); one, glandol (<LINK REF="STD-Kiehl-1994" TYPE="STUDY">Kiehl 1994</LINK>); one, miglyol (<LINK REF="STD-Henz-1999" TYPE="STUDY">Henz 1999</LINK>); one, maisbuoil (corn oil) (<LINK REF="STD-Borrek-1997" TYPE="STUDY">Borrek 1997</LINK>); and one, paraffin for adults and olive oil for children (<LINK REF="STD-Takwale-2003" TYPE="STUDY">Takwale 2003</LINK>).</LI>
</UL>
<UL>
<LI>Two studies had a third arm using EPO or fish oil not considered here (<LINK REF="STD-Berth_x002d_Jones-1993" TYPE="STUDY">Berth-Jones 1993</LINK>; <LINK REF="STD-MacLeod-2001" TYPE="STUDY">MacLeod 2001</LINK>).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes reported in the studies</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Major or primary outcomes</HEADING>
<P>Evening primrose oil</P>
<UL>
<LI>Participant-reported global improvement in 10 studies</LI>
<LI>Physician-reported global improvement in 14 studies</LI>
<LI>Only two studies used quality of life measures (<LINK REF="STD-Don-2003" TYPE="STUDY">Don 2003</LINK>; <LINK REF="STD-Finlay-2001" TYPE="STUDY">Finlay 2001</LINK>)</LI>
</UL>
<P>Borage oil</P>
<UL>
<LI>Participant-reported global improvement in two studies</LI>
<LI>Physician-reported global improvement in five studies</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Minor or secondary outcomes</HEADING>
<UL>
<LI>There was only one report involving severe allergic reaction to penicillin, causing the subject on EPO to withdraw from the study (<LINK REF="STD-MacKie-Adult-1990" TYPE="STUDY">MacKie Adult 1990</LINK>).</LI>
<LI>Four studies reported adverse effects.</LI>
<LI>Nine studies described adverse effects as minor side-effects: "none noted", "too few to evaluate statistically", or "not stated".</LI>
<LI>Eighteen cases mentioned minor side-effects. In these studies, there was a range of minor adverse effects: 17% (<LINK REF="STD-Hederos-1996" TYPE="STUDY">Hederos 1996</LINK>) to 50% (<LINK REF="STD-Finlay-2001" TYPE="STUDY">Finlay 2001</LINK>). Minor gastrointestinal symptoms (nausea, vomiting, diarrhoea, colic) were the most common (<LINK REF="STD-Bamford-1985" TYPE="STUDY">Bamford 1985</LINK>; <LINK REF="STD-Finlay-2001" TYPE="STUDY">Finlay 2001</LINK>; <LINK REF="STD-France-1988" TYPE="STUDY">France 1988</LINK>; <LINK REF="STD-Fraser-2001" TYPE="STUDY">Fraser 2001</LINK>; <LINK REF="STD-Hederos-1996" TYPE="STUDY">Hederos 1996</LINK>; <LINK REF="STD-Henz-1999" TYPE="STUDY">Henz 1999</LINK>; <LINK REF="STD-Kenicer-2001" TYPE="STUDY">Kenicer 2001</LINK>; <LINK REF="STD-Takwale-2003" TYPE="STUDY">Takwale 2003</LINK>; <LINK REF="STD-Valsecchi-2006" TYPE="STUDY">Valsecchi 2006</LINK>). Headache was equal in active and placebo groups in one study (<LINK REF="STD-Henz-1999" TYPE="STUDY">Henz 1999</LINK>).</LI>
<LI>No study mentioned protein deficiency versus no protein deficiency.</LI>
<LI>The trials used global measures of change more commonly than SCORAD (SCORing Atopic Dermatitis) (<LINK REF="REF-SCORAD-index-1993" TYPE="REFERENCE">SCORAD index 1993</LINK>), Atopic Dermatitis Area and Severity Index (ADASI) (<LINK REF="REF-Bahmer-1991" TYPE="REFERENCE">Bahmer 1991</LINK>), or <LINK REF="REF-Costa-1989" TYPE="REFERENCE">Costa 1989</LINK>'s scoring methods.</LI>
</UL>
<P>With regard to adverse effects, in our search of four databases mentioned, we found headaches and minor gastrointestinal adverse effects, including abdominal pain, nausea, increased bowel movement, and diarrhoea, had been attributed to oral EPO. Most adverse effects have been mild gastrointestinal symptoms/signs (<LINK REF="REF-Bayles-2009" TYPE="REFERENCE">Bayles 2009</LINK>).</P>
<P>With regard to subgroup analysis, firstly, we could not perform subgroup analysis with respect to whether placebos had vitamin E or not because there was only one study included in the second meta-analysis with vitamin E in the placebo. Secondly, with respect to infected versus non-infected eczema, most of the studies did not report the information. Thirdly, most studies also did not report information regarding IgE-associated eczema.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2013-03-23 01:42:11 +0000" MODIFIED_BY="[Empty name]">
<P>We excluded eight studies: <LINK REF="STD-Melnick-1995" TYPE="STUDY">Melnick 1995</LINK> did not have a placebo group; <LINK REF="STD-Biagi-1988" TYPE="STUDY">Biagi 1988</LINK> was an open study; <LINK REF="STD-Courage-1991" TYPE="STUDY">Courage 1991</LINK> and <LINK REF="STD-Coskery-1988" TYPE="STUDY">Coskery 1988</LINK> were found to be non-randomised, as was the study <LINK REF="STD-NCT00878670" TYPE="STUDY">NCT00878670</LINK>, which was initially listed as an RCT on the <A HREF="http://www.clinicaltrials.gov/">www.clinicaltrials.gov</A> website (the lead author then confirmed it was not an RCT). In the study by <LINK REF="STD-Swapan-2008" TYPE="STUDY">Swapan 2008</LINK>, even though randomisation was stated, we found that consecutive participant allocation had been carried out. The results of one study (<LINK REF="STD-Guenther-1987" TYPE="STUDY">Guenther 1987</LINK>) were not available, as correspondence with the trial investigator confirmed that the study results had been destroyed. For the study <LINK REF="STD-Bordoni-1988" TYPE="STUDY">Bordoni 1988</LINK>, we received no reply to queries addressed to the lead author.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2013-04-02 01:09:37 +0100" MODIFIED_BY="[Empty name]">
<P>We provide summaries of the risk of bias across the included studies in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>, <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>, and the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' tables.</P>
<SUBSECTION>
<HEADING LEVEL="3">Sequence Generation (selection bias)</HEADING>
<P>We judged bias related to randomisation to be low in two thirds (18) of the studies (<LINK REF="STD-Bamford-1985" TYPE="STUDY">Bamford 1985</LINK>; <LINK REF="STD-Berth_x002d_Jones-1993" TYPE="STUDY">Berth-Jones 1993</LINK>; <LINK REF="STD-Borrek-1997" TYPE="STUDY">Borrek 1997</LINK>; <LINK REF="STD-Don-2003" TYPE="STUDY">Don 2003</LINK>; <LINK REF="STD-Finlay-2001" TYPE="STUDY">Finlay 2001</LINK>; <LINK REF="STD-France-1988" TYPE="STUDY">France 1988</LINK>; <LINK REF="STD-Harper-1990" TYPE="STUDY">Harper 1990</LINK>; <LINK REF="STD-Hederos-1996" TYPE="STUDY">Hederos 1996</LINK>; <LINK REF="STD-Kenicer-2001" TYPE="STUDY">Kenicer 2001</LINK>; <LINK REF="STD-Kovar-1992" TYPE="STUDY">Kovar 1992</LINK>; <LINK REF="STD-Lovell-1981" TYPE="STUDY">Lovell 1981</LINK>; <LINK REF="STD-MacKie-Adult-1990" TYPE="STUDY">MacKie Adult 1990</LINK>; <LINK REF="STD-MacKie-Child-1990" TYPE="STUDY">MacKie Child 1990</LINK>; <LINK REF="STD-MacLeod-2001" TYPE="STUDY">MacLeod 2001</LINK>; <LINK REF="STD-Senapati-2008" TYPE="STUDY">Senapati 2008</LINK>; <LINK REF="STD-Takwale-2003" TYPE="STUDY">Takwale 2003</LINK>; <LINK REF="STD-Wishart-1992" TYPE="STUDY">Wishart 1992</LINK>; <LINK REF="STD-Wright-1982" TYPE="STUDY">Wright 1982</LINK>). Randomisation methods included computer-generated methods (<LINK REF="STD-Bamford-1985" TYPE="STUDY">Bamford 1985</LINK>; <LINK REF="STD-Berth_x002d_Jones-1993" TYPE="STUDY">Berth-Jones 1993</LINK>; <LINK REF="STD-Don-2003" TYPE="STUDY">Don 2003</LINK>; <LINK REF="STD-Finlay-2001" TYPE="STUDY">Finlay 2001</LINK>; <LINK REF="STD-France-1988" TYPE="STUDY">France 1988</LINK>; <LINK REF="STD-Harper-1990" TYPE="STUDY">Harper 1990</LINK>; <LINK REF="STD-Hederos-1996" TYPE="STUDY">Hederos 1996</LINK>; <LINK REF="STD-Kenicer-2001" TYPE="STUDY">Kenicer 2001</LINK>; <LINK REF="STD-Lovell-1981" TYPE="STUDY">Lovell 1981</LINK>; <LINK REF="STD-MacKie-Adult-1990" TYPE="STUDY">MacKie Adult 1990</LINK>; <LINK REF="STD-MacKie-Child-1990" TYPE="STUDY">MacKie Child 1990</LINK>; <LINK REF="STD-MacLeod-2001" TYPE="STUDY">MacLeod 2001</LINK>; <LINK REF="STD-Senapati-2008" TYPE="STUDY">Senapati 2008</LINK>; <LINK REF="STD-Takwale-2003" TYPE="STUDY">Takwale 2003</LINK>; <LINK REF="STD-Wishart-1992" TYPE="STUDY">Wishart 1992</LINK>; <LINK REF="STD-Wright-1982" TYPE="STUDY">Wright 1982</LINK>). We assumed the block randomisation by draw was computer-generated (<LINK REF="STD-Borrek-1997" TYPE="STUDY">Borrek 1997</LINK>).</P>
<P>The remaining studies were unclear. No study had inadequate methods of randomisation leading to high risk of bias.</P>
</SUBSECTION>
<ALLOCATION MODIFIED="2013-04-02 01:08:55 +0100" MODIFIED_BY="Finola M Delamere">
<P>We judged less than half of the studies (12) to have reported or carried out adequate allocation concealment. Only <LINK REF="STD-Bamford-1985" TYPE="STUDY">Bamford 1985</LINK>; <LINK REF="STD-Don-2003" TYPE="STUDY">Don 2003</LINK>; <LINK REF="STD-Finlay-2001" TYPE="STUDY">Finlay 2001</LINK>; <LINK REF="STD-France-1988" TYPE="STUDY">France 1988</LINK>; <LINK REF="STD-Harper-1990" TYPE="STUDY">Harper 1990</LINK>; <LINK REF="STD-Kenicer-2001" TYPE="STUDY">Kenicer 2001</LINK>; <LINK REF="STD-Kovar-1992" TYPE="STUDY">Kovar 1992</LINK>; <LINK REF="STD-MacKie-Adult-1990" TYPE="STUDY">MacKie Adult 1990</LINK>; <LINK REF="STD-MacKie-Child-1990" TYPE="STUDY">MacKie Child 1990</LINK>; <LINK REF="STD-MacLeod-2001" TYPE="STUDY">MacLeod 2001</LINK>; <LINK REF="STD-Takwale-2003" TYPE="STUDY">Takwale 2003</LINK>; and <LINK REF="STD-Wishart-1992" TYPE="STUDY">Wishart 1992</LINK> concealed the allocation sequence, and we judged them at low risk of bias. In the remaining studies, the method of allocation concealment was unclear in 12 studies and at high risk in the remaining 3 studies.</P>
<P>With <LINK REF="STD-Harper-1990" TYPE="STUDY">Harper 1990</LINK>, although we recorded "listing of randomization schedule and code is not available", we felt the other details (blinding, ITT analysis, randomisation) were enough to deem it as low bias for randomisation and concealment.</P>
</ALLOCATION>
<BLINDING MODIFIED="2013-03-18 17:37:25 +0000" MODIFIED_BY="Finola M Delamere">
<P>Adequate blinding of practitioners and participants was present in 60% (16/27) of studies. We noted possible bias due to failure to blind or inadequate reporting of blinding (both participant and personnel, including outcome assessors) in 33% (9/27) of the included studies, which we judged as 'unclear' (<LINK REF="STD-Berth_x002d_Jones-1993" TYPE="STUDY">Berth-Jones 1993</LINK>; <LINK REF="STD-Buslau-1996" TYPE="STUDY">Buslau 1996</LINK>; <LINK REF="STD-Don-2003" TYPE="STUDY">Don 2003</LINK>; <LINK REF="STD-Fraser-2001" TYPE="STUDY">Fraser 2001</LINK>; <LINK REF="STD-Heddle-1990" TYPE="STUDY">Heddle 1990</LINK>; <LINK REF="STD-Henz-1999" TYPE="STUDY">Henz 1999</LINK>; <LINK REF="STD-Schalin_x002d_Karrila-1987" TYPE="STUDY">Schalin-Karrila 1987</LINK>; <LINK REF="STD-Senapati-2008" TYPE="STUDY">Senapati 2008</LINK>; <LINK REF="STD-Takwale-2003" TYPE="STUDY">Takwale 2003</LINK>). Masking of personnel and participants were not separated in <LINK REF="STD-Kenicer-2001" TYPE="STUDY">Kenicer 2001</LINK> and <LINK REF="STD-Valsecchi-2006" TYPE="STUDY">Valsecchi 2006</LINK>, and we judged them to be at high risk of bias; the latter was not blinded.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2013-04-02 01:09:37 +0100" MODIFIED_BY="Finola M Delamere">
<P>We evaluated the majority of studies (20) as having a low risk of attrition bias, and we judged 2 studies, <LINK REF="STD-MacLeod-2001" TYPE="STUDY">MacLeod 2001</LINK> and <LINK REF="STD-Buslau-1996" TYPE="STUDY">Buslau 1996</LINK>, to be at high risk of bias as a large proportion of the participants dropped out, and this was not balanced between the groups. With regard to dealing with missing data, we judged five studies as unclear. We stated where no details could be obtained, so judged these studies as 'unclear' in terms of risk of bias.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2013-03-18 18:00:39 +0000" MODIFIED_BY="Finola M Delamere">
<P>Nine studies did not provide enough information to determine if the prespecified outcomes had been adequately reported; therefore, we judged these to be at an unclear risk of bias (<LINK REF="STD-France-1988" TYPE="STUDY">France 1988</LINK>; <LINK REF="STD-Henz-1999" TYPE="STUDY">Henz 1999</LINK>; <LINK REF="STD-Kiehl-1994" TYPE="STUDY">Kiehl 1994</LINK>; <LINK REF="STD-Kovar-1992" TYPE="STUDY">Kovar 1992</LINK>; <LINK REF="STD-Lovell-1981" TYPE="STUDY">Lovell 1981</LINK>; <LINK REF="STD-MacLeod-2001" TYPE="STUDY">MacLeod 2001</LINK>; <LINK REF="STD-Takwale-2003" TYPE="STUDY">Takwale 2003</LINK>; <LINK REF="STD-Wishart-1992" TYPE="STUDY">Wishart 1992</LINK>; <LINK REF="STD-Wright-1982" TYPE="STUDY">Wright 1982</LINK>). Reporting of outcomes was adequate in the remaining 18 studies.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2013-03-22 16:40:41 +0000" MODIFIED_BY="Finola M Delamere">
<P>Bias associated with other causes was rated as high in 10 studies (8 of which were unpublished, house studies), unclear in 7 studies, and low in 10 studies. The study <LINK REF="STD-Kenicer-2001" TYPE="STUDY">Kenicer 2001</LINK> had participants who did not meet their criteria, and the statistical methods were made after all the data were revealed (and used in published meta-analysis), so we classed this domain as at 'high risk of bias'.</P>
<P>We noted sources of medication and funding as possible other sources of potential bias, but the following information has not been used to make judgements about the risk of bias.</P>
<UL>
<LI>All of the studies (19) that mentioned a source for medication (<LINK REF="STD-Bamford-1985" TYPE="STUDY">Bamford 1985</LINK>; <LINK REF="STD-Berth_x002d_Jones-1993" TYPE="STUDY">Berth-Jones 1993</LINK>; <LINK REF="STD-Finlay-2001" TYPE="STUDY">Finlay 2001</LINK>; <LINK REF="STD-France-1988" TYPE="STUDY">France 1988</LINK>; <LINK REF="STD-Fraser-2001" TYPE="STUDY">Fraser 2001</LINK>; <LINK REF="STD-Harper-1990" TYPE="STUDY">Harper 1990</LINK>; <LINK REF="STD-Heddle-1990" TYPE="STUDY">Heddle 1990</LINK>; <LINK REF="STD-Hederos-1996" TYPE="STUDY">Hederos 1996</LINK>; <LINK REF="STD-Henz-1999" TYPE="STUDY">Henz 1999</LINK>; <LINK REF="STD-Kenicer-2001" TYPE="STUDY">Kenicer 2001</LINK>; <LINK REF="STD-Kiehl-1994" TYPE="STUDY">Kiehl 1994</LINK>; <LINK REF="STD-Kovar-1992" TYPE="STUDY">Kovar 1992</LINK>; <LINK REF="STD-Lovell-1981" TYPE="STUDY">Lovell 1981</LINK>; <LINK REF="STD-MacKie-Adult-1990" TYPE="STUDY">MacKie Adult 1990</LINK>; <LINK REF="STD-MacKie-Child-1990" TYPE="STUDY">MacKie Child 1990</LINK>; <LINK REF="STD-MacLeod-2001" TYPE="STUDY">MacLeod 2001</LINK>; <LINK REF="STD-Takwale-2003" TYPE="STUDY">Takwale 2003</LINK>) listed a drug company as having provided these.</LI>
</UL>
<UL>
<LI>Of 20 studies that mentioned funding, 18 (<LINK REF="STD-Berth_x002d_Jones-1993" TYPE="STUDY">Berth-Jones 1993</LINK>; <LINK REF="STD-Finlay-2001" TYPE="STUDY">Finlay 2001</LINK>; <LINK REF="STD-France-1988" TYPE="STUDY">France 1988</LINK>; <LINK REF="STD-Fraser-2001" TYPE="STUDY">Fraser 2001</LINK>; <LINK REF="STD-Harper-1990" TYPE="STUDY">Harper 1990</LINK>; <LINK REF="STD-Heddle-1990" TYPE="STUDY">Heddle 1990</LINK>; <LINK REF="STD-Hederos-1996" TYPE="STUDY">Hederos 1996</LINK>; <LINK REF="STD-Henz-1999" TYPE="STUDY">Henz 1999</LINK>; <LINK REF="STD-Kenicer-2001" TYPE="STUDY">Kenicer 2001</LINK>; <LINK REF="STD-Kiehl-1994" TYPE="STUDY">Kiehl 1994</LINK>; <LINK REF="STD-Kovar-1992" TYPE="STUDY">Kovar 1992</LINK>; <LINK REF="STD-Lovell-1981" TYPE="STUDY">Lovell 1981</LINK>; <LINK REF="STD-MacKie-Adult-1990" TYPE="STUDY">MacKie Adult 1990</LINK>; <LINK REF="STD-MacKie-Child-1990" TYPE="STUDY">MacKie Child 1990</LINK>; <LINK REF="STD-MacLeod-2001" TYPE="STUDY">MacLeod 2001</LINK>; <LINK REF="STD-Takwale-2003" TYPE="STUDY">Takwale 2003</LINK>; <LINK REF="STD-Wishart-1992" TYPE="STUDY">Wishart 1992</LINK>; <LINK REF="STD-Wright-1982" TYPE="STUDY">Wright 1982</LINK>) listed a drug company, and 2 listed non-profit foundations (<LINK REF="STD-Bamford-1985" TYPE="STUDY">Bamford 1985</LINK>; <LINK REF="STD-Schalin_x002d_Karrila-1987" TYPE="STUDY">Schalin-Karrila 1987</LINK>).</LI>
</UL>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2013-04-02 01:27:46 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Comparison 1: EPO versus placebo</HEADING>
<P>A total of 19 studies investigated the effect of EPO versus placebo for the treatment of eczema, of which 11 were unpublished house studies, and 8 were published studies. The house studies reported results both before and after trimming. The study reports describe trimming as a statistical method of removing participants with extreme baseline values from analysis. We used only untrimmed results (before trimming) in the analysis of this review.</P>
<P>All of the 11 house studies reported results for the analysis using models A, B, and C:</P>
<UL>
<LI>model A compared final values without adjustment for baseline values;</LI>
<LI>model B used change from baseline values (adjusted for baseline); and</LI>
<LI>model C used change from baseline values but not adjusted for baseline.</LI>
</UL>
<P>We used only results from model B in the analyses in this review, because they were the best statistically unbiased results among the three models. The results reported and therefore used in this review are the least squares means. The treatment duration for most of the house studies was 24 weeks, although some studies had a treatment duration of 16 or 20 weeks. For meta-analysis, we used results comparing week 16 and baseline. We chose week 16 because for most studies there would be very few participants left in the study by week 24 due to attrition. Where standard errors (SEs) were given, we calculated the corresponding standard deviations (SDs) by multiplying SEs with the square root of the corresponding sample sizes. Since the primary outcome was change from baseline, the fact that the mean is less than SD does not imply skewed data. Most of the results for the house studies were obtained from additional tables in the reports.</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">(a) Global degree of improvement in symptoms and signs as rated by participant or medical doctor</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">(i) Participant-reported</HEADING>
<P>Ten studies reported results for overall improvement in symptoms as rated by the participants. All of these were house studies. Nine studies reported using the VAS (0 to 100) scores. Seven of these house studies reported the participants' assessment of overall impression as reduction or improvement of VAS scores in terms of means (SE), and their results were pooled in a meta-analysis that showed that treatment with EPO failed to significantly improve eczema symptoms compared to placebo treatment, as measured by participants (MD -2.22, 95% CI -10.48 to 6.04, 176 participants, 7 studies, <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>, <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>). However, we detected statistically significant heterogeneity between the studies (Chi² statistic = 12.08, df = 6, P = 0.06, I² statistic = 50%, <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P>
<P>An inspection of the forest plot reveals that confidence intervals from six studies were overlapping, but there was one outlying study (<LINK REF="STD-MacKie-Child-1990" TYPE="STUDY">MacKie Child 1990</LINK>). While the results for the six studies showed non-statistically significant difference, the results from <LINK REF="STD-MacKie-Child-1990" TYPE="STUDY">MacKie Child 1990</LINK> showed statistically significant differences in favour of placebo. A sensitivity analysis through excluding this outlying study yielded statistically non-significant heterogeneity (I² statistic = 0%). This may indicate that this study is the source of heterogeneity. We also noted that exclusion of the study did not change the conclusion regarding the treatment effect. Subgroup analysis with respect to children only versus other (adults or adults and children) showed no significant subgroup differences (Chi² = 0.81, df = 1, P = 0.37, I² statistic = 0%, <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). Although significant heterogeneity was evident between the 2 children-only studies in the first subgroup (Chi² = 3.95, df = 1, P = 0.05, I² statistic = 75%, <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>), there was no significant heterogeneity detected in the second subgroup (Chi² = 4.35, df = 4, P = 0.36, I² statistic = 8%, <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). This supports the conclusion above that the significant heterogeneity observed in this meta-analysis is due to the one outlying study (<LINK REF="STD-MacKie-Child-1990" TYPE="STUDY">MacKie Child 1990</LINK>) that investigated children only. Also, we observed no significant difference in symptoms between the EPO and placebo groups in both subgroups.</P>
<P>One study (<LINK REF="STD-Hederos-1996" TYPE="STUDY">Hederos 1996</LINK>) reported the parents' global assessment of eczema (VAS 0 to 100) at the end of treatment as mean difference (MD) with corresponding 95% confidence interval. We used the confidence interval to calculate the standard error (SE), then we used the MD and SE in calculating a treatment effect through the generic inverse-variance method in RevMan 5. Treatment with EPO failed to significantly reduce the symptoms of eczema at the end of treatment as compared to placebo treatment (MD 2.90, 95% CI -8.80 to 14.60, 60 participants, 1 study, <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P>
<P>One house study (<LINK REF="STD-Kovar-1992" TYPE="STUDY">Kovar 1992</LINK>) reported parents' global assessment of eczema (VAS 0 to 100) at the end of treatment. We used data at 8 weeks, because all children were given the active treatment from 8 weeks to 16 weeks. The calculated treatment effect showed that treatment with EPO failed to significantly reduce eczema symptoms in children compared to the placebo treatment as assessed by the children's parents (MD -0.80, 95% CI -17.76 to 16.16, 32 participants, 1 study, <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P>
<P>
<LINK REF="STD-Bamford-1985" TYPE="STUDY">Bamford 1985</LINK> also reported the overall severity of eczema as assessed by participants. However, they reported the results for all the participants irrespective of their treatment groups. Therefore, we could not calculate a treatment effect, and attempts to obtain the individual participant data were unsuccessful. The statistician of the study informed us that the original data had been destroyed. Although some results were presented in the form of some figures, it was not possible to accurately extract data from them since the figures were presented separately by age and dose and also because standard deviations of change were not graphed.</P>
<P>
<LINK REF="STD-Wright-1982" TYPE="STUDY">Wright 1982</LINK> reported the overall improvement in eczema symptoms as assessed by the participants but reported the results in the form of a figure from which values of means (SD) could not be accurately extracted for the calculation of a treatment effect.</P>
<P>
<LINK REF="STD-Lovell-1981" TYPE="STUDY">Lovell 1981</LINK> reported the overall participants' assessment of eczema using a clinical grading scale (0 = no eczema, 10 = most severe), but the results were only given as MD of 0.52. Since the SE was not reported, we could not calculate a treatment effect.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">(ii) Physician-reported</HEADING>
<P>Fourteen studies reported results for the overall improvement in symptoms as rated by the physician or doctor. Ten of these were house studies. Eight house studies reported the physicians' assessment of overall impression as reduction or improvement of 0 to 100 VAS scores in terms of means (SE) and were pooled in a meta-analysis, which showed that treatment with EPO failed to significantly reduce the physician-reported eczema symptoms compared to placebo treatment (MD -3.26, 95% CI -6.96 to 0.45, 289 participants, 8 studies, <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>, <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>). There was no statistically significant heterogeneity detected between the studies (Chi² statistic = 4.45, df = 7, P = 0.73, I² statistic = 0%, <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). Subgroup analysis with respect to children only versus other (adult or adult and children) showed no significant subgroup differences (Chi² statistic = 0.01, df = 1, P = 0.91, I² statistic = 0%, <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>), and there were no significant differences in symptoms between the EPO and placebo groups in both subgroups.</P>
<P>One study (<LINK REF="STD-Hederos-1996" TYPE="STUDY">Hederos 1996</LINK>) reported the physician's global assessment of eczema (VAS 0 to 100) at the end of treatment as mean difference (MD) with corresponding 95% confidence interval. We used the confidence interval to calculate the standard error (SE), then we used the MD and SE in calculating a treatment effect through the generic inverse-variance method in RevMan 5. Treatment with EPO failed to significantly reduce the physicians' reported symptoms of eczema at the end of treatment as compared to placebo treatment (MD -2.80, 95% CI -14.50 to 8.90, 60 participants, 1 study, <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>).</P>
<P>One house cross-over study (<LINK REF="STD-Heddle-1990" TYPE="STUDY">Heddle 1990</LINK>) reported the overall physician assessment of change or improvement in VAS (0 to 50) as means (SD). We only extracted first-period data as we suspected a carry-over effect. The treatment effect calculated from these first-period data showed that treatment with EPO failed to significantly reduce the physician-reported eczema symptoms compared to placebo treatment (MD -0.43, 95% CI -1.65 to 0.79, 25 participants, 1 study, <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>).</P>
<P>One study (<LINK REF="STD-Biagi-1994" TYPE="STUDY">Biagi 1994</LINK>) reported the physician assessment of overall severity of eczema using a simplified rating scale from 0 to 3 (0 = absent, 1 = slight, 2 = moderate, 3 = severe). The results at the end of treatment were reported as means (SD) for the three treatment arms (low-dose EPO, high-dose EPO, and placebo). We calculated treatment effects separately for high-dose EPO versus placebo and for low-dose EPO versus placebo. The calculated treatment effect supports a statistically significant improvement of symptoms in favour of 'high dose' EPO compared to placebo (MD -0.56, 95% CI -1.09 to -0.03, 32 participants, 1 study, <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>), but there were no significant differences between the 'low dose' EPO versus placebo (MD -0.51, 95% CI -1.05 to 0.03, 32 participants, 1 study, <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>).</P>
<P>One study (<LINK REF="STD-Senapati-2008" TYPE="STUDY">Senapati 2008</LINK>) reported the overall physician assessment at the end of treatment using some total disease intensity scores (extent, intensity, itching, dryness), where lower values indicate less symptoms. The treatment effect from this study showed a statistically significant improvement in eczema symptoms in favour of EPO as compared to placebo treatment (MD -3.52, 95% CI -4.42 to -2.62, 50 participants, 1 study, <LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>).</P>
<P>One study (<LINK REF="STD-Berth_x002d_Jones-1993" TYPE="STUDY">Berth-Jones 1993</LINK>) reported improvement in the overall clinical severity score as measured by Leicester scores using three treatment arms (placebo, EPO, and EPO + fish oil). We used results for EPO versus placebo groups and excluded results for the other treatment EPO-fish oil arm. The calculated treatment effect showed that treatment with EPO failed to significantly reduce the physician-reported eczema symptoms compared to placebo treatment (MD 1.33, 95% CI -6.61 to 9.72, 67 participants, 1 study, <LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>).</P>
<P>
<LINK REF="STD-Schalin_x002d_Karrila-1987" TYPE="STUDY">Schalin-Karrila 1987</LINK> reported the overall severity of symptoms (0 = no symptoms and 100 = worst possible) at the end of treatment (12 weeks) in the form of a figure from which values of means (SE) were extracted. The SDs were calculated from the SEs and totals. The calculated treatment effect showed that treatment with EPO failed to significantly reduce the physician-reported eczema symptoms compared to placebo treatment (MD 1.30, 95% CI -13.64 to 16.24, 25 participants, 1 study, <LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>).</P>
<P>
<LINK REF="STD-Bamford-1985" TYPE="STUDY">Bamford 1985</LINK> also reported the overall severity of eczema as assessed by physicians. However, they reported the results for all the participants irrespective of their treatment groups. Therefore, we could not calculate any treatment effect, and attempts to obtain the individual participant data were unsuccessful. Although some results were presented in the form of some figures, it was not possible to accurately extract data from them since they presented figures separately by age and dose and also because they did not graph standard deviations of change.</P>
<P>
<LINK REF="STD-Wright-1982" TYPE="STUDY">Wright 1982</LINK> reported the overall improvement in eczema symptoms as assessed by doctors, but reported the results in the form of a figure, from which values of means (SD) could not be accurately extracted for the calculation of a treatment effect.</P>
<P>
<LINK REF="STD-Lovell-1981" TYPE="STUDY">Lovell 1981</LINK> reported the overall physicians' assessment of eczema using a clinical grading scale (0 = no eczema; 10 = most severe), but the results were only given as MD of 0.37. Since the report trial did not report the SE, we could not calculate a treatment effect.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">(b) Improvement in quality of life</HEADING>
<P>Only one house study (<LINK REF="STD-Finlay-2001" TYPE="STUDY">Finlay 2001</LINK>) reported the Dermatology Life Quality Index (DLQI). The calculated treatment effect showed that treatment with EPO failed to significantly improve quality of life compared to placebo treatment (MD 0.08, 95% CI -1.26 to 1.42, 36 participants, 1 study, <LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes  </HEADING>
<SUBSECTION>
<HEADING LEVEL="5">(a) Adverse events</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">(i) Severe adverse events (caused by EPO) requiring withdrawal from the trial, including severe skin irritation</HEADING>
<P>Only two house studies (<LINK REF="STD-Finlay-2001" TYPE="STUDY">Finlay 2001</LINK> and <LINK REF="STD-France-1988" TYPE="STUDY">France 1988</LINK>) reported this outcome. From both studies, there were too few adverse events to warrant any formal statistical analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">(ii) Minor participant-reported adverse events, including gastrointestinal irritation not sufficient to require cessation of treatment</HEADING>
<P>Four studies reported the number with adverse events without specifying the actual adverse events. We pooled these in a meta-analysis, and there was no difference in the proportion of participants experiencing adverse events between the EPO- and placebo-treated groups (RR 0.97, 95% CI 0.71 to 1.33, 264 participants, 4 studies, <LINK REF="CMP-001.13" TYPE="ANALYSIS">Analysis 1.13</LINK>). We did not detect any statistically significant heterogeneity between the studies (Chi² statistic = 1.97, df = 3, P = 0.58, I² statistic = 0%, <LINK REF="CMP-001.13" TYPE="ANALYSIS">Analysis 1.13</LINK>).</P>
<P>Three house studies reported minor signs or symptoms as an adverse event. There was no statistically significant difference in the proportion of participants with minor signs or symptoms between the EPO- and placebo-treated groups (RR 1.00, 95% CI 0.64 to 1.57, 172 participants, 3 studies, <LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>). We did not detect any statistically significant heterogeneity between the studies (Chi² statistic = 0.85, df = 2, P = 0.66, I² statistic = 0%, <LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>).</P>
<P>There were other minor adverse events reported by other studies, including headache, infection, diarrhoea, nausea and bloating, and hyperactivity, but their frequencies were too small to warrant any formal statistical analysis. Other studies either reported that there were no adverse events observed or did not report any information regarding adverse events.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">(b) Systemic or topical treatments taken concurrently with EPO or BO</HEADING>
<P>Only two studies reported this outcome. <LINK REF="STD-Hederos-1996" TYPE="STUDY">Hederos 1996</LINK> reported steroid usage classified into four categories of the most potent class of steroids used, and we could not calculate a treatment effect. <LINK REF="STD-Senapati-2008" TYPE="STUDY">Senapati 2008</LINK> reported the amount (in kg) of emollient cream and topical steroid consumed during the 12-week period of treatment. We calculated treatment effects for these 2 outcomes, and there was no significant difference in mean amount of emollient cream (MD -0.02, 95% CI -0.42 to 0.38, 24 participants, 1 study, <LINK REF="CMP-001.15" TYPE="ANALYSIS">Analysis 1.15</LINK>) used between the 2 groups, but there was significantly more topical steroid used by participants in the placebo group compared to the EPO group (MD -0.14, 95% CI -0.26 to -0.02, 24 participants, 1 study, <LINK REF="CMP-001.16" TYPE="ANALYSIS">Analysis 1.16</LINK>).</P>
<P>
<LINK REF="STD-Berth_x002d_Jones-1993" TYPE="STUDY">Berth-Jones 1993</LINK> reported topical steroid requirement for all the participants, irrespective of their treatment groups; therefore, we could not calculate a treatment effect.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 2: borage oil versus placebo</HEADING>
<P>A total of eight studies investigated the effect of BO versus placebo for the treatment of eczema.</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">(a) Global degree of improvement in symptoms and signs as rated by participant or medical doctor</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">(i) Participant-reported</HEADING>
<P>Only two studies reported overall improvement in symptoms by participants. <LINK REF="STD-Bahmer-1992" TYPE="STUDY">Bahmer 1992</LINK> reported the number with improvement in severity of skin changes. The calculated treatment effect showed that treatment with BO failed to significantly reduce the participant-reported eczema symptoms compared to placebo treatment (RR 3.57, 95% CI 0.58 to 21.92, 12 participants, 1 study, <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>). The confidence interval is wide because of the very small sample sizes and number of events. <LINK REF="STD-Borrek-1997" TYPE="STUDY">Borrek 1997</LINK> reported the participants' subjective complaints at the end of treatment in terms of means (SD). Again, a calculated treatment effect showed that treatment with BO failed to significantly reduce the participant-reported eczema symptoms compared to placebo treatment (MD 0.10, 95% CI -1.57 to 1.77, 22 participants, 1 study, <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">(ii) Physician-reported</HEADING>
<P>Five studies reported this outcome, but in different ways. <LINK REF="STD-Borrek-1997" TYPE="STUDY">Borrek 1997</LINK> reported the overall physician assessment using Costa (<LINK REF="REF-Costa-1989" TYPE="REFERENCE">Costa 1989</LINK>) scores at the end of treatment in terms of means (SD), from which we calculated a treatment effect. Borage oil failed to significantly reduce the physician-reported eczema symptoms compared to placebo treatment (MD -1.00, 95% CI -13.18 to 11.18, 22 participants, 1 study, <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>).</P>
<P>
<LINK REF="STD-Buslau-1996" TYPE="STUDY">Buslau 1996</LINK> reported the number showing significant improvement in the Atopic Dermatitis Area and Severity Index (ADASI score) as assessed by a physician at the end of treatment. A calculated treatment effect showed that treatment with BO failed to significantly reduce the physician-reported eczema symptoms compared to placebo treatment (RR 1.81, 95% CI 0.94 to 3.49, 32 participants, 1 study, <LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>).</P>
<P>
<LINK REF="STD-Don-2003" TYPE="STUDY">Don 2003</LINK> reported the assessment by physicians of clinical severity of eczema using the SCORAD index at the end of treatment. A calculated treatment effect showed that treatment with BO failed to significantly reduce the physician-reported eczema symptoms compared to placebo treatment (MD 4.53, 95% CI -10.34 to 19.40, 18 participants, 1 study, <LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>).</P>
<P>
<LINK REF="STD-Takwale-2003" TYPE="STUDY">Takwale 2003</LINK> reported the assessment by physicians of severity of eczema using the overall Six Area, Six Sign Atopic Dermatitis severity score (SASSAD score). Again, a calculated treatment effect showed that treatment with BO failed to significantly reduce the physician-reported eczema symptoms compared to placebo treatment (MD 4.00, 95% CI -1.56 to 9.56, 140 participants, 1 study, <LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>).</P>
<P>
<LINK REF="STD-Valsecchi-2006" TYPE="STUDY">Valsecchi 2006</LINK> reported the clinical score improvement in eczema symptoms from baseline. A calculated treatment effect showed that treatment with BO failed to significantly reduce the physician-reported eczema symptoms compared to placebo treatment (MD 22.31, 95% CI -8.97 to 53.59, 28 participants, 1 study, <LINK REF="CMP-002.07" TYPE="ANALYSIS">Analysis 2.7</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">(b) Improvement in quality of life</HEADING>
<P>Only one study (<LINK REF="STD-Don-2003" TYPE="STUDY">Don 2003</LINK>) reported the quality of life at the end of treatment using a four-point scale (four = calm, three = slightly distressed, two = moderately distressed, one = very distressed). The mean scores were 3.44 and 3.55 for the BO and placebo groups, respectively. Since the study did not provide the corresponding standard deviations, we could not calculate a treatment effect.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes  </HEADING>
<SUBSECTION>
<HEADING LEVEL="5">(a) Adverse events</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">(i) Severe adverse events caused by BO requiring withdrawal from trial, including severe skin irritation</HEADING>
<P>None of the studies in this comparison reported this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">(ii) Minor participant-reported adverse events, including gastrointestinal irritation not sufficient to require cessation of treatment</HEADING>
<P>Only two studies (<LINK REF="STD-Henz-1999" TYPE="STUDY">Henz 1999</LINK> and <LINK REF="STD-Takwale-2003" TYPE="STUDY">Takwale 2003</LINK>) reported minor adverse events. <LINK REF="STD-Henz-1999" TYPE="STUDY">Henz 1999</LINK> reported adverse events (not specific), but there were similar proportions of adverse events in the BO and placebo groups (RR 1.07, 95% CI 0.70 to 1.64, 158 participants, 1 study, <LINK REF="CMP-002.08" TYPE="ANALYSIS">Analysis 2.8</LINK>). There was also no difference in the proportion of participants experiencing flu-like symptoms by the end of treatment between the BO and placebo groups (RR 1.11, 95% CI 0.48 to 2.59, 158 participants, 1 study, <LINK REF="CMP-002.09" TYPE="ANALYSIS">Analysis 2.9</LINK>) (<LINK REF="STD-Henz-1999" TYPE="STUDY">Henz 1999</LINK>).</P>
<P>
<LINK REF="STD-Takwale-2003" TYPE="STUDY">Takwale 2003</LINK> reported upper respiratory tract infection, but there was no difference in the prevalence of this adverse event between the BO and placebo groups (RR 0.68, 95% CI 0.41 to 1.11, 140 participants, 1 study, <LINK REF="CMP-002.10" TYPE="ANALYSIS">Analysis 2.10</LINK>). The other adverse events reported by <LINK REF="STD-Takwale-2003" TYPE="STUDY">Takwale 2003</LINK>, albeit with too few numbers to warrant any statistical analysis, included diarrhoea, nausea and vomiting, abdominal pain, asthma, allergic rhinitis, urticaria, new rash, musculoskeletal pains, skin sepsis, glandular fever, and headache.</P>
<P>Other studies either reported that they did not observe adverse events, or they did not report any information regarding adverse events.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">(b) Systemic or topical treatments taken concurrently with EPO or BO</HEADING>
<P>
<LINK REF="STD-Don-2003" TYPE="STUDY">Don 2003</LINK> reported the number of children treated with topical steroids, oral antihistamine drugs, and moisturising lotion, but there were similar numbers in the borage group compared to the placebo group. The actual values reported for BO versus placebo were 4/9 versus 2/9, 4/9 versus 5/9, and 7/9 versus 7/9 for topical steroids, oral antihistamine drugs, and moisturising lotion, respectively.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2013-04-02 01:33:56 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2013-03-22 11:26:51 +0000" MODIFIED_BY="Cathy Bennett">
<P>The objective of this review was to assess the efficacy of oral evening primrose oil (EPO) and borage oil (BO) for treating the signs and symptoms of eczema. A comprehensive search of studies yielded a total of 27 studies (1596 participants), which we included in this review, where 19 studies assessed EPO against placebo, and the remaining 8 studies assessed BO against placebo. Eleven studies out of the 27 included studies were unpublished house pharmaceutical studies. The included studies varied in participants (adults, children, adults and children), duration of follow-up, and outcomes assessed. In some trials, the sample size was as small as 12, and the largest trial had a sample size of 160.</P>
<P>A meta-analysis of results from seven EPO studies demonstrated that the difference in global eczema symptoms between the EPO and placebo groups was not statistically significant as assessed by the participants. A second meta-analysis of results from eight studies also yielded no significant improvement of global eczema symptoms from EPO compared to placebo treatment, as measured by doctors.</P>
<P>Only two studies measured quality of life. Only a single study reported the results for quality of life improvement data, but no significant benefit in favour of EPO was evident. A few studies also reported adverse effects, but there was no significant difference between the EPO and placebo groups. Borage oil also did not show any significant benefit in terms of improving global eczema symptoms or reducing adverse events compared to the placebo treatment, although we could not carry out meta-analysis because the few studies assessing BO reported results in different ways. None of the studies reported costs.</P>
<P>We could not do sensitivity analyses to assess the effect of a large number of house studies on the outcomes, because we only included house studies in the meta-analyses.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2013-04-02 01:32:21 +0100" MODIFIED_BY="Cathy Bennett">
<P>A major limitation of the current evidence is the variation in how outcomes were reported, thus, making it impossible to pool all studies measuring the same outcome in meta-analyses. There was also variation in the duration of the included studies, from 6 weeks to 24 weeks. While some studies assessed children or adults separately, other studies evaluated both. Furthermore, we did not find any studies from developing countries except one study from India, but there were no studies from Africa or Asia. Therefore, we are unable to generalise our results, which show a lack of a significant effect of EPO and BO in reducing eczema symptoms to all populations and all age groups.</P>
<P>The available studies did not allow us to evaluate several secondary end points, which we hoped to cover: IgE, protein, cost, and quality of life. We encountered missing data problems, and attempts to obtain the missing data were not successful. Some of the reasons for this were due to failed execution of trial protocols, delayed evaluation and analysis, changing authors, and destruction of data after publication. We were also unable to carry out intention-to-treat (ITT) analyses, because of lack of data. We therefore carried out available case analyses instead. We could have investigated the dose-response effect of the interventions on the outcomes, but this was not necessary because the effect of the interventions were not statistically significant.</P>
<P>There were no studies completed within the last eight years that met the inclusion criteria. One study (clinicaltrials.gov identifier: <LINK REF="STD-NCT00878670" TYPE="STUDY">NCT00878670</LINK>) was completed during the period of writing this review; it was not a RCT but an open trial, which showed no benefit of EPO for eczema.</P>
<P>Both EPO and BO are commercially advertised on the internet as treatment for eczema.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2013-04-02 01:33:56 +0100" MODIFIED_BY="Cathy Bennett">
<P>The number of studies and their consistency in showing no benefit of EPO and BO over placebo oils seems persuasive. When we compared studies with paraffin (which contains no essential fatty acids) as placebo (<LINK REF="STD-Bamford-1985" TYPE="STUDY">Bamford 1985</LINK>; <LINK REF="STD-Berth_x002d_Jones-1993" TYPE="STUDY">Berth-Jones 1993</LINK>; <LINK REF="STD-France-1988" TYPE="STUDY">France 1988</LINK>; <LINK REF="STD-Lovell-1981" TYPE="STUDY">Lovell 1981</LINK>; <LINK REF="STD-MacLeod-2001" TYPE="STUDY">MacLeod 2001</LINK>; <LINK REF="STD-Schalin_x002d_Karrila-1987" TYPE="STUDY">Schalin-Karrila 1987</LINK>; <LINK REF="STD-Takwale-2003" TYPE="STUDY">Takwale 2003</LINK>; <LINK REF="STD-Valsecchi-2006" TYPE="STUDY">Valsecchi 2006</LINK>; <LINK REF="STD-Wright-1982" TYPE="STUDY">Wright 1982</LINK>) with those using various other placebos (palm, olive, corn, coconut, sunflower, glandol, or miglyol oils) (<LINK REF="STD-Biagi-1994" TYPE="STUDY">Biagi 1994</LINK>; <LINK REF="STD-Borrek-1997" TYPE="STUDY">Borrek 1997</LINK>; <LINK REF="STD-Buslau-1996" TYPE="STUDY">Buslau 1996</LINK>; <LINK REF="STD-Don-2003" TYPE="STUDY">Don 2003</LINK>; <LINK REF="STD-Finlay-2001" TYPE="STUDY">Finlay 2001</LINK>; <LINK REF="STD-Fraser-2001" TYPE="STUDY">Fraser 2001</LINK>; <LINK REF="STD-Harper-1990" TYPE="STUDY">Harper 1990</LINK>; <LINK REF="STD-Heddle-1990" TYPE="STUDY">Heddle 1990</LINK>; <LINK REF="STD-Hederos-1996" TYPE="STUDY">Hederos 1996</LINK>; <LINK REF="STD-Henz-1999" TYPE="STUDY">Henz 1999</LINK>; <LINK REF="STD-Kenicer-2001" TYPE="STUDY">Kenicer 2001</LINK>; <LINK REF="STD-Kiehl-1994" TYPE="STUDY">Kiehl 1994</LINK>; <LINK REF="STD-Kovar-1992" TYPE="STUDY">Kovar 1992</LINK>; <LINK REF="STD-MacKie-Adult-1990" TYPE="STUDY">MacKie Adult 1990</LINK>; <LINK REF="STD-MacKie-Child-1990" TYPE="STUDY">MacKie Child 1990</LINK>; <LINK REF="STD-Senapati-2008" TYPE="STUDY">Senapati 2008</LINK>; <LINK REF="STD-Wishart-1992" TYPE="STUDY">Wishart 1992</LINK>), the results were the same.</P>
<P>With regard to the risk of bias, the majority of studies were of low risk of bias; we judged two thirds of the included studies as having low risk of bias for random sequence generation, 40% for allocation concealment, 30% for other biases, and almost 60% for blinding. However, the sample sizes for the majority of the studies were small, and there were limitations regarding missing data in meta-analyses, mainly due to the longitudinal nature of the studies.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2013-03-22 11:41:33 +0000" MODIFIED_BY="[Empty name]">
<P>We conducted a comprehensive search of electronic databases to ensure that we identified all relevant studies. We also scanned through the reference lists of all the identified studies to look for any relevant studies. There were no language restrictions applied to studies for this review, and in fact, we translated four German articles and included them in the review. It is unlikely that we missed any relevant RCTs. We reduced potential bias in the conduct of this review by having two of the review authors independently scan through the search output, extract data, and assess the methodological quality of each study. However, we were unable to formally assess the likelihood of publication bias (selective reporting of positive findings) using funnel plots because of the small number of studies per meta-analysis. Although we did not carry out a Grading of Recommendations Assessment, Development and Evaluation (GRADE) appraisal for the review, we could comment on the quality of evidence using the magnitude of sample sizes, the results from meta-analyses, and the assessment of risk of bias.</P>
<P>The authors of this systematic review have had the following involvement with the subject of this review: The lead author, Mr Joel Bamford, MD, studied paraffin versus EPO in adults and children with atopic eczema (<LINK REF="STD-Bamford-1985" TYPE="STUDY">Bamford 1985</LINK>). Christel van Gool authored a trial of EPO to prevent eczema in children of mothers who had atopic dermatitis (<LINK REF="REF-van-Gool-2003" TYPE="REFERENCE">van Gool 2003</LINK>). Edzard Ernst has published widely on complementary therapies. Rosemary Humphreys has had personal experience of the use of EPO for atopic dermatitis.</P>
<P>We felt the delay in data becoming accessible and never being subject to peer review were sources of reporting bias. Defining statistical methods used six years after the last participant completed the study was also a source of concern (<LINK REF="STD-France-1988" TYPE="STUDY">France 1988</LINK>). Finally, it may be that there are articles that were never indexed and therefore were not available to our search methods.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2013-03-22 11:43:53 +0000" MODIFIED_BY="Cathy Bennett">
<P>This review found no significant improvement in global eczema symptoms from both EPO and BO, as measured by both participant and doctors. Our results are consistent with results from the included studies. We also assessed quality of life and adverse events, but few of the included studies reported this in sufficient detail to allow firm conclusions regarding these. Our review disagrees with an earlier meta-analysis of RCTs comparing EPO and placebo, which found a significant improvement in both participant- and doctor-reported global eczema symptoms in favour of EPO (<LINK REF="REF-Morse-1989" TYPE="REFERENCE">Morse 1989</LINK>). This meta-analysis used two of our included studies in print (<LINK REF="STD-Bamford-1985" TYPE="STUDY">Bamford 1985</LINK>; <LINK REF="STD-Wright-1982" TYPE="STUDY">Wright 1982</LINK>) and referenced nine unpublished RCTs from eight centres. A subsequent meta-analysis (<LINK REF="REF-Morse-2006" TYPE="REFERENCE">Morse 2006</LINK>) of 26 RCTs (1207 participants) found a beneficial effect of EPO on itch, crusting, oedema, and erythema. This meta-analysis also found a significant association of the treatment effect with increasing frequency of potent steroid use, but we could not assess this in our review because most studies did not properly report results on steroid use. Although we did not assess the specific symptoms, we included overall effects in the global measures used in this review.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-04-02 01:37:40 +0100" MODIFIED_BY="Joel Bamford">
<IMPLICATIONS_PRACTICE MODIFIED="2013-04-02 01:37:40 +0100" MODIFIED_BY="[Empty name]">
<P>Oral borage oil and evening primrose oil appear to be equivalent in their lack of effect on eczema. They had the same effect on global ratings as the placebos used. They do not seem to add any benefit to eczema as measured in this systematic review.</P>
<P>They seem to have the same fairly common mild transient adverse effects, which are mainly gastrointestinal (ranging from 7% to 15% in-house studies) (<LINK REF="STD-France-1988" TYPE="STUDY">France 1988</LINK>). There is evidence that EPO may increase bleeding for people on Coumadin® (warfarin) medication.</P>
<P>Over the years since the last study closed 10 years ago, there have been new developments in the use of systemic treatments for eczema: methotrexate for children, biologics, selective neuroepinephrine re-uptake inhibitors, serotonin uptake inhibitors, &#956;- and &#954;-opioid receptor agonists, and substance P antagonists, which are being evaluated (<LINK REF="REF-Patel-2011" TYPE="REFERENCE">Patel 2011</LINK>).</P>
<P>During the years since the protocol to this review was published, there have been changes in practice:</P>
<P>1. the term 'atopic eczema/dermatitis syndrome' (AEDS) to summarise all forms of eczema that have previously been called 'prurigo Besnier' or 'atopic dermatitis' (we did not find AEDS used in any included study);<BR/>2. the introduction of pseudo-ceramide, immunomodulator and biologic agents which came to the market after all our included studies;<BR/>3. disclosure of authorship and sponsorship requirements; and<BR/>4. the preregistration of protocols and the possibility of public posting of results on web sites such as <A HREF="http://www.clinicaltrials.gov/">www.clinicaltrials.gov</A>.</P>
<P>The latter two will bring greater transparency and reproducibility to clinical studies as well as helping to combine study data in meta-analyses.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2013-03-22 11:52:12 +0000" MODIFIED_BY="Joel Bamford">
<P>Noting that the confidence intervals between the active and placebo treatments are so narrow to exclude the possibility of any clinically useful difference, we conclude that further studies EPO or BO for eczema would be hard to justify.</P>
<P>In the future, as initial publication of trial protocols and early publication of detailed results become standard practice, all data will be available for evaluation by journal peer reviewers, readers, and researchers to those wishing to confirm or extend their investigations or carry out their own meta-analyses.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2013-03-22 11:59:42 +0000" MODIFIED_BY="Joel Bamford">
<P>We should like to thank Professor Hywel Williams for his useful suggestions on the draft protocol. Katja Bhoem (formerly Katja Schmidt: previous author) translated and extracted German articles for this review. Max Pittler participated as an author in earlier versions of this review. Diane Wennberg and Anna Robbins, Medical Librarians with Essentia Health Library, Duluth, Minnesota, secured the PDFs of articles for this review. Jo Leonardi-Bee extracted needed data from graphs. Cathy Bennett (Systematic Research Ltd.) provided consultancy advice about the format of the review. We also thank Anke Rohwer, a lecturer at Stellenbosch University, Faculty of Medicine and Health Sciences, in South Africa, for her assistance in translating the results sections of the four German studies to the English language.</P>
<P>We would like to thank the Trials Search Co-ordinator of the Skin Group editorial base, Liz Doney, for developing the search strategies and running the searches for the review.</P>
<P>The Cochrane Skin Group editorial base wishes to thank Ching-Chi Chi who was the Key Editor for this review; Matthew Grainge and Philippa Middleton who were the Statistical and Methods Editors, respectively; the clinical referees, Mandy Elvira Schram and Mary Glover; and the consumer referee, Amanda Roberts.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2013-03-22 12:06:10 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;This section must be revised near the end by CSG, who have conflicts information. JB and CvG authors of such studies.&lt;/p&gt;&lt;p&gt;JB study had placebo and EPO and lab evaluations and funding from Efamol Canada as well as a local foundation, Miller-Dawn Foundation.&lt;/p&gt;" NOTES_MODIFIED="2013-03-22 12:06:10 +0000" NOTES_MODIFIED_BY="[Empty name]">
<P>Joel Bamford's research was funded with a grant from the Miller-Dawn Foundation and repaid by the Effamol Pharmaceutical company, which supplied medication, placebo, and blood testing. Joel Bamford was neither involved in the selection nor data extraction of the <LINK REF="STD-Bamford-1985" TYPE="STUDY">Bamford 1985</LINK> included study for which he is a first author. Instead, the third review author (AM) took up these roles in the case of this included study.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2013-03-22 12:02:19 +0000" MODIFIED_BY="Joel Bamford">
<P>The following contributions were made by the authors stated.</P>
<P>JB updated the background section.<BR/>JB was the contact person with the editorial base, co-ordinated contributions from the co-authors, and wrote the final draft of the review.<BR/>JB and SR screened papers against eligibility criteria.<BR/>JB obtained data on ongoing and unpublished studies.<BR/>JB and SR appraised the quality of papers.<BR/>JB, SR, AM, and CvG extracted data for the review.<BR/>JB sought additional information about papers.<BR/>SR, AM, and JB entered data into RevMan.<BR/>AM analysed and interpreted data.<BR/>JB and SR worked on the methods sections.<BR/>JB drafted the clinical sections of the background and responded to the clinical comments of the referees.<BR/>JB, SR, AM, and RM responded to the methodology and statistics comments of the referees.<BR/>RH was the consumer co-author and checked the review for readability and clarity, as well as ensuring outcomes are relevant to consumers.<BR/>JB, SR, AM, CvG, RH, and EE drafted and approved the review.<BR/>JB is the guarantor of the update.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2013-04-02 01:41:51 +0100" MODIFIED_BY="Joel Bamford">
<P>We updated the Background section because of the date of protocol publication (2003).</P>
<P>As per CSG policy, we changed odds ratios to risk ratios in this review.</P>
<P>We used The Cochrane Collaboration's tool for assessing risk of bias (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>), rather than quality assessment. (Our protocol specified quality assessment, but 'Risk of bias' assessment superceded this.)</P>
<P>We added the secondary outcome 'Systemic or topical treatments taken concurrently with EPO or BO', which was not in our published protocol, because we thought it was important as most of the included studies allowed continued use of topical steroids.</P>
<P>Although not prespecified by the original authors of the protocol, we anticipated it would be beneficial to the review to carry out some subgroup analyses where there were sufficient studies.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2015-02-26 10:26:50 +0000" MODIFIED_BY="Laura E Prescott">
<P>We have deemed this review as stable and no longer in need of updating because the conclusion is so certain that the addition of new information will not change it, and there is unlikely to be any more research done on this topic. There were no ongoing studies or studies awaiting classification listed in the last published review.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2013-04-02 01:48:17 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2013-03-22 16:40:41 +0000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2013-03-22 16:40:41 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Bahmer-1992" MODIFIED="2012-12-16 14:37:57 +0000" MODIFIED_BY="Joel Bamford" NAME="Bahmer 1992" YEAR="1992">
<REFERENCE MODIFIED="2012-08-28 12:20:40 +0100" MODIFIED_BY="Joel Bamford" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bahmer FA, Schafer J</AU>
<TI>Treatment of Atopic Dermatitis with Borage Seed Oil (Glandol) - a Time Series Analysis Study</TI>
<TO>Die Behandlung der atopischen Dermatitis mit Borretschsamen-Ol (Glandol)--eine zeitreihenanalytische Studie</TO>
<SO>Kinderarztliche Praxis</SO>
<YR>1992</YR>
<VL>60</VL>
<NO>7</NO>
<PG>199-202</PG>
<IDENTIFIERS MODIFIED="2012-08-28 12:20:40 +0100" MODIFIED_BY="Joel Bamford">
<IDENTIFIER MODIFIED="2012-08-28 12:20:40 +0100" MODIFIED_BY="Joel Bamford" TYPE="MEDLINE" VALUE="1434338"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-11-17 17:21:24 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Bamford-1985" MODIFIED="2012-12-16 14:38:21 +0000" MODIFIED_BY="Joel Bamford" NAME="Bamford 1985" YEAR="1985">
<REFERENCE MODIFIED="2012-08-28 12:21:17 +0100" MODIFIED_BY="Joel Bamford" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bamford JT, Gibson RW, Renier CM</AU>
<TI>Atopic eczema unresponsive to evening primrose oil (linoleic and gammma-linolenic acids)</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>1985</YR>
<VL>13</VL>
<NO>6</NO>
<PG>959-65</PG>
<IDENTIFIERS MODIFIED="2011-07-26 12:47:11 +0100" MODIFIED_BY="Joel Bamford">
<IDENTIFIER MODIFIED="2011-07-26 12:47:11 +0100" MODIFIED_BY="Joel Bamford" TYPE="PUBMED" VALUE="3908514"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berth_x002d_Jones-1993" MODIFIED="2013-03-22 15:52:37 +0000" MODIFIED_BY="Joel Bamford" NAME="Berth-Jones 1993" YEAR="1993">
<REFERENCE MODIFIED="2013-03-22 15:52:37 +0000" MODIFIED_BY="Joel Bamford" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berth-Jones J, Graham-Brown RA</AU>
<TI>Placebo-controlled trial of essential fatty acid supplementation in atopic dermatitis</TI>
<SO>Lancet</SO>
<YR>1993</YR>
<VL>341</VL>
<NO>8860</NO>
<PG>1557-60</PG>
<IDENTIFIERS MODIFIED="2013-03-22 15:52:37 +0000" MODIFIED_BY="Joel Bamford">
<IDENTIFIER MODIFIED="2013-03-22 15:52:37 +0000" MODIFIED_BY="Joel Bamford" TYPE="MEDLINE" VALUE="8099640"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Biagi-1994" MODIFIED="2013-03-22 15:52:42 +0000" MODIFIED_BY="Joel Bamford" NAME="Biagi 1994" YEAR="1994">
<REFERENCE MODIFIED="2013-03-22 15:52:42 +0000" MODIFIED_BY="Joel Bamford" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Biagi PL, Bordoni A, Hrelia S, Celadon M, Ricci GP, Cannella V, et al</AU>
<TI>The effect of gamma-linolenic acid on clinical status, red cell fatty acid composition and membrane microviscosity in infants with atopic dermatitis</TI>
<SO>Drugs Under Experimental &amp; Clinical Research</SO>
<YR>1994</YR>
<VL>20</VL>
<NO>2</NO>
<PG>77-84</PG>
<IDENTIFIERS MODIFIED="2013-03-22 15:52:42 +0000" MODIFIED_BY="Joel Bamford">
<IDENTIFIER MODIFIED="2013-03-22 15:52:42 +0000" MODIFIED_BY="Joel Bamford" TYPE="MEDLINE" VALUE="7924900"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Borrek-1997" MODIFIED="2012-08-28 12:26:35 +0100" MODIFIED_BY="Joel Bamford" NAME="Borrek 1997" YEAR="1997">
<REFERENCE MODIFIED="2012-08-28 12:26:35 +0100" MODIFIED_BY="Joel Bamford" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Borrek S, Hildebrandt A, Forster J</AU>
<TI>Gamma-linolenic-acid-rich borage seed oil capsules in children with atopic dermatitis. A placebo-controlled double-blind study</TI>
<TO>Gammalinolensaure-reiche Borretschsamenol-Kapseln bei Kindern mit Atopischer Dermatitis. Eine placebo-kontrollierte Doppelblind-Studie</TO>
<SO>Klinische Padiatrie</SO>
<YR>1997</YR>
<VL>209</VL>
<NO>3</NO>
<PG>100-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Buslau-1996" MODIFIED="2012-08-28 12:30:29 +0100" MODIFIED_BY="Joel Bamford" NAME="Buslau 1996" YEAR="1996">
<REFERENCE MODIFIED="2012-08-28 12:30:29 +0100" MODIFIED_BY="Joel Bamford" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buslau M, Thaci D</AU>
<TI>Atopic dermatitis: Borage oil for systemic therapy</TI>
<TO>Atopische Dermatitis: Borretschol zur systemischen Therapie</TO>
<SO>Zeitschrift fur Dermatologie</SO>
<YR>1996</YR>
<VL>182</VL>
<NO>3</NO>
<PG>131-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Don-2003" MODIFIED="2012-12-16 14:39:54 +0000" MODIFIED_BY="Joel Bamford" NAME="Don 2003" YEAR="2003">
<REFERENCE MODIFIED="2012-08-28 12:30:43 +0100" MODIFIED_BY="Joel Bamford" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Don M, Melli P, Braida F, Comici A, Barbi E, Spano C, et al</AU>
<TI>Efficacy of essential fatty acids in the treatment of atopic dermatitis and correlations of their changes with clinical response</TI>
<TO>Efficacia degli acidi grassi essenziali nel trattamento della dermatite atopica e correlazione de; loro cambiamenti con la risposta clinica</TO>
<SO>Italian Journal of Pediatrics</SO>
<YR>2003</YR>
<VL>29</VL>
<NO>6</NO>
<PG>427-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Finlay-2001" MODIFIED="2013-03-22 14:10:51 +0000" MODIFIED_BY="Joel Bamford" NAME="Finlay 2001" YEAR="1997">
<REFERENCE MODIFIED="2013-03-22 14:10:51 +0000" MODIFIED_BY="Joel Bamford" PRIMARY="NO" TYPE="OTHER">
<AU>Finlay AY, Marks R, Wilson AM, Huntley C</AU>
<TI>Epogam in Children with Atopic Eczema</TI>
<SO>Pharmacia (Formerly Searle Division of Monsanto)</SO>
<YR>2001</YR>
<PG>1-473</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-07-21 11:00:12 +0100" MODIFIED_BY="Joel Bamford">
<IDENTIFIER MODIFIED="2011-07-21 11:00:12 +0100" MODIFIED_BY="Joel Bamford" TYPE="OTHER" VALUE="Protocol U4E-93-02-001"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-France-1988" MODIFIED="2012-08-28 12:34:24 +0100" MODIFIED_BY="Joel Bamford" NAME="France 1988" YEAR="1988">
<REFERENCE MODIFIED="2012-08-28 12:34:24 +0100" MODIFIED_BY="Joel Bamford" PRIMARY="NO" TYPE="OTHER">
<AU>France et al</AU>
<TI>Epogam in Severe Atopic Eczema</TI>
<SO>Pharmacia</SO>
<YR>2001(18 October)</YR>
<IDENTIFIERS MODIFIED="2012-08-28 12:34:24 +0100" MODIFIED_BY="Joel Bamford">
<IDENTIFIER MODIFIED="2012-08-28 12:34:24 +0100" MODIFIED_BY="Joel Bamford" TYPE="OTHER" VALUE="ISN 880002/3/4/24/25/128/130/890141"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Fraser-2001" MODIFIED="2011-11-17 17:29:04 +0000" MODIFIED_BY="Joel Bamford" NAME="Fraser 2001" YEAR="1990">
<REFERENCE MODIFIED="2011-11-17 17:28:30 +0000" MODIFIED_BY="Joel Bamford" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Fraser</AU>
<TI>Efamol in Atopic Eczema</TI>
<SO>Pharmacia</SO>
<YR>2001 (22 October)</YR>
<IDENTIFIERS MODIFIED="2011-11-17 17:22:29 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-11-17 17:22:29 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="ISSN 86004/5/6/7"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-11-17 17:29:04 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Harper-1990" MODIFIED="2011-11-18 13:11:34 +0000" MODIFIED_BY="Joel Bamford" NAME="Harper 1990" YEAR="1990">
<REFERENCE MODIFIED="2011-11-18 13:09:45 +0000" MODIFIED_BY="Joel Bamford" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Harper J statician authors: Jaderberg M and Wilson A</AU>
<TI>Efamol in Moderate to Severe Atopic Eczema</TI>
<SO>Pharmacia</SO>
<YR>2001</YR>
<IDENTIFIERS MODIFIED="2011-11-18 13:05:46 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-11-18 13:05:46 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SN 890136/7"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-11-18 13:11:34 +0000" MODIFIED_BY="Joel Bamford"/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Heddle-1990" MODIFIED="2012-08-28 12:35:18 +0100" MODIFIED_BY="Joel Bamford" NAME="Heddle 1990" YEAR="1990">
<REFERENCE MODIFIED="2012-08-28 12:35:18 +0100" MODIFIED_BY="Joel Bamford" PRIMARY="NO" TYPE="OTHER">
<AU>Heddle RJ, Forsyth K, Gordon LA, TAO BK, Gibson RA</AU>
<TI>Oral Evening Primrose Oil (EPO) in Atopic Eczema</TI>
<SO>Pharmacia</SO>
<YR>2001</YR>
<IDENTIFIERS MODIFIED="2011-11-17 17:35:15 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-11-17 17:35:15 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="ISN 910033"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-11-17 17:35:30 +0000" MODIFIED_BY="Joel Bamford"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hederos-1996" MODIFIED="2013-03-22 16:40:41 +0000" MODIFIED_BY="Joel Bamford" NAME="Hederos 1996" YEAR="1996">
<REFERENCE MODIFIED="2013-03-22 16:40:21 +0000" MODIFIED_BY="Joel Bamford" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hederos CA, Berg A</AU>
<TI>Epogam evening primrose oil treatment in atopic dermatitis and asthma</TI>
<SO>Archives of Diseases in Childhood</SO>
<YR>1996</YR>
<VL>75</VL>
<NO>6</NO>
<PG>494-7</PG>
<IDENTIFIERS MODIFIED="2011-11-18 13:15:34 +0000" MODIFIED_BY="Joel Bamford">
<IDENTIFIER MODIFIED="2011-11-18 13:15:34 +0000" MODIFIED_BY="Joel Bamford" TYPE="OTHER" VALUE="PMID 9014601"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-11-18 13:15:55 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Henz-1999" MODIFIED="2012-08-28 12:39:26 +0100" MODIFIED_BY="Joel Bamford" NAME="Henz 1999" YEAR="1999">
<REFERENCE MODIFIED="2012-08-28 12:39:26 +0100" MODIFIED_BY="Joel Bamford" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Henz BM, Jablonska S, van de Kerkhof PC, Stingl G, Blaszczyk M, Vandervalk PG, et al</AU>
<TI>Double-blind, multicenter analysis of the efficacy of borage oil in patients with atopic eczema</TI>
<SO>British Journal of Dermatology</SO>
<YR>1999</YR>
<VL>140</VL>
<NO>4</NO>
<PG>685-8</PG>
<IDENTIFIERS MODIFIED="2012-08-28 12:38:54 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-08-28 12:38:54 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="10233322"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-11-18 13:14:30 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Kenicer-2001" MODIFIED="2012-09-06 13:42:59 +0100" MODIFIED_BY="Joel Bamford" NAME="Kenicer 2001" YEAR="2001">
<REFERENCE MODIFIED="2012-09-06 13:42:59 +0100" MODIFIED_BY="Joel Bamford" PRIMARY="NO" TYPE="OTHER">
<AU>Kenicer K, Keczkes K, Green C, George S</AU>
<TI>Evening Primrose Oil in the Treatment of Atopic Dermatitis: a Placebo-controlled Study</TI>
<SO>Pharmacia Company</SO>
<YR>2001</YR>
<IDENTIFIERS MODIFIED="2011-07-26 12:59:46 +0100" MODIFIED_BY="Joel Bamford">
<IDENTIFIER MODIFIED="2011-07-26 12:59:46 +0100" MODIFIED_BY="Joel Bamford" TYPE="OTHER" VALUE="ISN: 900210/910098"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kiehl-1994" MODIFIED="2012-09-06 13:43:06 +0100" MODIFIED_BY="Joel Bamford" NAME="Kiehl 1994" YEAR="1994">
<REFERENCE MODIFIED="2012-09-06 13:43:06 +0100" MODIFIED_BY="Joel Bamford" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kiehl R, Ionescu G, Manuel P, Stern LP, Peters G, Niemann A, et al</AU>
<TI>Clinical, Immuno- and Lipid Modulating Effects of Unsaturated Fatty Acids in Patients with Atopic Eczema</TI>
<TO>Klinische, immun- und lipidmodulatorische effekte einer behandlung mit ungesattigten fettsauren bei atopischer dermatitis</TO>
<SO>H+G Zeitschrift fur Hautkrankheiten</SO>
<YR>1994</YR>
<VL>69</VL>
<NO>1</NO>
<PG>42-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Kovar-1992" MODIFIED="2012-08-28 13:21:11 +0100" MODIFIED_BY="Joel Bamford" NAME="Kovar 1992" YEAR="1992">
<REFERENCE MODIFIED="2012-08-28 13:21:11 +0100" MODIFIED_BY="Joel Bamford" PRIMARY="NO" TYPE="OTHER">
<AU>Kovar IZ, Wright S</AU>
<TI>An assessment of efamol evening primrose oil in moderate to severe atopic eczema in young children</TI>
<SO>Pharmacia Corporation</SO>
<YR>1992</YR>
<IDENTIFIERS MODIFIED="2011-07-21 15:40:50 +0100" MODIFIED_BY="Joel Bamford">
<IDENTIFIER MODIFIED="2011-07-21 15:40:50 +0100" MODIFIED_BY="Joel Bamford" TYPE="OTHER" VALUE="ISN 900158"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Lovell-1981" MODIFIED="2012-12-16 14:41:33 +0000" MODIFIED_BY="Joel Bamford" NAME="Lovell 1981" YEAR="1981">
<REFERENCE MODIFIED="2012-08-28 13:22:19 +0100" MODIFIED_BY="Joel Bamford" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lovell CR, Burton JL, Horrobin DF</AU>
<TI>Treatment of atopic eczema with evening primrose oil</TI>
<SO>Lancet</SO>
<YR>1981</YR>
<VL>1</VL>
<NO>8214</NO>
<PG>278</PG>
<IDENTIFIERS MODIFIED="2011-07-21 15:47:37 +0100" MODIFIED_BY="Joel Bamford">
<IDENTIFIER MODIFIED="2011-07-21 15:47:37 +0100" MODIFIED_BY="Joel Bamford" TYPE="PUBMED" VALUE="6109930"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-MacKie-Adult-1990" MODIFIED="2012-08-28 13:22:45 +0100" MODIFIED_BY="Joel Bamford" NAME="MacKie Adult 1990" YEAR="1990">
<REFERENCE MODIFIED="2012-08-28 13:22:45 +0100" MODIFIED_BY="Joel Bamford" PRIMARY="NO" TYPE="OTHER">
<AU>MacKie R</AU>
<TI>A Clinical and Mechanistic Assessment of Eamol Evening Primrose Oil in Atopic Eczema (Adults)</TI>
<SO>Pharmacia</SO>
<YR>2001</YR>
<IDENTIFIERS MODIFIED="2011-07-21 16:18:27 +0100" MODIFIED_BY="Joel Bamford">
<IDENTIFIER MODIFIED="2011-07-21 16:18:27 +0100" MODIFIED_BY="Joel Bamford" TYPE="OTHER" VALUE="ISN 890054"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-11-18 13:00:41 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-MacKie-Child-1990" MODIFIED="2012-08-28 13:22:51 +0100" MODIFIED_BY="Joel Bamford" NAME="MacKie Child 1990" YEAR="1990">
<REFERENCE MODIFIED="2012-08-28 13:22:51 +0100" MODIFIED_BY="Joel Bamford" PRIMARY="NO" TYPE="OTHER">
<AU>MacKie R</AU>
<TI>A clinical and mechanistic assessment of efamol evening primrose oil in atopic eczema in Children</TI>
<SO>Pharmacia</SO>
<YR>2001</YR>
<IDENTIFIERS MODIFIED="2011-07-21 16:25:30 +0100" MODIFIED_BY="Joel Bamford">
<IDENTIFIER MODIFIED="2011-07-21 16:25:30 +0100" MODIFIED_BY="Joel Bamford" TYPE="OTHER" VALUE="ISN 890067"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-MacLeod-2001" MODIFIED="2012-08-28 13:23:03 +0100" MODIFIED_BY="Joel Bamford" NAME="MacLeod 2001" YEAR="">
<REFERENCE MODIFIED="2012-08-28 13:23:03 +0100" MODIFIED_BY="Joel Bamford" PRIMARY="NO" TYPE="OTHER">
<AU>MacLeod A, Misch KJ</AU>
<TI>A Comparative Assessment of Efamol Evening Primrose Oil and Efamol Marine in Severe Atopic Eczema</TI>
<SO>Pharmacia</SO>
<YR>2001</YR>
<IDENTIFIERS MODIFIED="2011-11-17 17:47:05 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-11-17 17:47:05 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="ISN 89100"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-11-17 17:46:35 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schalin_x002d_Karrila-1987" MODIFIED="2012-08-28 13:23:57 +0100" MODIFIED_BY="Joel Bamford" NAME="Schalin-Karrila 1987" YEAR="1987">
<REFERENCE MODIFIED="2012-08-28 13:23:57 +0100" MODIFIED_BY="Joel Bamford" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schalin-Karrila M, Mattila L, Jansen CT, Uotila P</AU>
<TI>Evening primrose oil in the treatment of atopic eczema: effect on clinical status, plasma phospholipid fatty acids and circulating blood prostaglandins</TI>
<SO>British Journal of Dermatology</SO>
<YR>1987</YR>
<VL>117</VL>
<NO>1</NO>
<PG>11-9</PG>
<IDENTIFIERS MODIFIED="2011-07-26 12:40:01 +0100" MODIFIED_BY="Joel Bamford">
<IDENTIFIER MODIFIED="2011-07-26 12:40:01 +0100" MODIFIED_BY="Joel Bamford" TYPE="PUBMED" VALUE="3307886"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Senapati-2008" MODIFIED="2012-08-28 13:25:10 +0100" MODIFIED_BY="Joel Bamford" NAME="Senapati 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-08-28 13:25:10 +0100" MODIFIED_BY="Joel Bamford" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Senapati S, Banerjee S, Gangopadhyay DN</AU>
<TI>Evening primrose oil is effective in atopic dermatitis: A randomized placebo-controlled trial</TI>
<SO>Indian Journal of Dermatology, Venereology and Leprology</SO>
<YR>2008</YR>
<VL>74</VL>
<NO>5</NO>
<PG>447-52</PG>
<IDENTIFIERS MODIFIED="2011-07-21 16:32:45 +0100" MODIFIED_BY="Joel Bamford">
<IDENTIFIER MODIFIED="2011-07-21 16:32:45 +0100" MODIFIED_BY="Joel Bamford" TYPE="PUBMED" VALUE="19052401"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Takwale-2003" MODIFIED="2012-08-28 13:26:09 +0100" MODIFIED_BY="Joel Bamford" NAME="Takwale 2003" YEAR="2003">
<REFERENCE MODIFIED="2012-08-28 13:26:09 +0100" MODIFIED_BY="Joel Bamford" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Takwale A, Tan E, Agarwal S, Barclay G, Ahmed I, Hotchkiss K, et al</AU>
<TI>Efficacy and tolerability of borage oil in adults and children with atopic eczema: randomized, double blind, placebo controlled, parallel group trial</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7428</NO>
<PG>1385</PG>
<IDENTIFIERS MODIFIED="2012-08-28 13:25:39 +0100" MODIFIED_BY="Joel Bamford">
<IDENTIFIER MODIFIED="2011-07-21 17:33:27 +0100" MODIFIED_BY="Joel Bamford" TYPE="PUBMED" VALUE="14670885"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Valsecchi-2006" MODIFIED="2012-08-28 13:29:49 +0100" MODIFIED_BY="Joel Bamford" NAME="Valsecchi 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-08-28 13:29:49 +0100" MODIFIED_BY="Joel Bamford" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Valsecchi R, Di Landro A, Pansera B, Reseghetti A</AU>
<TI>Gamma-lenolenic acid in the treatment of atopic dermatitis</TI>
<SO>Journal of European Academy of Dermatology &amp; Venereology</SO>
<YR>2006 July</YR>
<VL>7</VL>
<NO>1</NO>
<PG>77-9</PG>
<IDENTIFIERS MODIFIED="2012-08-28 13:29:49 +0100" MODIFIED_BY="Joel Bamford"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Wishart-1992" MODIFIED="2012-08-28 13:27:06 +0100" MODIFIED_BY="Joel Bamford" NAME="Wishart 1992" YEAR="1992">
<REFERENCE MODIFIED="2012-08-28 13:27:06 +0100" MODIFIED_BY="Joel Bamford" PRIMARY="NO" TYPE="OTHER">
<AU>Wishart J, Macdonald K, Oakley A</AU>
<TI>A Multi-center Assessment of Efamol Evening Primrose Oil in Severe Atopic Eczema</TI>
<SO>Pharmacia</SO>
<YR>October 2001</YR>
<IDENTIFIERS MODIFIED="2011-07-21 17:57:19 +0100" MODIFIED_BY="Joel Bamford">
<IDENTIFIER MODIFIED="2011-07-21 17:57:19 +0100" MODIFIED_BY="Joel Bamford" TYPE="OTHER" VALUE="ISN 900196/197/198"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Wright-1982" MODIFIED="2012-12-16 14:42:08 +0000" MODIFIED_BY="Joel Bamford" NAME="Wright 1982" YEAR="1982">
<REFERENCE MODIFIED="2012-09-06 13:43:24 +0100" MODIFIED_BY="Joel Bamford" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wright S, Burton JL</AU>
<TI>Oral evening-primrose-seed oil improves atopic eczema</TI>
<SO>Lancet</SO>
<YR>1982</YR>
<VL>2</VL>
<NO>8308</NO>
<PG>1120-2</PG>
<IDENTIFIERS MODIFIED="2012-08-28 13:27:48 +0100" MODIFIED_BY="Joel Bamford">
<IDENTIFIER MODIFIED="2011-07-21 18:01:57 +0100" MODIFIED_BY="Joel Bamford" TYPE="OTHER" VALUE="6128449"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2012-12-16 14:32:37 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Biagi-1988" MODIFIED="2012-12-16 12:35:33 +0000" MODIFIED_BY="[Empty name]" NAME="Biagi 1988" YEAR="1988">
<REFERENCE MODIFIED="2012-08-28 13:34:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Biagi PL, Bordoni A, Masi M, Ricci G, Fanelli C, Patrizi A, et al</AU>
<TI>A long-term study on the use of evening primrose oil (Efamol) in atopic children</TI>
<SO>Drugs Under Experimental &amp; Clinical Research</SO>
<YR>1988</YR>
<VL>14</VL>
<NO>4</NO>
<PG>285-90</PG>
<IDENTIFIERS MODIFIED="2012-08-28 13:33:15 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-08-28 13:33:14 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="3048952"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bordoni-1988" MODIFIED="2012-08-28 13:36:48 +0100" MODIFIED_BY="[Empty name]" NAME="Bordoni 1988" YEAR="1988">
<REFERENCE MODIFIED="2012-08-28 13:36:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bordoni A, Biagi PL, Masi M, Ricci G, Fanelli C, Patrizi A, et al</AU>
<TI>Evening primrose oil (Efamol) in the treatment of children with atopic eczema</TI>
<SO>Drugs Under Experimental &amp; Clinical Research</SO>
<YR>1988</YR>
<VL>14</VL>
<NO>4</NO>
<PG>291-7</PG>
<IDENTIFIERS MODIFIED="2011-07-26 12:53:46 +0100" MODIFIED_BY="Joel Bamford">
<IDENTIFIER MODIFIED="2011-07-26 12:53:46 +0100" MODIFIED_BY="Joel Bamford" TYPE="PUBMED" VALUE="3048953"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-11-17 17:51:36 +0000" MODIFIED_BY="Joel Bamford"/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Coskery-1988" MODIFIED="2012-08-28 13:44:11 +0100" MODIFIED_BY="Joel Bamford" NAME="Coskery 1988" YEAR="1988">
<REFERENCE MODIFIED="2012-08-28 13:44:11 +0100" MODIFIED_BY="Joel Bamford" PRIMARY="NO" TYPE="OTHER">
<AU>Coskery G, Cowley N, Allen R</AU>
<TI>The Effect of Dietary Supplementation with Evening Primrose Oil on Skin Surface Texture in Atopic Dermatitis, A quantitative method of assessment. [Abstract 216]. The 18th Annual Meeting of the European Society for Dermatologic Research 19-22 June 1988, Munich, Germany</TI>
<SO>Journal of Investigative Dermatology</SO>
<YR>1988</YR>
<VL>91</VL>
<NO>4</NO>
<PG>413</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-07-17 13:11:47 +0100" MODIFIED_BY="Joel Bamford">
<IDENTIFIER MODIFIED="2011-07-17 13:11:47 +0100" MODIFIED_BY="Joel Bamford" TYPE="OTHER" VALUE=""/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Courage-1991" MODIFIED="2012-09-06 13:43:34 +0100" MODIFIED_BY="[Empty name]" NAME="Courage 1991" YEAR="1991">
<REFERENCE MODIFIED="2012-09-06 13:43:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Courage B, Nissen HP, Wehrmann W, Biltz H</AU>
<TI>Influence of polyunsaturated Fatty Acids on the Plasma Catecholamines of Patients with Atopic Eczema</TI>
<TO>Veranderungen des Katecholaminspiegels bei Neurodermatitis - Beeinflussung durch ungesattigte Fettsauren</TO>
<SO>H+G Zeitschrift fur Hautkrankheiten</SO>
<YR>1991</YR>
<VL>66</VL>
<NO>6</NO>
<PG>509-10</PG>
<IDENTIFIERS MODIFIED="2012-05-08 11:49:27 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-05-08 11:49:27 +0100" MODIFIED_BY="[Empty name]" TYPE="EMBASE" VALUE="1991249008"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Guenther-1987" MODIFIED="2012-09-06 13:43:42 +0100" MODIFIED_BY="Joel Bamford" NAME="Guenther 1987" YEAR="1987">
<REFERENCE MODIFIED="2012-09-06 13:43:42 +0100" MODIFIED_BY="Joel Bamford" PRIMARY="NO" TYPE="OTHER">
<AU>Guenther L, Wexler D</AU>
<TI>Efamol in the treatment of atopic dermatitis</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>1987</YR>
<VL>17</VL>
<NO>5 Pt 1</NO>
<PG>860</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-11-11 22:20:22 +0000" MODIFIED_BY="Joel Bamford">
<IDENTIFIER MODIFIED="2011-11-11 22:20:22 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="3680673"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Melnick-1995" MODIFIED="2012-09-06 13:43:48 +0100" MODIFIED_BY="Joel Bamford" NAME="Melnick 1995" YEAR="1995">
<REFERENCE MODIFIED="2012-09-06 13:43:48 +0100" MODIFIED_BY="Joel Bamford" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Melnik BC, Bahmer FA</AU>
<TI>Treatment of Atopic Dermatitis with Glandol and Epoleum - A Comparative Study</TI>
<TO>Die behandlung des atopischen ekzems mit glandol und epoleum - eine vergleichende studie</TO>
<SO>Aktuelle Dermatologie</SO>
<YR>1995</YR>
<VL>21</VL>
<NO>7</NO>
<PG>215-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT00878670" MODIFIED="2012-12-16 14:32:37 +0000" MODIFIED_BY="[Empty name]" NAME="NCT00878670" YEAR="2011">
<REFERENCE MODIFIED="2012-12-16 14:32:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00878670</AU>
<TI>Investigation of Efficacy and Safety of EPOGAM</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00878670</SO>
<YR>(accessed 16 December 2012)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NCT00878670 "/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Swapan-2008" MODIFIED="2012-08-28 14:34:07 +0100" MODIFIED_BY="[Empty name]" NAME="Swapan 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-08-28 14:10:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Swapan S, Banerjee S, Gangopadhyay DN</AU>
<TI>Evening primrose oil is effective in atopic dermatitis: A randomized placebo-controlled trial</TI>
<SO>Indian Journal of Dermatology, Venereology &amp; Leprology</SO>
<YR>2008</YR>
<VL>74</VL>
<NO>5</NO>
<PG>447-52</PG>
<IDENTIFIERS MODIFIED="2012-08-28 14:10:58 +0100" MODIFIED_BY="Liz Doney">
<IDENTIFIER MODIFIED="2012-08-28 14:10:58 +0100" MODIFIED_BY="Liz Doney" TYPE="PUBMED" VALUE="19052401"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2012-12-16 14:32:37 +0000" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2013-04-02 01:48:17 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2013-04-02 01:48:17 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Al_x002d_Khamees-2011" MODIFIED="2012-08-28 14:12:10 +0100" MODIFIED_BY="Joel Bamford" NAME="Al-Khamees 2011" TYPE="JOURNAL_ARTICLE">
<AU>Al-Khamees WA, Schwartz MD, Alrashdi S, Algren DA, Morgan BW</AU>
<TI>Status epilepticus associated with borage oil ingestion</TI>
<SO>Journal of Medical Toxicology</SO>
<YR>2011</YR>
<VL>7</VL>
<NO>2</NO>
<PG>154-7</PG>
<IDENTIFIERS MODIFIED="2011-07-20 18:20:52 +0100" MODIFIED_BY="Joel Bamford">
<IDENTIFIER MODIFIED="2011-07-20 18:20:52 +0100" MODIFIED_BY="Joel Bamford" TYPE="OTHER" VALUE="PMID  21387119"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Augustin-1999" MODIFIED="2012-08-28 14:13:40 +0100" MODIFIED_BY="[Empty name]" NAME="Augustin 1999" TYPE="JOURNAL_ARTICLE">
<AU>Augustin M, Zschocke I, Buhrke U</AU>
<TI>Attitudes and prior experience with respect to alternative medicine among dermatological patients: the Freiburg Questionnaire on attitudes to naturopathy (FAN)</TI>
<SO>Forschende Komplementarmedizin</SO>
<YR>1999</YR>
<VL>6</VL>
<NO>Suppl 2</NO>
<PG>26-9</PG>
<IDENTIFIERS MODIFIED="2011-11-11 22:26:14 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-11-11 22:26:14 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="10352379"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bahmer-1991" MODIFIED="2013-04-01 20:40:36 +0100" MODIFIED_BY="[Empty name]" NAME="Bahmer 1991" TYPE="JOURNAL_ARTICLE">
<AU>Bahmer FA, Schubert PH-J</AU>
<TI>Quantification of the extent and the severity of atopic dermatitis: the ADASI score</TI>
<SO>Archives of Dermatology</SO>
<YR>1991</YR>
<VL>127</VL>
<NO>8</NO>
<PG>1239-1240</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barnetson-2002" MODIFIED="2012-08-28 14:14:16 +0100" MODIFIED_BY="Diane A  Horsley" NAME="Barnetson 2002" TYPE="JOURNAL_ARTICLE">
<AU>Barnetson RS, Rogers M</AU>
<TI>Childhood atopic eczema</TI>
<SO>BMJ</SO>
<YR>2002</YR>
<VL>324</VL>
<NO>7350</NO>
<PG>1376-9</PG>
<IDENTIFIERS MODIFIED="2011-11-11 22:27:16 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-11-11 22:27:16 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="12052810"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Batchelor-2010" MODIFIED="2012-08-28 14:15:28 +0100" MODIFIED_BY="[Empty name]" NAME="Batchelor 2010" TYPE="OTHER">
<AU>Batchelor JM, Grindlay DJ, Williams HC</AU>
<TI>What's new in atopic eczema? An analysis of systemic reviews published in 2008 and 2009</TI>
<SO>Clinical &amp; Experimental Dermatology</SO>
<YR>2010</YR>
<VL>35</VL>
<NO>8</NO>
<PG>823-7</PG>
<IDENTIFIERS MODIFIED="2012-08-28 14:15:11 +0100" MODIFIED_BY="Liz Doney">
<IDENTIFIER MODIFIED="2012-08-28 14:15:11 +0100" MODIFIED_BY="Liz Doney" TYPE="OTHER" VALUE="PMID: 20649899"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bayles-2009" MODIFIED="2012-08-28 14:16:53 +0100" MODIFIED_BY="Joel TM Bamford" NAME="Bayles 2009" TYPE="JOURNAL_ARTICLE">
<AU>Bayles B, Usatine R</AU>
<TI>Evening Primrose Oil</TI>
<SO>American Family Physician</SO>
<YR>2009</YR>
<VL>80</VL>
<NO>12</NO>
<PG>1405-1408</PG>
<IDENTIFIERS MODIFIED="2012-08-28 14:16:53 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-08-28 14:16:53 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="20000302"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Belch-2000" MODIFIED="2012-08-28 14:17:59 +0100" MODIFIED_BY="Joel Bamford" NAME="Belch 2000" TYPE="JOURNAL_ARTICLE">
<AU>Belch JJ, Hill A</AU>
<TI>Evening primrose oil and borage oil in rheumatologic conditions</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2000</YR>
<VL>71</VL>
<NO>1 Suppl</NO>
<PG>352S-6S</PG>
<IDENTIFIERS MODIFIED="2012-08-28 14:17:59 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-08-28 14:17:59 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="10617996"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Beswick-2011" MODIFIED="2012-08-28 14:22:41 +0100" MODIFIED_BY="[Empty name]" NAME="Beswick 2011" TYPE="JOURNAL_ARTICLE">
<AU>Beswick T, Morton J, Allen P</AU>
<TI>Report of two cases of chronic atopic dermatitis treated with adalimubab [P1318]</TI>
<SO>Journal of American Academy of Dermatology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>2 Suppl 1</NO>
<PG>AB60</PG>
<IDENTIFIERS MODIFIED="2012-05-02 16:07:39 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-05-02 16:07:39 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="PIIS19096221001354X"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bos-2010" MODIFIED="2012-08-28 14:25:28 +0100" MODIFIED_BY="Joel TM Bamford" NAME="Bos 2010" TYPE="JOURNAL_ARTICLE">
<AU>Bos JD, Brenninkmeijer EE, Schram ME, Middelkamp-Hup MA, Spuls PI, Smitt JH</AU>
<TI>Atopic eczema or atopiform dermatitis</TI>
<SO>Experimental Dermatology</SO>
<YR>Apr 2010</YR>
<VL>19</VL>
<NO>4</NO>
<PG>325-31</PG>
<IDENTIFIERS MODIFIED="2012-08-28 14:25:28 +0100" MODIFIED_BY="Joel TM Bamford">
<IDENTIFIER MODIFIED="2011-02-14 19:35:14 +0000" MODIFIED_BY="Joel TM Bamford" TYPE="OTHER" VALUE="20100192"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Charman-2000" MODIFIED="2011-12-09 20:37:57 +0000" MODIFIED_BY="[Empty name]" NAME="Charman 2000" TYPE="JOURNAL_ARTICLE">
<AU>Charman CR, Morris AD, Williams HC</AU>
<TI>Topical corticosteroid phobia in patients with atopic eczema</TI>
<SO>British Journal of Dermatology</SO>
<YR>2000</YR>
<VL>142</VL>
<NO>5</NO>
<PG>931-6</PG>
<IDENTIFIERS MODIFIED="2011-11-11 22:29:28 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-11-11 22:29:28 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="10809850"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cork-2009" MODIFIED="2012-08-28 14:29:11 +0100" MODIFIED_BY="Joel Bamford" NAME="Cork 2009" TYPE="JOURNAL_ARTICLE">
<AU>Cork MJ, Danby SG, Vasilopoulos Y, Hadgraft J, Lane ME, Moustafa M, et al</AU>
<TI>Epidermal Barrier Dysfunction in Atopic Dermatitis</TI>
<SO>Journal of Investigative Dermatology</SO>
<YR>2009</YR>
<VL>129</VL>
<NO>8</NO>
<PG>1892-908</PG>
<IDENTIFIERS MODIFIED="2012-08-28 14:29:11 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-08-28 14:29:11 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="19494826"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Costa-1989" MODIFIED="2013-04-02 01:48:17 +0100" MODIFIED_BY="[Empty name]" NAME="Costa 1989" TYPE="JOURNAL_ARTICLE">
<AU>Costa C, Rilliet A, Nicolet M and Surat JH</AU>
<TI>Scoring Atopic Dermatitis: The Simpler the Better?</TI>
<SO>Acta Dermato-Venereologica</SO>
<YR>1989</YR>
<VL>69</VL>
<PG>41-45</PG>
<IDENTIFIERS MODIFIED="2012-12-05 23:39:42 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-12-05 23:39:42 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="PMID: 2563607 "/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Diezel-1993" MODIFIED="2012-08-28 14:33:10 +0100" MODIFIED_BY="[Empty name]" NAME="Diezel 1993" TYPE="JOURNAL_ARTICLE">
<AU>Diezel W, Schulz E, Shanks M, Heise H</AU>
<TI>Plant oils: topical application and anti-inflammatory effects (Croton oil test)</TI>
<TO>Pflanzliche ole: ausserliche anwendung und antientzundliche wirkungen (crotonol-test)</TO>
<SO>Dermatologische Monatsschrift</SO>
<YR>1993</YR>
<VL>179</VL>
<NO>5</NO>
<PG>173-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dove-1999" MODIFIED="2012-08-28 14:31:06 +0100" MODIFIED_BY="Cathy Bennett" NAME="Dove 1999" TYPE="JOURNAL_ARTICLE">
<AU>Dove D, Johnson P</AU>
<TI>Oral evening primrose oil: its effect on length of pregnancy and selected intrapartum outcomes in low-risk nulliparous women</TI>
<SO>Journal of Nurse-Midwifery</SO>
<YR>1999</YR>
<VL>44</VL>
<NO>3</NO>
<PG>320-4</PG>
<IDENTIFIERS MODIFIED="2012-08-28 14:31:06 +0100" MODIFIED_BY="Liz Doney">
<IDENTIFIER MODIFIED="2012-08-28 14:31:04 +0100" MODIFIED_BY="Liz Doney" TYPE="MEDLINE" VALUE="10380450 "/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Draelos-2008" MODIFIED="2013-04-01 20:19:27 +0100" MODIFIED_BY="[Empty name]" NAME="Draelos 2008" TYPE="JOURNAL_ARTICLE">
<AU>Draelos ZD</AU>
<TI>The effect of ceramide-containing skin care products on eczema resolution duration</TI>
<SO>Cutis</SO>
<YR>2008</YR>
<VL>81</VL>
<NO>1</NO>
<PG>87-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Draelos-2011" MODIFIED="2012-08-28 14:38:37 +0100" MODIFIED_BY="[Empty name]" NAME="Draelos 2011" TYPE="JOURNAL_ARTICLE">
<AU>Draelos ZD, Koutatsu B, Butcher D, Billhimer W</AU>
<TI>Delivery of a pseudoceramide to atopic skin is related to objective and subjective improvement [P1306]</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>2 Suppl 1</NO>
<PG>AB57</PG>
<IDENTIFIERS MODIFIED="2012-08-28 14:38:37 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Eisenberg-1998" MODIFIED="2012-08-28 14:46:29 +0100" MODIFIED_BY="Diane A  Horsley" NAME="Eisenberg 1998" TYPE="JOURNAL_ARTICLE">
<AU>Eisenberg DM, David RB, Ettner SL, Appel S, Wilkey S, Van Rompay M, et al</AU>
<TI>Trends in alternative medicne use in the United States 1990-1997: results of a follow-up national survey</TI>
<SO>Journal of the American Medical Association</SO>
<YR>1998</YR>
<VL>280</VL>
<NO>18</NO>
<PG>1569-75</PG>
<IDENTIFIERS MODIFIED="2012-08-28 14:46:29 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-08-28 14:46:29 +0100" MODIFIED_BY="[Empty name]" TYPE="EMBASE" VALUE="1998386275"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ellis-2002" MODIFIED="2012-08-28 14:47:37 +0100" MODIFIED_BY="Diane A  Horsley" NAME="Ellis 2002" TYPE="JOURNAL_ARTICLE">
<AU>Ellis CN, Drake LA, Prendergast MM, Abramovits W, Boguniewitcz M, Daniel CR, et al</AU>
<TI>Cost of atopic dermatitis and eczema in the United States</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>2002</YR>
<VL>46</VL>
<NO>3</NO>
<PG>361-70</PG>
<IDENTIFIERS MODIFIED="2011-11-11 22:31:05 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-11-11 22:31:05 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="11862170"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ernst-2000" MODIFIED="2012-08-28 14:48:28 +0100" MODIFIED_BY="[Empty name]" NAME="Ernst 2000" TYPE="JOURNAL_ARTICLE">
<AU>Ernst E</AU>
<TI>The usage of complementary therapies by dermatological patients: a systematic review</TI>
<SO>British Journal of Dermatology</SO>
<YR>2000</YR>
<VL>142</VL>
<NO>5</NO>
<PG>857-61</PG>
<IDENTIFIERS MODIFIED="2012-08-28 14:48:27 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-08-28 14:48:27 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="10809840"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Finnigan-1991" MODIFIED="2012-08-28 14:49:21 +0100" MODIFIED_BY="Joel Bamford" NAME="Finnigan 1991" TYPE="JOURNAL_ARTICLE">
<AU>Finnigan MD</AU>
<TI>The Centre for the Study of Complementary Medicine: an attempt to understand its popularity through psychological, demographic and operational criteria</TI>
<SO>Complementary Medical Research</SO>
<YR>1991</YR>
<VL>5</VL>
<NO>2</NO>
<PG>83-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Friedmann-2002" MODIFIED="2011-12-09 20:38:24 +0000" MODIFIED_BY="[Empty name]" NAME="Friedmann 2002" TYPE="JOURNAL_ARTICLE">
<AU>Friedmann PS</AU>
<TI>The pathogenesis of atopic eczema</TI>
<SO>Hospital Medicine</SO>
<YR>2002</YR>
<VL>63</VL>
<NO>11</NO>
<PG>653-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gfesser-1997" MODIFIED="2012-08-28 14:54:34 +0100" MODIFIED_BY="Diane A  Horsley" NAME="Gfesser 1997" TYPE="JOURNAL_ARTICLE">
<AU>Gfesser M, Abeck D, Rugemer J, Schreiner V, Stab F, Disch R, et al</AU>
<TI>The early phase of epidermal barrier regeneration is faster in patients with atopic eczema</TI>
<SO>Dermatology</SO>
<YR>1997</YR>
<VL>195</VL>
<NO>4</NO>
<PG>332-6</PG>
<IDENTIFIERS MODIFIED="2012-08-28 14:54:34 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-08-28 14:54:34 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="9529552"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hanifin-1980" MODIFIED="2011-12-09 20:38:35 +0000" MODIFIED_BY="Diane A  Horsley" NAME="Hanifin 1980" TYPE="JOURNAL_ARTICLE">
<AU>Hanifin J, Rajka G</AU>
<TI>Diagnostic features of atopic dermatitis</TI>
<SO>Acta Dermato-Venereologica</SO>
<YR>1980</YR>
<VL>92</VL>
<PG>44-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Herd-1996" MODIFIED="2012-08-28 16:12:10 +0100" MODIFIED_BY="[Empty name]" NAME="Herd 1996" TYPE="JOURNAL_ARTICLE">
<AU>Herd RM, Tidman MJ, Prescot RJ, Hunter JA</AU>
<TI>The cost of atopic eczema</TI>
<SO>British Journal of Dermatology</SO>
<YR>1996</YR>
<VL>135</VL>
<NO>1</NO>
<PG>20-3</PG>
<IDENTIFIERS MODIFIED="2012-08-28 16:12:10 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-08-28 16:12:10 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="8776353"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2012-08-28 14:57:39 +0100" MODIFIED_BY="Joel Bamford" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<PB>Available from www.cochrane-handbook.org.</PB>
<IDENTIFIERS MODIFIED="2012-08-28 14:57:39 +0100" MODIFIED_BY="Joel TM Bamford"/>
</REFERENCE>
<REFERENCE ID="REF-Hoare-2000" MODIFIED="2012-08-28 14:58:31 +0100" MODIFIED_BY="[Empty name]" NAME="Hoare 2000" TYPE="JOURNAL_ARTICLE">
<AU>Hoare C, Li Wan Po A, Williams H</AU>
<TI>Systematic review of treatments for atopic eczema</TI>
<SO>Health Technology Assessment</SO>
<YR>2000</YR>
<VL>4</VL>
<NO>37</NO>
<PG>1-191</PG>
<IDENTIFIERS MODIFIED="2012-08-28 14:58:31 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-08-28 14:58:31 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="11134919"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Horrobin-2000" MODIFIED="2012-08-28 14:59:55 +0100" MODIFIED_BY="[Empty name]" NAME="Horrobin 2000" TYPE="JOURNAL_ARTICLE">
<AU>Horrobin DF</AU>
<TI>Essential fatty acid metabolism and its modification in atopic eczema</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2000</YR>
<VL>71</VL>
<NO>1 Suppl</NO>
<PG>367S-72S</PG>
<IDENTIFIERS MODIFIED="2012-08-28 14:59:55 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-08-28 14:59:55 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="10617999"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Imokawa-1991" MODIFIED="2012-08-28 15:00:49 +0100" MODIFIED_BY="Diane A  Horsley" NAME="Imokawa 1991" TYPE="JOURNAL_ARTICLE">
<AU>Imokawa G, Abe A, Jin K, Higaki Y, Kawashima M, Hidano A</AU>
<TI>Decreased level of ceramides in stratum corneum of atopic dermatitis: an etiologic factor in atopic dry skin</TI>
<SO>Journal of Investigative Dermatology</SO>
<YR>1991</YR>
<VL>96</VL>
<NO>4</NO>
<PG>523-6</PG>
<IDENTIFIERS MODIFIED="2012-08-28 15:00:49 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-08-28 15:00:49 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="2007790"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jellin-2005" MODIFIED="2013-02-26 12:05:17 +0000" MODIFIED_BY="Finola M Delamere" NAME="Jellin 2005" TYPE="BOOK">
<AU>Jellin JM, editorial staff at Therapeutic Research Center</AU>
<SO>Natural Medicines: Comprehensive Database (Natural Medicines)</SO>
<YR>2005</YR>
<EN>7th</EN>
<PB>Pharmacist's Letter / Prescriber's Letter</PB>
<CY>Stockton CA</CY>
<IDENTIFIERS MODIFIED="2013-02-26 12:00:33 +0000" MODIFIED_BY="Liz Doney">
<IDENTIFIER MODIFIED="2013-02-26 12:00:33 +0000" MODIFIED_BY="Liz Doney" TYPE="OTHER" VALUE="ISBN 0974706221"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jensen-1990" MODIFIED="2012-08-28 15:01:34 +0100" MODIFIED_BY="Diane A  Horsley" NAME="Jensen 1990" TYPE="JOURNAL_ARTICLE">
<AU>Jensen P</AU>
<TI>Use of alternative medicine by patients with atopic dermatitis and psoriasis</TI>
<SO>Acta Dermato-Venereologica</SO>
<YR>1990</YR>
<VL>70</VL>
<NO>5</NO>
<PG>421-4</PG>
<IDENTIFIERS MODIFIED="2012-08-28 15:01:34 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-08-28 15:01:34 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="1980977"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Johansson-2001" MODIFIED="2012-08-28 15:03:54 +0100" MODIFIED_BY="Diane A  Horsley" NAME="Johansson 2001" TYPE="JOURNAL_ARTICLE">
<AU>Johansson SG, Hourihane JO, Bousquet J, Bruijnzeel-Koomen C, Dreborg S, Haahteela T, et al</AU>
<TI>A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force</TI>
<SO>Allergy</SO>
<YR>2001</YR>
<VL>56</VL>
<NO>9</NO>
<PG>813-24</PG>
<IDENTIFIERS MODIFIED="2012-08-28 15:03:54 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-08-28 15:03:54 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="11551246"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Johnson-1984" MODIFIED="2012-08-28 15:04:38 +0100" MODIFIED_BY="[Empty name]" NAME="Johnson 1984" TYPE="JOURNAL_ARTICLE">
<AU>Johnson ML, Johnson KG, Engel A</AU>
<TI>Prevalence, morbidity and cost of dermatological diseases</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>1984</YR>
<VL>11</VL>
<NO>5 Pt 2</NO>
<PG>930-6</PG>
<IDENTIFIERS MODIFIED="2012-08-28 15:04:38 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-08-28 15:04:38 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="6501612"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kramer-2012" MODIFIED="2013-01-15 05:59:07 +0000" MODIFIED_BY="[Empty name]" NAME="Kramer 2012" TYPE="JOURNAL_ARTICLE">
<AU>Kramer MS, Kakuma R</AU>
<TI>Maternal dietary antigen avoidance during pregancy or lactation, or both, for preventing or treating atopic disease in the child</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<VL>9</VL>
<PG>published on line</PG>
<IDENTIFIERS MODIFIED="2012-12-05 17:42:53 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-12-05 17:42:53 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000133.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kubica-2011" MODIFIED="2012-08-28 15:05:54 +0100" MODIFIED_BY="[Empty name]" NAME="Kubica 2011" TYPE="JOURNAL_ARTICLE">
<AU>Kubica E, Ezzedine K, Lalanne N, Dartial Y, Taieb A, Milpied B</AU>
<TI>Oral alitretinoin in chronic refactory hand eczema: a "real life" case-series of 12 patients</TI>
<SO>European Journal of Dermatology</SO>
<YR>2011</YR>
<VL>21</VL>
<NO>3</NO>
<PG>454-6</PG>
<IDENTIFIERS MODIFIED="2012-08-28 15:05:54 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-08-28 15:05:53 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="21680291"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Larsen-2002" MODIFIED="2012-08-28 16:03:49 +0100" MODIFIED_BY="Diane A  Horsley" NAME="Larsen 2002" TYPE="JOURNAL_ARTICLE">
<AU>Larsen FS, Hanifin JM</AU>
<TI>Epidemiology of atopic dermatitis</TI>
<SO>Immunology &amp; Allergy Clinics of North America</SO>
<YR>2002</YR>
<VL>22</VL>
<NO>1</NO>
<PG>1-24</PG>
<IDENTIFIERS MODIFIED="2012-08-28 16:03:47 +0100" MODIFIED_BY="Liz Doney">
<IDENTIFIER MODIFIED="2012-08-28 16:03:47 +0100" MODIFIED_BY="Liz Doney" TYPE="EMBASE" VALUE="2002061960"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Leung-2003" MODIFIED="2012-08-28 15:06:38 +0100" MODIFIED_BY="[Empty name]" NAME="Leung 2003" TYPE="JOURNAL_ARTICLE">
<AU>Leung DY, Bieber T</AU>
<TI>Atopic dermatitis</TI>
<SO>Lancet</SO>
<YR>2003</YR>
<VL>361</VL>
<NO>9352</NO>
<PG>151-60</PG>
<IDENTIFIERS MODIFIED="2012-08-28 15:06:38 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-08-28 15:06:38 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="12531593"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Leung-2008" MODIFIED="2012-12-05 18:01:55 +0000" MODIFIED_BY="[Empty name]" NAME="Leung 2008" TYPE="BOOK_SECTION">
<AU>Leung DYM, Eichenfield LF and Bogunlewicz M</AU>
<TI>Atopic dermatitis (atopic eczema)</TI>
<SO>Fitzpatrick's Dermatology in General Medicine</SO>
<YR>2008</YR>
<VL>1</VL>
<PG>146-158</PG>
<EN>7th</EN>
<ED>Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller A and Leffel DJ</ED>
<PB>McGraw=Hill</PB>
<CY>NYC</CY>
<IDENTIFIERS MODIFIED="2012-12-05 18:01:55 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-12-05 18:01:55 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="ISBN = 9780071466905"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lewis-Jones-1995" MODIFIED="2012-08-28 15:08:32 +0100" MODIFIED_BY="[Empty name]" NAME="Lewis Jones 1995" TYPE="JOURNAL_ARTICLE">
<AU>Lewis-Jones MS, Finlay AY</AU>
<TI>The Childrens' Dermatology Life Quality Index (CDLQI): initial validation and practical use.</TI>
<SO>British Journal of Dermatology</SO>
<YR>1995</YR>
<VL>132</VL>
<NO>6</NO>
<PG>942-9</PG>
<IDENTIFIERS MODIFIED="2012-08-28 15:08:32 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-08-28 15:08:32 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="7662573"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Manku-1982" MODIFIED="2012-08-28 15:09:45 +0100" MODIFIED_BY="[Empty name]" NAME="Manku 1982" TYPE="JOURNAL_ARTICLE">
<AU>Manku MS, Horrobin DF, Morse NL, Kyte V, Jenkins K, Wright S, et al</AU>
<TI>Reduced levels of prostaglandin precursors in the blood of atopic patients: defective delta-6-desaturated function as a biochemical basis for atopy</TI>
<SO>Prostaglandins Leukotrienes &amp; Medicine</SO>
<YR>1982</YR>
<VL>9</VL>
<NO>6</NO>
<PG>615-28</PG>
<IDENTIFIERS MODIFIED="2012-08-28 15:09:45 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-08-28 15:09:45 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="6961468"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Matsumoto-2000" MODIFIED="2012-08-28 15:10:37 +0100" MODIFIED_BY="[Empty name]" NAME="Matsumoto 2000" TYPE="JOURNAL_ARTICLE">
<AU>Matsumoto M, Sugiura H, Uehara M</AU>
<TI>Skin barrier function in patients with completely healed atopic dermatitis</TI>
<SO>Journal of Dermatological Science</SO>
<YR>2000</YR>
<VL>23</VL>
<NO>3</NO>
<PG>178-82</PG>
<IDENTIFIERS MODIFIED="2012-08-28 15:10:37 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-08-28 15:10:37 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="10959043"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-McNally-1998" MODIFIED="2012-08-28 15:11:35 +0100" MODIFIED_BY="[Empty name]" NAME="McNally 1998" TYPE="JOURNAL_ARTICLE">
<AU>McNally NJ, Williams HC, Smallman-Raynor M, Lewis S, Venn A, Britton J</AU>
<TI>Atopic eczema and domestic water hardness</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<NO>9127</NO>
<PG>527-31</PG>
<IDENTIFIERS MODIFIED="2012-08-28 15:11:35 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-08-28 15:11:35 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="9716057"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-McNally-2001" MODIFIED="2012-08-28 15:12:20 +0100" MODIFIED_BY="[Empty name]" NAME="McNally 2001" TYPE="JOURNAL_ARTICLE">
<AU>McNally NJ, Williams HC, Phillips DR</AU>
<TI>Atopic eczema and the home environment</TI>
<SO>British Journal of Dermatology</SO>
<YR>2001</YR>
<VL>145</VL>
<NO>5</NO>
<PG>730-6</PG>
<IDENTIFIERS MODIFIED="2012-08-28 15:12:20 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-08-28 15:12:20 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="11736896"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Melnik-1992" MODIFIED="2012-08-28 15:14:45 +0100" MODIFIED_BY="Diane A  Horsley" NAME="Melnik 1992" TYPE="JOURNAL_ARTICLE">
<AU>Melnik B, Plewig G</AU>
<TI>Are disturbances of omega-6-fatty acid metabolism involved in the pathogenesis of atopic dermatitis?</TI>
<SO>Acta Dermato-Venereologica</SO>
<YR>1992</YR>
<VL>176</VL>
<PG>77-85</PG>
<IDENTIFIERS MODIFIED="2012-08-28 15:14:45 +0100" MODIFIED_BY="Liz Doney">
<IDENTIFIER MODIFIED="2012-08-28 15:14:45 +0100" MODIFIED_BY="Liz Doney" TYPE="MEDLINE" VALUE="1476044 "/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Moore-2009" MODIFIED="2012-08-28 15:16:24 +0100" MODIFIED_BY="Joel TM Bamford" NAME="Moore 2009" TYPE="JOURNAL_ARTICLE">
<AU>Moore EJ, Williams A, Manias E, Varigos G, Donath S</AU>
<TI>Eczema workshops reduce severity of childhood atopic eczema</TI>
<SO>Australasian Journal of Dermatology</SO>
<YR>2009</YR>
<VL>50</VL>
<NO>2</NO>
<PG>100-6</PG>
<IDENTIFIERS MODIFIED="2012-08-28 15:16:24 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-08-28 15:16:24 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="19397561"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Morse-1989" MODIFIED="2012-08-28 15:17:19 +0100" MODIFIED_BY="[Empty name]" NAME="Morse 1989" TYPE="JOURNAL_ARTICLE">
<AU>Morse PF, Horrobin DF, Manku MS, Stewart JC, Allen R, Littlewood S, et al</AU>
<TI>Meta-analysis of placebo-controlled studies of the efficacy of Epogam in the treatment of atopic eczema. Relationship between plasma essential fatty acid changes and clinical response</TI>
<SO>British Journal of Dermatology</SO>
<YR>1989</YR>
<VL>121</VL>
<NO>1</NO>
<PG>75-90</PG>
<IDENTIFIERS MODIFIED="2012-08-28 15:17:19 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-08-28 15:17:19 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="2667620"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Morse-2006" MODIFIED="2012-08-28 15:18:06 +0100" MODIFIED_BY="[Empty name]" NAME="Morse 2006" TYPE="JOURNAL_ARTICLE">
<AU>Morse NL, Clough PM</AU>
<TI>A meta-analysis of randomized, placebo-controlled clinical trials of Efamol evening primrose oil in atopic eczema. Where do we go from here in light of more recent discoveries?</TI>
<SO>Current Pharmaceutical Biotechechnology</SO>
<YR>2006</YR>
<VL>7</VL>
<NO>6</NO>
<PG>503-24</PG>
<IDENTIFIERS MODIFIED="2012-08-28 15:18:06 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-08-28 15:18:06 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="17168667"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Nankervis-2010" MODIFIED="2013-02-26 11:40:52 +0000" MODIFIED_BY="Liz Doney" NAME="Nankervis 2010" TYPE="COCHRANE_PROTOCOL">
<AU>Nankervis H, Smith EV, Boyle RJ, Rushton L, Williams HC, Hewson DM, et al</AU>
<TI>House dust mite reduction and avoidance measures for treating eczema</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2013-02-26 11:40:52 +0000" MODIFIED_BY="Liz Doney">
<IDENTIFIER MODIFIED="2013-02-26 11:40:51 +0000" MODIFIED_BY="Liz Doney" TYPE="DOI" VALUE="10.1002/14651858.CD008426"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-NHIS-2007" MODIFIED="2012-08-28 15:19:41 +0100" MODIFIED_BY="Joel Bamford" NAME="NHIS 2007" TYPE="OTHER">
<AU>National Health Interview Survey (NHIS)</AU>
<TI>2007 CAM Use Data</TI>
<SO>http://nccam.nih.gov/news/camstats/</SO>
<YR>(accessed 28 August 2012)</YR>
<IDENTIFIERS MODIFIED="2012-08-28 15:19:41 +0100" MODIFIED_BY="Joel Bamford"/>
</REFERENCE>
<REFERENCE ID="REF-Nordstrom-1995" MODIFIED="2012-08-28 15:22:08 +0100" MODIFIED_BY="[Empty name]" NAME="Nordstrom 1995" TYPE="JOURNAL_ARTICLE">
<AU>Nordstrom DC, Honkanen VE, Nasu Y, Antila E, Friman C, Konttinen YT</AU>
<TI>Alpha-linolenic acid in the treatment of rheumatoid arthritis. A double-blind, placebo-controlled and randomized study: flaxseed vs. safflower seed</TI>
<SO>Rheumatology International</SO>
<YR>1995</YR>
<VL>14</VL>
<NO>6</NO>
<PG>231-4</PG>
<IDENTIFIERS MODIFIED="2012-08-28 15:21:38 +0100" MODIFIED_BY="Liz Doney">
<IDENTIFIER MODIFIED="2012-08-28 15:21:38 +0100" MODIFIED_BY="Liz Doney" TYPE="MEDLINE" VALUE="7597378"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Pastar-2005" MODIFIED="2012-08-28 15:26:31 +0100" MODIFIED_BY="Joel Bamford" NAME="Pastar 2005" TYPE="JOURNAL_ARTICLE">
<AU>Pastar Z, Lipozencic J, Ljubojevic S</AU>
<TI>Etiopathogenesis of atopic dermatitis-an overview</TI>
<SO>Acta Dermatovenerologica Croatica</SO>
<YR>2005</YR>
<VL>13</VL>
<NO>1</NO>
<PG>54-62</PG>
<IDENTIFIERS MODIFIED="2012-08-28 15:26:31 +0100" MODIFIED_BY="Joel TM Bamford">
<IDENTIFIER MODIFIED="2012-08-28 15:26:31 +0100" MODIFIED_BY="Joel TM Bamford" TYPE="MEDLINE" VALUE="15788148"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Patel-2011" MODIFIED="2012-08-28 16:11:05 +0100" MODIFIED_BY="[Empty name]" NAME="Patel 2011" TYPE="JOURNAL_ARTICLE">
<AU>Patel T, Gosipovitch G</AU>
<TI>Therapy of Pruritus</TI>
<SO>Expert Opinion in Pharmacotherapy</SO>
<YR>2011</YR>
<VL>11</VL>
<NO>10</NO>
<PG>1673-82</PG>
<IDENTIFIERS MODIFIED="2012-08-28 16:11:05 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-08-28 16:11:05 +0100" MODIFIED_BY="Liz Doney" TYPE="PUBMED" VALUE="20426711"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Phinney-1994" MODIFIED="2012-08-28 15:28:20 +0100" MODIFIED_BY="[Empty name]" NAME="Phinney 1994" TYPE="JOURNAL_ARTICLE">
<AU>Phinney S</AU>
<TI>Potential risk of prolonged gamma-linolenic acid use</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1994</YR>
<VL>120</VL>
<NO>8</NO>
<PG>692</PG>
<IDENTIFIERS MODIFIED="2012-08-28 15:28:20 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-08-28 15:28:20 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="8135457"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Pl_x00f6_tz-2010" MODIFIED="2012-08-28 15:28:56 +0100" MODIFIED_BY="Joel TM Bamford" NAME="Plötz 2010" TYPE="JOURNAL_ARTICLE">
<AU>Plötz SG, Ring J</AU>
<TI>What's new in atopic eczema?</TI>
<SO>Expert Opinion on Emerging Drugs</SO>
<YR>2010</YR>
<VL>15</VL>
<NO>2</NO>
<PG>249-67</PG>
<IDENTIFIERS MODIFIED="2012-08-28 15:28:56 +0100" MODIFIED_BY="Joel TM Bamford">
<IDENTIFIER MODIFIED="2011-11-11 22:46:39 +0000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="20433363"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Poyner-2001" MODIFIED="2011-12-09 20:40:44 +0000" MODIFIED_BY="[Empty name]" NAME="Poyner 2001" TYPE="JOURNAL_ARTICLE">
<AU>Poyner T</AU>
<TI>PCDS atopic eczema guidelines optimise GP management</TI>
<SO>Guidelines in Practice</SO>
<YR>2001</YR>
<VL>4</VL>
<NO>1</NO>
<PG>33-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Puri-2007" MODIFIED="2012-08-28 15:30:11 +0100" MODIFIED_BY="Joel Bamford" NAME="Puri 2007" TYPE="JOURNAL_ARTICLE">
<AU>Puri BK</AU>
<TI>The safety of evening primrose oil in epilepsy</TI>
<SO>Prostaglandins Leukotrienes &amp; Essential Fatty Acids</SO>
<YR>2007</YR>
<VL>77</VL>
<NO>2</NO>
<PG>101-3</PG>
<IDENTIFIERS MODIFIED="2012-08-28 15:29:48 +0100" MODIFIED_BY="Joel Bamford">
<IDENTIFIER MODIFIED="2011-08-02 13:35:13 +0100" MODIFIED_BY="Joel Bamford" TYPE="PUBMED" VALUE="17764919"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rabahi-2010" MODIFIED="2012-08-28 15:31:14 +0100" MODIFIED_BY="Joel Bamford" NAME="Rabahi 2010" TYPE="JOURNAL_ARTICLE">
<AU>Rabahi MF, Ferreira AA, Madeira JG, Galvao PM, Pinto SA</AU>
<TI>Lipoid pneumonia secondary to long-term use of evening primrose oil</TI>
<SO>Jornal Brasileiro De Pneumologia</SO>
<YR>2010</YR>
<VL>36</VL>
<NO>5</NO>
<PG>657-61</PG>
<IDENTIFIERS MODIFIED="2012-08-28 15:30:43 +0100" MODIFIED_BY="Joel Bamford">
<IDENTIFIER MODIFIED="2011-08-02 13:02:57 +0100" MODIFIED_BY="Joel Bamford" TYPE="PUBMED" VALUE="21085832"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rajka-1989" MODIFIED="2012-09-06 13:51:59 +0100" MODIFIED_BY="[Empty name]" NAME="Rajka 1989" TYPE="BOOK">
<AU>Rajka G</AU>
<SO>Essential aspects of atopic dermatitis</SO>
<YR>1989</YR>
<PB>Springer Verlag</PB>
<CY>Berlin</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reid-1995" MODIFIED="2012-08-28 15:32:29 +0100" MODIFIED_BY="[Empty name]" NAME="Reid 1995" TYPE="JOURNAL_ARTICLE">
<AU>Reid P, Lewis-Jones MS</AU>
<TI>Sleep difficulties and their management in preschoolers with atopic eczema</TI>
<SO>Clinical &amp; Experimental Dermatology</SO>
<YR>1995</YR>
<VL>20</VL>
<NO>1</NO>
<PG>38-41</PG>
<IDENTIFIERS MODIFIED="2011-11-11 22:47:11 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-11-11 22:47:11 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="7671394"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Riaz-2009" MODIFIED="2012-08-28 15:33:43 +0100" MODIFIED_BY="Joel Bamford" NAME="Riaz 2009" TYPE="JOURNAL_ARTICLE">
<AU>Riaz A, Khan RA, Ahmed SP</AU>
<TI>Assessment of anticoagulant effect of evening primrose oil</TI>
<SO>Pakistan Journal of Pharmaceutical Sciences</SO>
<YR>2009</YR>
<VL>22</VL>
<NO>4</NO>
<PG>355-9</PG>
<IDENTIFIERS MODIFIED="2012-08-28 15:32:59 +0100" MODIFIED_BY="Joel TM Bamford">
<IDENTIFIER MODIFIED="2011-11-11 22:48:02 +0000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="19783511"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Roberts-2010" MODIFIED="2012-08-28 15:34:24 +0100" MODIFIED_BY="[Empty name]" NAME="Roberts 2010" TYPE="JOURNAL_ARTICLE">
<AU>Roberts H, Orchard D</AU>
<TI>Methotrexate is a safe and effective treatment for paediatric discoid (nummular) eczema: a case series of 25 children</TI>
<SO>Australasian Journal of Dermatology</SO>
<YR>2010</YR>
<VL>51</VL>
<NO>2</NO>
<PG>128-30</PG>
<IDENTIFIERS MODIFIED="2012-05-02 15:23:28 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-05-02 15:23:28 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="20546220"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Saito-2005" MODIFIED="2012-08-28 15:35:20 +0100" MODIFIED_BY="Joel Bamford" NAME="Saito 2005" TYPE="JOURNAL_ARTICLE">
<AU>Saito, H</AU>
<TI>Much Atopy about the Skin: Genome-Wide Molecular Analysis of Atopic Eczema</TI>
<SO>International Archives of Allergy &amp; Immunology</SO>
<YR>2005</YR>
<VL>137</VL>
<NO>4</NO>
<PG>319-25</PG>
<IDENTIFIERS MODIFIED="2012-08-28 15:35:20 +0100" MODIFIED_BY="Joel Bamford">
<IDENTIFIER MODIFIED="2011-08-02 13:52:18 +0100" MODIFIED_BY="Joel Bamford" TYPE="OTHER" VALUE="15970641"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sampson-1992" MODIFIED="2012-08-28 15:35:41 +0100" MODIFIED_BY="[Empty name]" NAME="Sampson 1992" TYPE="JOURNAL_ARTICLE">
<AU>Sampson HA</AU>
<TI>Atopic dermatitis</TI>
<SO>Annals of Allergy</SO>
<YR>1992</YR>
<VL>69</VL>
<NO>6</NO>
<PG>469-79</PG>
<IDENTIFIERS MODIFIED="2011-11-11 22:49:11 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-11-11 22:49:11 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="1471777"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Schmitt-2007" MODIFIED="2012-12-05 17:52:20 +0000" MODIFIED_BY="[Empty name]" NAME="Schmitt 2007" TYPE="JOURNAL_ARTICLE">
<AU>Schmitt J, Schakel K, Schmitt N and Meurer M</AU>
<TI>Systematic Treatment of Severe Atopic Eczema: A Systematic Review</TI>
<SO>Acta Dermato-Venereologica</SO>
<YR>2007</YR>
<VL>87</VL>
<PG>100-111</PG>
<IDENTIFIERS MODIFIED="2012-12-05 17:52:20 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-12-05 17:50:49 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.2340/00015555-0207"/>
<IDENTIFIER MODIFIED="2012-12-05 17:52:20 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="ISSN 0001-5555"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Schram-2010" MODIFIED="2012-08-28 15:36:44 +0100" MODIFIED_BY="Joel TM Bamford" NAME="Schram 2010" TYPE="JOURNAL_ARTICLE">
<AU>Schram ME, Tedja AM, Spijker R, Bos JD, Williams HC, Spurls PI</AU>
<TI>Is there a rural/urban gradient in prevalence of eczema? A systematic review</TI>
<SO>British Journal of Dermatology</SO>
<YR>2010</YR>
<VL>162</VL>
<NO>5</NO>
<PG>964-73</PG>
<IDENTIFIERS MODIFIED="2012-08-28 15:36:44 +0100" MODIFIED_BY="Joel TM Bamford">
<IDENTIFIER MODIFIED="2011-11-11 22:49:50 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="20331459"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Schultz_x002d_Larsen-1993" MODIFIED="2012-08-28 15:37:22 +0100" MODIFIED_BY="[Empty name]" NAME="Schultz-Larsen 1993" TYPE="JOURNAL_ARTICLE">
<AU>Schultz Larsen F</AU>
<TI>Atopic dermatitis: a genetic-epidemiological study in a population-based twin sample</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>1993</YR>
<VL>28</VL>
<NO>5 Pt 1</NO>
<PG>719-23</PG>
<IDENTIFIERS MODIFIED="2011-11-11 22:50:22 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-11-11 22:50:22 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="8496415"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-SCORAD-index-1993" MODIFIED="2013-04-01 20:31:30 +0100" MODIFIED_BY="[Empty name]" NAME="SCORAD index 1993" TYPE="JOURNAL_ARTICLE">
<TI>Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis</TI>
<SO>Dermatology</SO>
<YR>1993</YR>
<VL>186</VL>
<NO>1</NO>
<PG>23-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shahidi-1997" MODIFIED="2012-08-28 16:08:04 +0100" MODIFIED_BY="Joel Bamford" NAME="Shahidi 1997" TYPE="JOURNAL_ARTICLE">
<AU>Shahidi F, Amarowicz R, He Y, Wettasinghe M</AU>
<TI>Antioxidant activity of phenolic extracts of evening primrose (Oenothera biennis): a preliminary study</TI>
<SO>Journal of Food Lipids</SO>
<YR>1997</YR>
<VL>4</VL>
<PG>75-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sheehan-1992" MODIFIED="2012-08-28 15:41:02 +0100" MODIFIED_BY="[Empty name]" NAME="Sheehan 1992" TYPE="JOURNAL_ARTICLE">
<AU>Sheehan MP, Rustin MH, Atherton DJ, Buckley C, Harris DW, Brostoff J, et al</AU>
<TI>Efficacy of traditional Chinese herbal therapy in adult atopic dermatitis</TI>
<SO>Lancet</SO>
<YR>1992</YR>
<VL>340</VL>
<NO>8810</NO>
<PG>13-7</PG>
<IDENTIFIERS MODIFIED="2012-08-28 15:40:15 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-08-28 15:40:15 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="1351600"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Su-1997" MODIFIED="2012-08-28 15:41:52 +0100" MODIFIED_BY="[Empty name]" NAME="Su 1997" TYPE="JOURNAL_ARTICLE">
<AU>Su JC, Kemp AS, Varigos GA, Nolan TM</AU>
<TI>Atopic eczema: its impact on the family and financial cost</TI>
<SO>Archives of Diseases of Childhood</SO>
<YR>1997</YR>
<VL>76</VL>
<NO>2</NO>
<PG>159-62</PG>
<IDENTIFIERS MODIFIED="2011-11-11 22:51:32 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-11-11 22:51:32 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="9068310"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Terreehorst-2002" MODIFIED="2012-08-28 15:43:16 +0100" MODIFIED_BY="[Empty name]" NAME="Terreehorst 2002" TYPE="JOURNAL_ARTICLE">
<AU>Terreehorst I, Duivenvoorden HJ, Temples-Pavlica Z, Oosting AJ, de Monchy JG, Bruijnzeel-Koomen CA, et al</AU>
<TI>The unfavourable effects of concomitant asthma and sleeplessness due to the atopic eczema/dermatitis syndrome (AEDS) on quality of life in subjects allergic to house-dust mites</TI>
<SO>Allergy</SO>
<YR>2002</YR>
<VL>57</VL>
<NO>10</NO>
<PG>919-25</PG>
<IDENTIFIERS MODIFIED="2012-08-28 15:43:16 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-08-28 15:43:16 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="12269938"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Thestrup_x002d_Pedersen-2003" MODIFIED="2012-08-28 15:44:03 +0100" MODIFIED_BY="Joel TM Bamford" NAME="Thestrup-Pedersen 2003" TYPE="JOURNAL_ARTICLE">
<AU>Thestrup-Pedersen, K</AU>
<TI>Tacrolimus treatment of atopic eczema/dermatitis syndrome</TI>
<SO>Current Opinion in Allergy &amp; Clinical Immunology</SO>
<YR>2003</YR>
<VL>3</VL>
<NO>5</NO>
<PG>359-62</PG>
<IDENTIFIERS MODIFIED="2012-08-28 15:44:03 +0100" MODIFIED_BY="Joel TM Bamford">
<IDENTIFIER MODIFIED="2011-02-14 20:06:32 +0000" MODIFIED_BY="Joel TM Bamford" TYPE="OTHER" VALUE="14501435"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tofte-2001" MODIFIED="2012-08-28 15:45:16 +0100" MODIFIED_BY="[Empty name]" NAME="Tofte 2001" TYPE="JOURNAL_ARTICLE">
<AU>Tofte SJ, Hanifin JM</AU>
<TI>Current management and therapy of atopic dermatitis</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>2001</YR>
<VL>44</VL>
<NO>1 Suppl</NO>
<PG>S13-16</PG>
<IDENTIFIERS MODIFIED="2012-08-28 15:45:05 +0100" MODIFIED_BY="Liz Doney">
<IDENTIFIER MODIFIED="2012-08-28 15:45:05 +0100" MODIFIED_BY="Liz Doney" TYPE="MEDLINE" VALUE="11145791"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Triebskorn-1989" MODIFIED="2012-08-28 15:46:45 +0100" MODIFIED_BY="[Empty name]" NAME="Triebskorn 1989" TYPE="JOURNAL_ARTICLE">
<AU>Triebskorn A, Drosner M</AU>
<TI>Methods of alternative medicine treatment assessed by patients with allergies and patients with chronic skin diseases</TI>
<TO>"Alternativ-medizinische" Behandlungsmethoden in der Beurteilung vonAllergikern und chronisch Hautkranken</TO>
<SO>H+G Zeitschrift für Hautkrankheiten</SO>
<YR>1989</YR>
<VL>64</VL>
<NO>6</NO>
<PG>487-94</PG>
<IDENTIFIERS MODIFIED="2012-08-28 15:46:45 +0100" MODIFIED_BY="Liz Doney">
<IDENTIFIER MODIFIED="2012-08-28 15:46:45 +0100" MODIFIED_BY="Liz Doney" TYPE="MEDLINE" VALUE="2763615"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-van-Gool-2003" MODIFIED="2013-02-26 12:10:45 +0000" MODIFIED_BY="Finola M Delamere" NAME="van Gool 2003" TYPE="JOURNAL_ARTICLE">
<AU>van Gool CJ, Thijs C, Henquet CJ, van Houwelingen AC, Dagnelie PC, Schrander J, et al</AU>
<TI>Gamma-linolenic acid supplementation for prophylaxis of atopic dermatitis - a randomized controlled trial in infants at high familial risk</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2003</YR>
<VL>77</VL>
<NO>4</NO>
<PG>943-51</PG>
<IDENTIFIERS MODIFIED="2013-02-26 12:10:45 +0000" MODIFIED_BY="Liz Doney">
<IDENTIFIER MODIFIED="2013-02-26 12:10:45 +0000" MODIFIED_BY="Liz Doney" TYPE="PUBMED" VALUE="12663296"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-van-Odijk-2003" MODIFIED="2012-08-28 15:25:27 +0100" MODIFIED_BY="Joel Bamford" NAME="van Odijk 2003" TYPE="JOURNAL_ARTICLE">
<AU>van Odijk J, Kull I, Borres MP, Brandtzaeg P, Edberg U, Hanson LA, et al</AU>
<TI>Breastfeeding and allergic disease: a multidisciplinary review of the literature (1966-2001) on the mode of early feeding in infancy and its impact on later atopic manifestations</TI>
<SO>Allergy</SO>
<YR>2003</YR>
<VL>58</VL>
<NO>9</NO>
<PG>833-43</PG>
<IDENTIFIERS MODIFIED="2012-08-28 15:25:27 +0100" MODIFIED_BY="Liz Doney">
<IDENTIFIER MODIFIED="2012-08-28 15:25:27 +0100" MODIFIED_BY="Liz Doney" TYPE="MEDLINE" VALUE="12911410"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wang-2007" MODIFIED="2012-08-28 15:48:25 +0100" MODIFIED_BY="Joel Bamford" NAME="Wang 2007" TYPE="JOURNAL_ARTICLE">
<AU>Wang IJ, Guo YL, Weng HJ, Hsieh WS, Chuang YL, Lin SJ, Chen PC</AU>
<TI>Environmental risk factors for early infantile atopic dermatitis</TI>
<SO>Pediatric Allergy &amp; Immunology </SO>
<YR>2007</YR>
<VL>18</VL>
<NO>5</NO>
<PG>441-7</PG>
<IDENTIFIERS MODIFIED="2012-08-28 15:48:25 +0100" MODIFIED_BY="Joel Bamford">
<IDENTIFIER MODIFIED="2011-08-09 22:01:36 +0100" MODIFIED_BY="Joel Bamford" TYPE="PUBMED" VALUE="17617812"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Weller-2009" MODIFIED="2012-12-16 12:42:33 +0000" MODIFIED_BY="[Empty name]" NAME="Weller 2009" TYPE="JOURNAL_ARTICLE">
<AU>Weller RPJB, Hunter JAA, Savin JA, Dahl MV</AU>
<TI>Eczema and Dermatitis</TI>
<SO>chapter in Clinical Dermatology</SO>
<YR>2009</YR>
<VL>Chapter 7</VL>
<PG>79-103</PG>
<IDENTIFIERS MODIFIED="2012-12-03 12:55:15 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-12-03 12:55:15 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="http://dx.doi.org/10.1002/9781444300086.ch7"/>
<IDENTIFIER MODIFIED="2012-12-03 12:54:33 +0000" MODIFIED_BY="[Empty name]" OTHERTYPE="SN" TYPE="OTHER" VALUE="9781444300086.ch7"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Williams-1994" MODIFIED="2012-08-28 15:48:57 +0100" MODIFIED_BY="Diane A  Horsley" NAME="Williams 1994" TYPE="JOURNAL_ARTICLE">
<AU>Williams HC, Strachan DP, Hay RJ</AU>
<TI>Childhood eczema: disease of the advantaged?</TI>
<SO>BMJ</SO>
<YR>1994</YR>
<VL>308</VL>
<NO>6937</NO>
<PG>1132-5</PG>
<IDENTIFIERS MODIFIED="2011-11-11 22:53:47 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-11-11 22:53:47 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="8173454"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Williams-2000" MODIFIED="2012-08-28 15:52:51 +0100" MODIFIED_BY="[Empty name]" NAME="Williams 2000" TYPE="BOOK_SECTION">
<AU>Williams HC, Wüthrich B</AU>
<TI>The natural history of atopic dermatitis</TI>
<SO>Atopic Dermatitis</SO>
<YR>2000</YR>
<PG>49-59</PG>
<ED>Williams HC</ED>
<PB>Cambridge University Press</PB>
<IDENTIFIERS MODIFIED="2012-08-28 15:52:51 +0100" MODIFIED_BY="Liz Doney">
<IDENTIFIER MODIFIED="2012-08-28 15:52:51 +0100" MODIFIED_BY="Liz Doney" TYPE="OTHER" VALUE="978-0521570756"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Williams-2008" MODIFIED="2012-08-28 15:50:49 +0100" MODIFIED_BY="[Empty name]" NAME="Williams 2008" TYPE="OTHER">
<AU>Williams HC, Grindlay DJ</AU>
<TI>What's new in atopic eczema? An analysis of the clinical significance of systemic reviews on atopic eczema published in 2006 and 2007</TI>
<SO>Clinical &amp; Experimental Dermatology</SO>
<YR>2008</YR>
<VL>33</VL>
<NO>6</NO>
<PG>685-8</PG>
<IDENTIFIERS MODIFIED="2012-08-28 15:50:49 +0100" MODIFIED_BY="Liz Doney">
<IDENTIFIER MODIFIED="2012-08-28 15:50:49 +0100" MODIFIED_BY="Liz Doney" TYPE="PUBMED" VALUE="186911244"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2011-11-17 12:33:03 +0000" MODIFIED_BY="Joel Bamford"/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2013-04-02 11:49:49 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2013-04-02 11:49:13 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2013-04-02 11:45:43 +0100" MODIFIED_BY="Joel Bamford" STUDY_ID="STD-Bahmer-1992">
<CHAR_METHODS MODIFIED="2013-03-22 16:05:55 +0000" MODIFIED_BY="Joel Bamford">
<P>Design: randomised, placebo-controlled, parallel</P>
<P>Duration: 3 months</P>
<P>Interval of assessment: baseline, 6 weeks, 3 months</P>
<P>This was a randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-04-02 11:45:43 +0100" MODIFIED_BY="Joel Bamford">
<P>Number randomised: 12 (7 in the active group and 5 in the placebo group)</P>
<P>Sex (M/F): 6/6 total (3/4 in the active group and 3/2 in the placebo group)</P>
<P>Age of participants: active group = 31 (mean), placebo group = 27 (mean)</P>
<P>Unit of allocation: whole person</P>
<P>Country and setting: Saarlandes, Germany; single university dermatology clinic</P>
<P>
<B>
<U>Inclusion criteria of the study (specified)</U>
</B>
</P>
<UL>
<LI>Participants having atopic dermatitis</LI>
<LI>Having used topical steroids</LI>
<LI>Diagnostic criteria: not reported</LI>
<LI>Severity of condition: "mild to moderate", glandol group ADASI score = 1.63, control group ADASI score = 1.89</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the study</U>
</B>
</P>
<UL>
<LI>Participants using systemic steroids or antimetabolites</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-04-02 02:06:57 +0100" MODIFIED_BY="Joel Bamford">
<UL>
<LI>Treatment group: glandol (BO), 3 capsules twice daily, each capsule 500 mg</LI>
<LI>Placebo group: palm kernel oil, 3 capsules twice daily, each capsule 500 mg</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-23 17:25:46 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>ADASI score by clinician (method of scoring by mapping)</LI>
<LI>Skin condition by participant (method of assessment subjective: participant diary)</LI>
<LI>Serum lipids (lab)</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-03-23 17:25:44 +0000" MODIFIED_BY="[Empty name]">
<P>Previous treatment was not stopped ("no limitations regarding other treatment were required")</P>
<P>Assessment of compliance was not undertaken</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-04-02 11:48:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bamford-1985">
<CHAR_METHODS MODIFIED="2013-04-02 11:48:33 +0100" MODIFIED_BY="[Empty name]">
<P>Design: randomised, double-blind, placebo-controlled, cross-over</P>
<P>Duration: 6 months (3 months then 3 months reversed)</P>
<P>Interval of assessment: 3 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-04-02 02:07:53 +0100" MODIFIED_BY="[Empty name]">
<P>Number randomised: 154</P>
<P>Sex (M/F): not stated</P>
<P>Age of participants: completers were 49 children aged 2 to 16 years (mean age = 9.1) and 74 adults aged 16 to 66 years (mean age = 37.7)</P>
<P>Unit of allocation: single participant</P>
<P>Country and setting: USA, single dermatology outpatient department</P>
<P>
<B>
<U>Inclusion criteria of the study</U>
</B>
</P>
<UL>
<LI>Participants having atopic dermatitis</LI>
<LI>Having used topical steroids</LI>
<LI>Diagnostic criteria: clinical</LI>
<LI>Severity of condition: mild to moderate</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the study</U>
</B>
</P>
<UL>
<LI>Participants using systemic steroids or antimetabolites</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-23 17:28:44 +0000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Treatment group divided as follows:</LI>
</UL>
<UL>
<UL>
<LI>children &lt; 15 years of age, who received 2 or 4 capsules twice daily each with 500 mg of EPO for 3 months, then crossed over;</LI>
<LI>children &gt; 15 years of age, who received 6 or 8 capsules twice daily each with 500 mg of EPO</LI>
</UL>
</UL>
<UL>
<LI>Placebo group divide in the same way as above and same dosage schedule with each capsule having 500 mg of paraffin oil</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-22 23:33:59 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Symptoms and signs of eczema (erythema, scaling, excoriation, weeping, etc) by physician (method = 0 to 10 scale, where 0 is none and 10 is most severe)</LI>
<LI>Symptoms and signs of eczema (erythema, scaling, excoriation, weeping, etc) and effect on daily living (level of discomfort, inability to sleep, etc) by participant (method = 0 to 10 scale, where 0 is none and 10 is most severe)</LI>
</OL>
<P>Interval of assessment: unclear</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-03-23 17:29:20 +0000" MODIFIED_BY="[Empty name]">
<P>Concomittent treatment: permitted emollients, topical steroids, and antihistaminics</P>
<P>Compliance to treatment: undertaken</P>
<P>Previous treatment: continued</P>
<P>The trial report did not state the numbers randomised to each group (further information obtained from trial investigator)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-04-02 02:08:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Berth_x002d_Jones-1993">
<CHAR_METHODS MODIFIED="2013-03-23 17:29:39 +0000" MODIFIED_BY="Joel Bamford">
<P>Design: double-blind, randomised, parallel with 3 treatment arms</P>
<P>Duration: 24 weeks</P>
<P>Interval of assessment: Assessment was done at 4, 8, and 16 weeks, and then 8 weeks after wash-out</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-04-02 02:08:08 +0100" MODIFIED_BY="Joel Bamford">
<P>Number randomised: 123 (41 in the active EPO group, 41 in the active EPO and Marine group, and 41 in the placebo group)</P>
<P>Sex (M/F): 25/16 in the active group, 22/19 in the active EPO and Marine group, and 22/19 in the placebo group</P>
<P>Age of participants: well-matched for age above and over 12 years</P>
<P>Unit of allocation: whole person</P>
<P>Country and setting: UK, single centre</P>
<P>
<B>
<U>Inclusion criteria of the study</U>
</B>
</P>
<UL>
<LI>Outpatients attending the dermatology department for treatment of AD, of either sex and all ages</LI>
<LI>Diagnostic criteria: Hanifin and Rajka</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the study</U>
</B>
</P>
<UL>
<LI>Not specified</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-04-02 01:43:22 +0100" MODIFIED_BY="Joel Bamford">
<UL>
<LI>2 treatment groups:</LI>
<UL>
<LI>first treatment group: 6 capsules twice daily, each capsule contained 500 mg of evening primrose oil, largely made up of the n6 series EFAs linoleic (321 mg) and gamma-linolenic acid (40 mg)</LI>
<LI>second treatment group: 6 capsules twice daily, each contained 430 mg of evening primrose oil and 107 mg of marine fish oil. This fish oil included the n3 series EFAs eicosapentaenoic acid (17 mg) and docosahexaenoic acid (11 mg)</LI>
</UL>
<LI>Placebo group: 6 capsules: Each capsule contained liquid paraffin for adults and olive oil for children</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-23 17:35:08 +0000" MODIFIED_BY="Joel Bamford">
<OL>
<LI>Disease activity monitored by clinical severity scores (2 types of scoring systems were used) as recorded by the investigator (methods for scoring: Leicester Score, the body was divided into 10 zones: face, neck, abdomen, back, elbows, antecubital fossae, dorsa of hands, palms and wrists, popliteal fossae, and feet. Each zone was scored on a scale: 0 (absent) to 3 (severe) for erythema, excoriation, dryness, cracking, and lichenification. A second, simpler scoring system for clinical severity, as described by <LINK REF="REF-Costa-1989" TYPE="REFERENCE">Costa 1989</LINK>, was also used. In this system, only the most severely affected site was assessed. Erythema, oedema, vesiculation, crusting, excoriation scaling, lichenification, pigmentation, pruritus, and sleep disturbance were each graded on a 7-point scale. This score was only briefly reported)</LI>
<LI>Topical steroid requirement (usage was assessed by weighing returned tubes of medication)</LI>
<LI>Symptom scores recorded by participants. Every participant was given a diary containing a page of 10 cm visual analogue scales for baseline and each of the next 24 weeks. Scales were provided for itch, dryness, scaling, redness, and overall impression. All scales were labelled "none" at the left-hand end and "worst ever" at the right. Scores were added to give a maximum of 50 cm</LI>
</OL>
<P>Interval of assessment: 4, 8, and 16 weeks on treatment, and again after an 8-week wash-out</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-03-22 23:37:42 +0000" MODIFIED_BY="Joel Bamford">
<P>Concomittent treatment: allowed continued emollients and low-dose steroids</P>
<P>Compliance to treatment: unsure</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-04-02 02:20:57 +0100" MODIFIED_BY="Joel Bamford" STUDY_ID="STD-Biagi-1994">
<CHAR_METHODS MODIFIED="2013-03-22 23:42:58 +0000" MODIFIED_BY="[Empty name]">
<P>Design: double-blind, placebo-controlled using 2 different dosages</P>
<P>Duration: 8 weeks</P>
<P>Interval of assessment: start and end of study<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-04-02 02:08:32 +0100" MODIFIED_BY="Joel Bamford">
<P>Number randomised: 48 (16 in each group)</P>
<P>Sex (M/F): 24/27 total (this applied to the whole group; there was no separation for the active and placebo groups)</P>
<P>Age of participants: children average 4.2 years (2.2 to 8.5 years)</P>
<P>Unit of allocation: whole person</P>
<P>Country and setting: Italy, single referral outpatient department</P>
<P>
<B>
<U>Inclusion criteria of the study</U>
</B>
</P>
<UL>
<LI>Diagnostic criteria: Hanifin and Rajka</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the study</U>
</B>
</P>
<UL>
<LI>Not specified</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-04-02 02:20:57 +0100" MODIFIED_BY="Joel Bamford">
<UL>
<LI>2 treatment groups:</LI>
<UL>
<LI>first treatment group: high-dose group, EPO capsules (dose = 0.5 mg/kg body weight)</LI>
<LI>second treatment group: low-dose group, 50% EPO capsule and 50% placebo capsule (dose = 0.5 mg/kg body weight)</LI>
</UL>
<LI>Placebo group: capsules of olive oil and vitamin E (0.5 mg/kg body weight)</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-22 23:44:35 +0000" MODIFIED_BY="Joel Bamford">
<OL>
<LI>Severity of symptoms (method: clinical assessment by scoring 10 symptoms. Scoring from 0 to 3, 0 = absent, 1 = mild, 2 = moderate, 3 = severe)</LI>
<LI>Red cell membrane fatty acid concentration</LI>
<LI>Red cell membrane viscosity</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-03-22 23:43:30 +0000" MODIFIED_BY="Joel Bamford">
<P>Concomittent treatment: allowed continued emollients and topical steroids</P>
<P>Compliance to treatment: unsure</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-04-02 02:22:29 +0100" MODIFIED_BY="Joel Bamford" STUDY_ID="STD-Borrek-1997">
<CHAR_METHODS MODIFIED="2013-03-22 23:47:20 +0000" MODIFIED_BY="Joel Bamford">
<P>Design: randomised by draw, double-blind, placebo-controlled, cross-over</P>
<P>Duration: 20 to 24 weeks</P>
<P>Interval of assessment: 4 to 3 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-04-02 02:08:59 +0100" MODIFIED_BY="Joel Bamford">
<P>Number randomised: 24 children and teenagers from 3 to 17 years of age</P>
<P>Sex (M/F): 14/10 total</P>
<P>Age of participants: 3 to 17 years (mean age = 10 years)</P>
<P>Unit of allocation: single person</P>
<P>Country and setting: Germany, 1 university pediatric clinic</P>
<P>
<B>
<U>Inclusion criteria of the study</U>
</B>
</P>
<UL>
<LI>Chronic recurrent atopic dermatitis at the time of enrolment in the study</LI>
<LI>Was clinically symptomatic within the last 6 months</LI>
<LI>Diagnostic criteria: Hanifin Rajka's criteria</LI>
<LI>Severity of condition: mild to moderate</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the study</U>
</B>
</P>
<UL>
<LI>Epilepsy</LI>
<LI>Fat storage disease</LI>
<LI>Participating in another study</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-23 17:37:51 +0000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Treatment group: 3 capsules daily, each with 60 mg borage seed oil and 5 mg vitamin E</LI>
<LI>Placebo group: 3 capsules daily, each with 60 mg corn oil and 5 mg vitamin E</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-04-02 02:22:29 +0100" MODIFIED_BY="Joel Bamford">
<OL>
<LI>Costa (<LINK REF="REF-Costa-1989" TYPE="REFERENCE">Costa 1989</LINK>) score by clinician (method: this simple scoring system (SSS) scores 10 severity criteria (0 to 7) and 10 topographic sites (0 to 3) giving a maximum score of 100)</LI>
<LI>Acute, chronic, and subjective symptoms by participants (method: diaries)</LI>
<LI>Use of steroidal creme and antihistamines (method: questionnaires)</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-04-02 01:50:57 +0100" MODIFIED_BY="Joel Bamford">
<P>Concommitant treatment: permitted</P>
<P>Assessment of compliance: unsure</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-04-02 02:09:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Buslau-1996">
<CHAR_METHODS MODIFIED="2013-03-22 23:54:47 +0000" MODIFIED_BY="[Empty name]">
<P>Design: randomised, double-blind, placebo-controlled, parallel</P>
<P>Duration: 12 weeks</P>
<P>Interval of assessment: daily by participant</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-04-02 02:09:26 +0100" MODIFIED_BY="[Empty name]">
<P>Number randomised: 50 (25 each in the active and placebo groups)</P>
<P>Sex (M/F): 18/32 total (8/17 in the active group and 10/15 in the placebo group)</P>
<P>Age of participants: not mentioned</P>
<P>Unit of allocation: whole person</P>
<P>Country and setting: Germany, not noted</P>
<P>
<B>
<U>Inclusion criteria of the study</U>
</B>
</P>
<UL>
<LI>Severity of condition: mild to moderate</LI>
<LI>Diagnostic criteria: Hanifin Rajka's criteria</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the study</U>
</B>
</P>
<UL>
<LI>Not specified</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-22 23:55:34 +0000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Treatment group: 2 capsules daily each with 500 mg of BO</LI>
<LI>Placebo group: 2 capsules daily each with 500 mg of palm kernel oil</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-22 23:56:08 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>ADASI score (method of assessment: mapping with the help of coloured markers)</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-03-22 23:56:06 +0000" MODIFIED_BY="[Empty name]">
<P>Concomitant treatment: not permitted</P>
<P>Compliance to treatment: not undertaken</P>
<P>Previous treatment: unsure</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-04-02 02:34:33 +0100" MODIFIED_BY="Joel Bamford" STUDY_ID="STD-Don-2003">
<CHAR_METHODS MODIFIED="2013-04-02 02:34:33 +0100" MODIFIED_BY="Joel Bamford">
<P>Design: double-blind, randomised, placebo-controlled, parallel</P>
<P>Duration: 12 weeks</P>
<P>Interval of evaluation: 4 weeks and 12 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-04-02 02:10:26 +0100" MODIFIED_BY="Joel Bamford">
<P>Number randomised: 20 (10 each in the active and placebo groups)</P>
<P>Sex (M/F): 8/1 in the active group and 5/4 in the placebo group</P>
<P>Age of participants: 20 children aged 7 to 48 months (mean age = 22.9)</P>
<P>Unit of allocation: whole person</P>
<P>Country and setting: Italy, 1 centre</P>
<P>Duration of eczema: placebo = 9.44 years, borage = 9.66 years (averages)</P>
<P>
<B>
<U>Inclusion criteria of the study</U>
</B>
</P>
<UL>
<LI>Severity of condition: SCORAD figures at start = 39.44 for borage group, 44.93 for placebo group</LI>
<LI>Diagnostic criteria: Hanifin Rajka's criteria</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the study</U>
</B>
</P>
<UL>
<LI>Not specified</LI>
</UL>
<P>Number: 20</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-22 23:57:21 +0000" MODIFIED_BY="Joel Bamford">
<UL>
<LI>Treatment group: 60 drops daily of BO</LI>
<LI>Control group: 60 drops daily of olive oil</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-22 23:58:55 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>SCORAD (method of assessment: standard method)</LI>
<LI>Quality of life (parents' evaluation) (method of assessment: scores of calm = 4, slightly distressed = 3, moderately distressed = 2, very distressed = 1)</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-03-22 23:59:06 +0000" MODIFIED_BY="Joel Bamford">
<P>Concomittent treatment: allowed continued emollients and low-dose steroids</P>
<P>Compliance to treatment: undertaken by parental information and serum level changes</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-04-02 11:46:08 +0100" MODIFIED_BY="Joel Bamford" STUDY_ID="STD-Finlay-2001">
<CHAR_METHODS MODIFIED="2013-03-22 23:59:19 +0000" MODIFIED_BY="Joel Bamford">
<P>Design: double-blind, placebo-controlled, randomised</P>
<P>Duraton: 3 months</P>
<P>Interval of assessment: 3 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-04-02 11:46:08 +0100" MODIFIED_BY="Joel Bamford">
<P>Number randomised: 60 (30 each in the active and placebo groups)</P>
<P>Sex (M/F): not stated</P>
<P>Age of participants: 5 to 12 years for both groups</P>
<P>Unit of allocation: whole person</P>
<P>Country and setting: UK, 12 sites</P>
<P>Duration of condition: problems for over a year, some intermittent</P>
<P>
<B>
<U>Inclusion criteria of the study</U>
</B>
</P>
<UL>
<LI>Children under 10 years of age from 12 sites in UK (1 to 17 cases per site) with AD</LI>
<LI>Diagnostic criteria: UK working party criteria and requiring treatment (though ~24% used none during the 30 days prior to joining)</LI>
<LI>Severity of condition: not specified but stated equal in both groups</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the study</U>
</B>
</P>
<UL>
<LI>Any other itch condition</LI>
<LI>Active infection</LI>
<LI>Use of phenothiazines</LI>
<LI>Severe illness</LI>
<LI>Seizures</LI>
<LI>Use of anything stronger than 1% hydrocortisone</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-23 00:01:19 +0000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Treatment group: 8 capsules daily each with 40 mg EPO and vitamin E</LI>
<LI>Placebo group: 8 capsules daily each with 40 mg coconut oil and vitamin E</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-23 17:40:07 +0000" MODIFIED_BY="Joel Bamford">
<OL>
<LI>Pruritis by physician (method: VAS 0 to 100, where 0 = none and 100 = severe)</LI>
<LI>Itch, erythema, edema, dryness, infection, scale, overall by physician (method: VAS 0 to 100, where 0 = none and 100 = severe)</LI>
<LI>Overall by medical doctor (method: 1, 2, 3 = mild, moderate, severe)</LI>
<LI>Quality of life (method: DLQI)</LI>
<LI>Hydrocortisone use (method: weight of tubes)</LI>
<LI>Area (method: rule of 9)</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-03-23 00:04:26 +0000" MODIFIED_BY="Joel Bamford">
<P>Pretreatment: stated needed treatment, but 25% not doing any treatment</P>
<P>Compliance: stated and undertaken</P>
<P>The results were evaluated - by other individuals - 6 years after the study completed</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-04-02 11:49:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-France-1988">
<CHAR_METHODS MODIFIED="2013-03-23 00:04:36 +0000" MODIFIED_BY="[Empty name]">
<P>Design: double-blind, placebo-controlled, randomised, parallel</P>
<P>Duraton: 16 weeks</P>
<P>Interval of assessment: 4 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-04-02 11:49:11 +0100" MODIFIED_BY="[Empty name]">
<P>Number randomised: 45 (25 in the active group and 20 in the placebo group)</P>
<P>Sex (M/F): numbers for sites were not recorded</P>
<P>Age of participants: not recorded (page 24)</P>
<P>Unit of allocation: whole person</P>
<P>Country and setting: UK in 10 centres</P>
<P>
<B>
<U>Inclusion criteria of the study</U>
</B>
</P>
<UL>
<LI>Either sex</LI>
<LI>Age 5 to 75 years</LI>
<LI>Written informed consent</LI>
<LI>Diagnosed with severe atopic eczema, as defined by extensive body involvement with a regular need for Betnovate or equivalent steroid, frequent need for more potent steroid or for systemic steroids, or both; cytotoxic therapy; combined with other measures (page 13)</LI>
<LI>Must begin out of hospital, continue into hospital. May start immediately after discharge from a hospital</LI>
<LI>Diagnostic criteria: not specified</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the study</U>
</B>
</P>
<UL>
<LI>Other itch cause, inflammatory, malignant, severe (liver/renal)</LI>
<LI>Pregnant/lactating</LI>
<LI>Needing cytotoxic currently</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-23 00:06:38 +0000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Treatment group: EPO, 12 capsules daily, each capsule 500 mg</LI>
<LI>Placebo group: paraffin oil, 12 daily, each capsule 500 mg</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-23 17:44:17 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Participant perception of itch (method: VAS, from none to worst ever)</LI>
<LI>Other Skin condition, such as itch, dryness, etc, by participant (method of assessment: VAS)</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-03-23 00:07:38 +0000" MODIFIED_BY="[Empty name]">
<P>Previous treatment not stopped</P>
<P>Concomittant treatment permitted</P>
<P>Assessment of compliance undertaken but incomplete</P>
<P>The results were evaluated - by other individuals - 6 years after the study completed</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-04-02 11:46:23 +0100" MODIFIED_BY="Joel Bamford" STUDY_ID="STD-Fraser-2001">
<CHAR_METHODS MODIFIED="2013-03-23 17:44:50 +0000" MODIFIED_BY="Joel Bamford">
<P>Design: randomised, double-blind, parallel, placebo-controlled<BR/>
</P>
<P>Duration: 3 months</P>
<P>Interval of assessment: 3 weeks</P>
<P>Unit of randomisation: whole person<BR/>Unit of analysis: whole person</P>
<P>Duration of trial: 12 weeks</P>
<P>Interval of assessment: 4 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-04-02 11:46:23 +0100" MODIFIED_BY="Joel Bamford">
<P>Number randomised: 90 (43 in the active group and 47 in the placebo group)</P>
<P>Sex (M/F): 17/28 in the active group and 23/24 in the placebo group</P>
<P>Age of participants: 10 to 29 years old in the majority; both groups had 4 participants under 10 years old</P>
<P>Country and setting; UK, 4 sites</P>
<P>Duration of condition: average duration = 20.8 years for Efamol® and 16.7 years for placebo</P>
<P>
<B>
<U>Inclusion criteria of the study</U>
</B>
</P>
<UL>
<LI>Patients over the age of 3, attending dermatology clinic with a "history of signs and symptoms suggestive of a diagnosis of atopic eczema"</LI>
<LI>Diagnostic criteria: not stated</LI>
<LI>Severity of condition: moderate: 44.4% Efamol®, 57.9 % placebo group, rest not stated</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the study</U>
</B>
</P>
<UL>
<LI>Taking systemic steroids, NSAIDS, beta blockers, or phenothiazine</LI>
<LI>Having Epilepsy</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-23 00:09:08 +0000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Treatment group: 8 capsules daily, each with 500 mg EPO</LI>
<LI>Placebo group: 8 capsules daily, each with 500 mg Olive oil</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-04-02 02:02:29 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Participant assessment of itch (method: VAS 1 to 100, where 0 = none and 100 = worst ever)</LI>
<LI>All other measures by doctor and participant: redness, scale, dryness, and overall improvement (method: VAS, as above)</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-03-23 00:18:10 +0000" MODIFIED_BY="[Empty name]">
<P>Pretreatment in both groups: 4 weeks' placebo</P>
<P>The results were evaluated - by other individuals - 6 years after the study completed</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-04-02 02:31:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Harper-1990">
<CHAR_METHODS MODIFIED="2013-03-23 00:18:45 +0000" MODIFIED_BY="Joel Bamford">
<P>Design: randomised, double-blind, placebo-controlled, parallel<BR/>
</P>
<P>Duration of trial: 16 weeks</P>
<P>Interval of assessment: first weekly, then 4 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-04-02 02:30:55 +0100" MODIFIED_BY="Joel Bamford">
<P>Number randomised: 20 (9 in the active group and 11 in the placebo group)</P>
<P>Sex (M/F): 1/8 in the active group and 4/7 in the placebo group</P>
<P>Age of participants: active group = 7.0, placebo group = 4.3</P>
<P>Unit of analysis: whole person</P>
<P>Country and setting: patients from single centre dermatology in UK, no other specifications</P>
<P>
<B>
<U>Inclusion criteria of the study</U>
</B>
</P>
<UL>
<LI>"Moderate to severe atopic eczema requiring constant treatment with mild to moderate potent steroids, emollients or antihistamines"</LI>
<LI>Aged 6 months to 12 years</LI>
<LI>No trial treatment to be started in hospital setting, none to be discontinued, if hospitalised. May enter study immediately after leaving hospital</LI>
<LI>Diagnostic criteria: clinical</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the study</U>
</B>
</P>
<UL>
<LI>Other cause of itch</LI>
<LI>Any other inflammatory disorder</LI>
<LI>Any severe intercurrent illness, including renal liver failure or cancer</LI>
<LI>Epilepsy</LI>
<LI>Phenothiazines</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-04-02 02:31:24 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Treatment (active) group:</LI>
<UL>
<LI>8 capsules daily, each with 500 mg EPO, for children between 6 months to 2 years;</LI>
<LI>12 capsules daily, each with 500 mg EPO, for children between 2 years to 12 years</LI>
</UL>
<LI>Placebo group: capsules each with 500 mg olive oil, divided into 2 groups as above</LI>
</UL>
<P>Duration: 16 weeks' treatment and 8 weeks' off therapy</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-23 17:51:46 +0000" MODIFIED_BY="Joel Bamford">
<OL>
<LI>Parent evaluation of itch (method: VAS, from none to worst ever)</LI>
<LI>Parental assessments of the participant's skin dryness, scaling, redness, and overall impression (method of assessment: VAS)</LI>
<LI>Dermatologist assessments of the patient's skin dryness, scaling, redness, and overall impression (method of assessment: VAS)</LI>
<LI>Adverse events</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-03-23 00:23:21 +0000" MODIFIED_BY="Joel Bamford">
<P>Previous treatment not stopped ("no limitations regarding other treatment were required")</P>
<P>Asessment of compliance: "Insufficient data were available to evaluate compliance"</P>
<P>Compliance treatment of the children's eczema was permitted to continue as usual</P>
<P>The results were evaluated - by other individuals - 6 years after the study completed</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-04-02 11:49:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Heddle-1990">
<CHAR_METHODS MODIFIED="2013-04-02 11:49:13 +0100" MODIFIED_BY="[Empty name]">
<P>Design: randomised, double-blind, placebo-controlled, single-centre, cross-over</P>
<P>Unit of randomisation: whole person<BR/>Unit of analysis: whole person</P>
<P>Duration: There was a 4-week run-in period during which all participants received olive oil. Participants then received treatment with either EPO or safflower oil (SAFF) for 8 weeks (period 1)</P>
<P>Following a wash-out period of 4 weeks, during which participants again received olive oil, participants received the opposite treatment to that which they had received in period 1 for 8 weeks (period) (page 4)</P>
<P>"Number of patients (planned and analysed): Planned: not known. Enrolled and analysed: 25 patients." (page 3)</P>
<P>Use of concomitant treatment: not specified/mentioned</P>
<P>Previous treatment stopped/continued: not specified</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-04-02 02:32:53 +0100" MODIFIED_BY="[Empty name]">
<P>Number randomised: 25 (12 received EPO first and 13 received SAFF first)</P>
<P>Sex (M/F): not specified</P>
<P>Age of participants: 8 years (mean)</P>
<P>Unit of allocation/randomisation/analysis: whole person</P>
<P>Country/setting: participants from single centre in UK, no other specifications</P>
<P>
<B>
<U>Inclusion criteria of the study</U>
</B>
</P>
<UL>
<LI>Although no inclusion criteria are listed in the final report, we choose to believe that a physician made the diagnosis of eczema clinically and that was used as an inclusion criteria</LI>
<LI>Diagnosis: "dermatologist's assessment"</LI>
<LI>Severity of condition: not specified</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the study</U>
</B>
</P>
<UL>
<LI>Not specified</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-04-02 02:33:04 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Treatment group: 500 mg EPO in each capsule, total dose 1000 mg/kg body weight/per day</LI>
<LI>Placebo group: 500 mg olive in each capsule, total dose 1000 mg/kg body weight/per day</LI>
</UL>
<P>"Each capsule had 20 mg/gm vitamin E as an antioxidant"</P>
<P>Follow-up: treatment schedule = 8 weeks' treatment, 4 weeks' wash-out, then 2 groups switched over for the last 8 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-23 17:58:50 +0000" MODIFIED_BY="[Empty name]">
<P>Timing of outcome assessment: baseline and 8 weeks for each period of treatment (periods 1 and 2)</P>
<P>
<B>
<U>Primary outcomes</U>
</B>
</P>
<OL>
<LI>Participant perception of itch (method: VAS, from none to worst ever)</LI>
<LI>Participant/parent assessments of sleep loss due to itch and changes in general health and eczema (method of assessment: VAS)</LI>
<LI>Dermatologist assessments of the participant's skin dryness, scaling, redness, and overall impression of all symptoms and signs of AD (method of assessment: VAS)</LI>
</OL>
<P>
<U>
<B>Secondary outcomes</B>
</U>
</P>
<OL>
<LI>"EFA levels and cellular determinations were considered secondary efficacy endpoints"</LI>
<LI>Asessment of compliance undertaken: "At each clinic visit patients returned all unused capsules. The returned capsules were used to assess treatment compliance"</LI>
</OL>
<P>Adverse events: none listed</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-03-23 17:59:12 +0000" MODIFIED_BY="[Empty name]">
<P>Previous treatment stopped/continued: not specified</P>
<P>Asessment of compliance undertaken: "At each clinic visit patients returned all unused capsules. The returned capsules were used to assess treatment compliance"</P>
<P>Concommitant treatment permitted/not permitted: not specified</P>
<P>The sponsor was contacted and had no further information about the investigator or study</P>
<P>The results were evaluated - by other individuals - 6 years after the study completed</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-04-02 11:12:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hederos-1996">
<CHAR_METHODS MODIFIED="2013-04-02 02:34:13 +0100" MODIFIED_BY="[Empty name]">
<P>Design: randomised, double-blind, parallel</P>
<P>Duration: 16-week</P>
<P>Interval of assessment: 4-week</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-04-02 02:12:25 +0100" MODIFIED_BY="[Empty name]">
<P>Number randomised: 60 Active (30 each in the active and placebo groups)</P>
<P>Sex (M/F): 13/17 in the active group and 13/17 in the placebo group</P>
<P>Age of participants: active group = 7.5, placebo group = 8.6</P>
<P>Unit of allocation: whole person</P>
<P>Country and setting: Karlstad, Sweden, paediatric department of central hospital - 2 clinics</P>
<P>
<B>
<U>Inclusion criteria of the study</U>
</B>
</P>
<UL>
<LI>Outpatients</LI>
<LI>Either sex</LI>
<LI>1 to 16 years of age</LI>
<LI>Diagnosis: Hanifin and Rajka</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the study</U>
</B>
</P>
<UL>
<LI>Not specified</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-04-02 02:35:35 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Treatment group:</LI>
<UL>
<LI>&lt; 12 years, = 8 Epogam® capsules daily (each containing 500 mg evening primrose oil providing 40 mg GLA with 10 mg vitamin E)</LI>
<LI>&gt; 12 years = 12 Epogam® capsules daily (same composition)</LI>
</UL>
<LI>Placebo group: same number of identical gelatin capsules as for the treatment group according to age (containing 500 mg of sunflower oil with 10 mg vitamin E)</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-04-02 11:12:29 +0100" MODIFIED_BY="Joel Bamford">
<OL>
<LI>Clinician rating of redness, dryness, crusts, excoriation, itch, scaling, lichenification, fidget, overall impression of condition, area of involvement (method of assessment: VAS, scale = 0 to 10)</LI>
<LI>Global assessment by parents (method: diary booklet)</LI>
<LI>Total IgE and essential fatty acids (laboratory)</LI>
<LI>Skin prick test with allergens (laboratory)</LI>
<LI>DGLA levels (laboratory)</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-03-23 00:32:22 +0000" MODIFIED_BY="Cathy Bennett">
<P>N/A</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-04-02 11:46:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Henz-1999">
<CHAR_METHODS MODIFIED="2013-04-02 11:10:55 +0100" MODIFIED_BY="[Empty name]">
<P>Design: randomised, parallel, double-blind, placebo-controlled</P>
<P>Duration: -</P>
<P>Interval of assessment: -</P>
<P>Unit of randomisation: whole person<BR/>Unit of analysis: whole person</P>
<P>Duration of trial: 24 weeks</P>
<P>Interval of assessment: at 1, 2, 6, 12, 18, and 24 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-04-02 11:46:37 +0100" MODIFIED_BY="[Empty name]">
<P>Number randomised: 160 (80 each in the active and placebo groups)</P>
<P>Sex (M/F): 66% women in the borage oil group and 54% women in the miglyol group</P>
<P>Age of participants: 14 to 65 years</P>
<P>Unit of allocation: whole person</P>
<P>Country and setting: Switzerland, multicentre</P>
<P>Duration of condition: average duration = 22 years for BO and 20 years for miglyol</P>
<P>
<B>
<U>Inclusion criteria of the study</U>
</B>
</P>
<UL>
<LI>Severity of condition: moderate</LI>
<LI>Diagnostic criteria: Hanifin Rajka's criteria</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the study</U>
</B>
</P>
<UL>
<LI>Not specified</LI>
</UL>
<P>
<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-04-01 21:34:56 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Treatment group: BO, 6 capsules per day, each capsule 500 mg</LI>
<LI>Placebo group: miglyol, 6 capsules per day, each capsule 500 mg</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-23 00:36:04 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Improvement of individual eczema symptoms</LI>
<LI>Method of assessment by 50% reduction in Costa score</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-03-23 00:36:18 +0000" MODIFIED_BY="[Empty name]">
<P>Previous treatment: stopped at the beginning of study</P>
<P>Concommitant treatment: allowed and assessed</P>
<P>Asessment of compliance undertaken by measuring blood levels of drug and use of corticosteroids</P>
<P>"The primary efficacy of the treatment was assessed by counting the number of patients achieving a 50% reduction in Costa score (as defined as clinical response) as a function of corticosteroid use"</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-04-02 11:14:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kenicer-2001">
<CHAR_METHODS MODIFIED="2013-03-23 00:36:33 +0000" MODIFIED_BY="Joel Bamford">
<P>Design: randomised, double-blind, placebo-controlled</P>
<P>Duration: 16 weeks</P>
<P>Interval of assessment: start, 4 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-03-23 18:01:46 +0000" MODIFIED_BY="[Empty name]">
<P>Number randomised: 66 (32 in the active group and 34 in the placebo group)</P>
<P>Sex (M/F): both</P>
<P>Age of participants: between 10 and 70 years of age</P>
<P>Unit of allocation: whole body</P>
<P>Country and setting: UK at Ninewells Hospital, Dundee or Hull Royal Infirmary</P>
<P>
<B>
<U>Inclusion criteria of the study</U>
</B>
</P>
<UL>
<LI>Diagnosis: satisfying previously defined and published criteria for atopic eczema (<LINK REF="REF-Hanifin-1980" TYPE="REFERENCE">Hanifin 1980</LINK>)</LI>
<LI>Informed consent</LI>
<LI>Active disease</LI>
<LI>No severe intercurrent disease</LI>
</UL>
<P>
<U>
<B>Exclusion criteria of the study</B>
</U>
</P>
<UL>
<LI>Not pregnant, lactating</LI>
<LI>Child-bearing age and not on contraception</LI>
<LI>Non-compliant</LI>
<LI>Epileptic</LI>
<LI>Taking phenothiazines or immunosuppressive drugs</LI>
<LI>Receiving UV treatments</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-04-02 11:13:27 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Treatment group: 8 capsules daily, with 400 mg GLA and 11 mg vitamin A in each capsule</LI>
<LI>Placebo group: 8 capsules daily, with 500 mg olive oil in each capsule</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-23 00:38:47 +0000" MODIFIED_BY="Joel Bamford">
<OL>
<LI>Participant assessment of itch</LI>
<LI>Participant assessment of dermatology (global score)</LI>
<LI>Physician assessment of dermatology (global score)</LI>
<LI>Physician assessment of redness (method of assessment: all participant and dermatological assessment were done on a VAS and scoring system used as 0 = no lesion to 100 = worse lesion)</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-04-02 11:14:08 +0100" MODIFIED_BY="Joel Bamford">
<P>Concomittent treatment: previous treatment with moderate to potent topical steroids, emollients continued for first 8 weeks of study, or both Next 8 weeks' steroids discontinued</P>
<P>Compliance to treatment: Although the protocol called for pill counting and cream weighing to determine use of treatments, the final report did not include any evaluation of these measures</P>
<P>Quote (page 29): "34% of Active and 32% of placebo participants did not satisfy the inclusion criterion"</P>
<P>The results were evaluated - by other individuals - 6 years after the study completed</P>
<P>There were a large number of dropouts</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-04-02 11:46:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kiehl-1994">
<CHAR_METHODS MODIFIED="2013-03-23 00:40:39 +0000" MODIFIED_BY="[Empty name]">
<P>Design: double-blind, placebo-controlled</P>
<P>Duration of trial: 3 months</P>
<P>Interval of assessment: at baseline, after 4 weeks, and at end of study (12 weeks)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-04-02 11:46:48 +0100" MODIFIED_BY="[Empty name]">
<P>Number randomised: not reported</P>
<P>Sex (M/F): not reported</P>
<P>Age of participants: not reported</P>
<P>Unit of allocation: whole person</P>
<P>Country and setting: single centre in Germany</P>
<P>Duration of disease: not reported</P>
<P>
<B>
<U>Inclusion criteria of the study</U>
</B>
</P>
<UL>
<LI>Mild to moderate eczema</LI>
<LI>Diagnostic criteria: clinical</LI>
<LI>Severity of disease: not reported</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the study</U>
</B>
</P>
<UL>
<LI>If participants were not corticoid-free 1 month before start of the trial, they were excluded</LI>
<LI>Participants using corticosteroids during trial</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-23 00:43:28 +0000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Treatment: 6 capsules twice daily for 4 weeks, each with 40 mg of glandol, followed by 3 capsules twice daily for 10 days</LI>
<LI>Placebo group: 4 capsules daily, each with 480 mg GLA for 4 weeks, followed by 2 capsules daily for children 1 to 3 years of age, and 3 capsules daily for children 4 to 12 years of age</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-23 18:05:48 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Immune profile (method of assessment: blood)</LI>
<LI>ADASI score (method: not reported)</LI>
<LI>Plasma concentrations of linolenic acid (method of assessment: blood)</LI>
<LI>Plasma gamma-linolenic acid concentration (method of assessment: blood)</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-03-23 00:43:38 +0000" MODIFIED_BY="[Empty name]">
<P>Previous treatment stopped for 4 weeks</P>
<P>Concomittent treatment: antihistaminics permitted</P>
<P>Compliance to treatment: unstated</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-04-02 02:13:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kovar-1992">
<CHAR_METHODS MODIFIED="2013-03-23 00:44:29 +0000" MODIFIED_BY="Joel Bamford">
<P>Design: 2 separate phases: first phase was double-blind and placebo-controlled with a trial duration of 8 weeks; the second phase was single-blind - with no placebo control - with a trial duration of 8 weeks</P>
<P>Duration: 8 weeks each phase</P>
<P>Interval of assessment: 4 weeks by physician and weekly by parent</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-04-02 02:13:14 +0100" MODIFIED_BY="[Empty name]">
<P>Number randomised: 48 (24 each in the active and placebo groups)</P>
<P>Sex (M/F): 16/8 in the active group and 12/12 in the placebo group</P>
<P>Age of participants: active group = 1.9 years, placebo group = 1.7 years</P>
<P>Duration of eczema before trial: 1.3 years for both groups</P>
<P>Unit of allocation: whole person</P>
<P>Country and setting: single centre in Germany</P>
<P>
<B>
<U>Inclusion criteria of the study</U>
</B>
</P>
<UL>
<LI>Children of either sex</LI>
<LI>Children up to 5 years of age</LI>
<LI>Children with moderate to severe atopic eczema requiring constant treatment with mild to moderately potent topical steroids, emollients, antihistamines, or a combination of the aforementioned</LI>
<LI>Diagnostic criteria: clinical, Hanifin</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the study</U>
</B>
</P>
<UL>
<LI>Children with pruritus from any other cause</LI>
<LI>Children with an inflammatory skin disorder other than atopic eczema</LI>
<LI>Children with systemic inflammatory disorders.</LI>
<LI>Children with severe intercurrent illnesses, including liver failure, renal failure, or malignancy</LI>
<LI>Children with epilepsy or on phenothiazines</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-23 00:49:00 +0000" MODIFIED_BY="Joel Bamford">
<UL>
<LI>Treatment group: 8 capsules per day, each containing 500 mg of EPO (total dose of 4000 mg per day)</LI>
<LI>Control group: 8 capsules per day, each containing 500 mg of paraffin oil (total dose of 4000 mg per day)</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-04-02 02:06:35 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Parent assessment of itching (for assessment, the status of itch was recorded by placing a vertical mark in the diary card on a 100 mm VAS), ranging from none/no symptoms to worst ever for itch and from worst ever to best ever for overall impression</LI>
<LI>Parent assessment of overall symptoms and clinical picture</LI>
<LI>Physician assessment of itch, redness, and overall symptoms (method used again was VAS - 2 types: 1 as by parent, other as mild, moderate, or severe)</LI>
<LI>Laboratory assessments of IgE, RAST (radioallergosorbent test) essential fatty acid (EFAs) in plasma phospholipids and in red blood cells</LI>
<LI>Profilometric (surface roughness or texture) measurements of silicon casts were performed</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-03-23 00:46:37 +0000" MODIFIED_BY="[Empty name]">
<P>The results were evaluated - by other individuals - 6 years after the study completed</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-04-02 11:46:56 +0100" MODIFIED_BY="Joel Bamford" STUDY_ID="STD-Lovell-1981">
<CHAR_METHODS MODIFIED="2013-03-23 00:49:21 +0000" MODIFIED_BY="[Empty name]">
<P>Design: randomised, double-blind, placebo-controlled, cross-over</P>
<P>Duration: 6 weeks (2 periods of 3 weeks each)</P>
<P>Interval of assessment: 4 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-04-02 11:46:56 +0100" MODIFIED_BY="Joel Bamford">
<P>Number randomised: 64 (32 each in the active and placebo groups)</P>
<P>Sex (M/F): not listed</P>
<P>Age of participants: 17 children = 3 months to 13 years, 15 adults = 24 to 32 years</P>
<P>Unit of allocation: whole person</P>
<P>Country and setting: Bistol, United Kingdom; single centre</P>
<P>Duration of eczema: 6 months and more</P>
<P>
<B>
<U>Inclusion criteria of the study</U>
</B>
</P>
<UL>
<LI>Diagnosis: "had atopic dermatis"</LI>
<LI>Severity of condition: not stated</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the study</U>
</B>
</P>
<UL>
<LI>Not specified</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-23 18:09:16 +0000" MODIFIED_BY="Joel Bamford">
<UL>
<LI>Treatment group: 8 capsules daily for adult and 4 capsules daily for child, each with 500 mg EPO</LI>
<LI>Placebo group: 8 capsules daily for adult and 4 capsules daily for child, each with 500 mg paraffin oil</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-04-02 01:52:51 +0100" MODIFIED_BY="Joel Bamford">
<OL>
<LI>Severity of eczema rated by physician (method of assessment: severity as measured on a continuous 10 cm linear scale ranging from no eczema (zero) to most severe (10 cm))</LI>
<LI>Severity of eczema rated by participant (method of assessment: severity as measured on a continuous 10 cm linear scale ranging from no eczema (zero) to most severe (10 cm))</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-04-02 01:52:43 +0100" MODIFIED_BY="Joel Bamford">
<P>Previous treatment: unsure</P>
<P>Concommitant treatment: mild topical steroids and emollient allowed</P>
<P>Asessment of compliance: not undertaken</P>
<P>No power calculation</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-04-02 11:21:07 +0100" MODIFIED_BY="Joel Bamford" STUDY_ID="STD-MacKie-Adult-1990">
<CHAR_METHODS MODIFIED="2013-03-23 00:52:23 +0000" MODIFIED_BY="Joel Bamford">
<P>Design: randomised, double-blind, placebo-controlled</P>
<P>Duration: 24 weeks (16 weeks' therapy and 8 weeks off therapy)</P>
<P>Interval of assessment: 4 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-04-02 11:21:07 +0100" MODIFIED_BY="Joel Bamford">
<P>Number randomised: 20 (10 each in the active and placebo groups)</P>
<P>Sex (M/F): 11/9 total (5/5 in the active group and 6/4 in the placebo group)</P>
<P>Age of participants: active group = 26.8, placebo group = 25.0 (means)</P>
<P>Unit of allocation: whole body</P>
<P>Country and setting: Glasgow, UK; single dermatology centre</P>
<P>
<B>
<U>Inclusion criteria of the study</U>
</B>
</P>
<UL>
<LI>Diagnosis: patients with "moderate to severe atopic eczema, as defined by extensive body involvement with a regular need for moderately potent or potent steroids (MIMS (Monthly Index of Medical Specialties) classification) or frequent need for very potent steroid or for systemic steroids, cytotoxic therapy, combined with other measures, particularly antipruritic agents and antibiotics as require" (page 15)</LI>
<LI>Participants of either sex</LI>
<LI>Participants between the ages of 12 and 75 years</LI>
<LI>Outpatients. No one could start in the hospital; no treatment was to be stopped if going into hospital. On hospital discharge they could immediately enter the study</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the study</U>
</B>
</P>
<UL>
<LI>Pruritis of any other cause</LI>
<LI>Any other inflammatory skin disorder or any systemic disorder</LI>
<LI>Any severe intercurrent illness, including liver failure, renal failure, malignancy</LI>
<LI>Participants pregnant or trying to conceive</LI>
<LI>Participants with epilepsy</LI>
<LI>Participants on phenothiazines</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-23 00:53:55 +0000" MODIFIED_BY="Joel Bamford">
<OL>
<LI>Treatment group: 8 capsules daily, each with 40 mg GLA and 11 mg vitamin E</LI>
<LI>Placebo group: 8 capsules daily, each with 500 mg olive oil</LI>
</OL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-23 00:58:18 +0000" MODIFIED_BY="Joel Bamford">
<OL>
<LI>Participant assessment of itching (method of assessment: VAS 0 to 100; none to worst ever)</LI>
<LI>Participant assessment of all other signs and symptoms of eczema except itch (method of assessment: VAS)</LI>
<LI>Skin assessments by the dermatologist (method of assessment: Glasgow method and skin profilimetry)</LI>
<LI>EFA levels</LI>
<LI>Adverse events</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-03-23 00:55:24 +0000" MODIFIED_BY="[Empty name]">
<P>Asessment of compliance: "There were no details relating to any assessments of compliance in the protocol. All unused capsules were returned to Scotia Pharmaceuticals at the end of the study"</P>
<P>Continued or new concomitant treatment of eczema was permitted</P>
<P>The results were evaluated - by other individuals - 6 years after the study completed</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-04-02 11:22:52 +0100" MODIFIED_BY="Joel Bamford" STUDY_ID="STD-MacKie-Child-1990">
<CHAR_METHODS MODIFIED="2013-03-23 00:55:48 +0000" MODIFIED_BY="Joel Bamford">
<P>Design: double-blind, randomised, placebo-controlled</P>
<P>Duration: 24 weeks (16 weeks' intervention, 8 weeks off treatment)</P>
<P>Interval of assessment: 4 weeks<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-04-02 11:22:52 +0100" MODIFIED_BY="Joel Bamford">
<P>Number randomised: 19 (10 in the active group and 9 in the placebo group)</P>
<P>Sex (M/F): 10/10 total (3/7 in the active group and 7/3 in the placebo group)</P>
<P>Age of participants: active group = 6.2, placebo group = 5.8 (means)</P>
<P>Unit of allocation: whole person</P>
<P>Country and setting: Glasgow, UK; single dermatology centre</P>
<P>
<B>
<U>Inclusion criteria of the study</U>
</B>
</P>
<UL>
<LI>Participants of either sex</LI>
<LI>Participants &lt; 12 years</LI>
<LI>Participants with moderate to severe atopic eczema, as defined by extensive body involvement</LI>
<LI>Diagnosis: severity of condition: moderate to severe eczema defined as extensive body involvement with regular need for moderately potent or potent steroid or frequent need for systemic steroids, cytotoxic therapy, combined with other measures, particularly antipruritic agents or antibiotics as required</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the study</U>
</B>
</P>
<UL>
<LI>Pruritis of any other cause</LI>
<LI>Any other inflammatory skin disorder or any systemic disorder</LI>
<LI>Any severe intercurrent illness, including liver failure, renal failure, malignancy</LI>
<LI>Participants pregnant or trying to conceive</LI>
<LI>Participants with epilepsy</LI>
<LI>Participants on phenothiazines</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-23 00:57:23 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Treatment group: 8 capsules daily, each with 40 mg GLA and 11 mg vitamin E</LI>
<LI>Placebo group: 8 capsules daily, each with 500 mg olive oil</LI>
</OL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-23 00:58:56 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Participant assessment of itching (method of assessment: VAS 0 to 100; none to worst ever)</LI>
<LI>Participant assessment of all other signs and symptoms of eczema except itch (method of assessment: VAS)</LI>
<LI>Skin assessments by the dermatologist (method of assessment: Glasgow method and skin profilimetry)</LI>
<LI>EFA levels</LI>
<LI>Adverse events (mild, moderate, severe)</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-03-23 00:59:20 +0000" MODIFIED_BY="[Empty name]">
<P>Previous treatment not stopped</P>
<P>Assessment of compliance: "There were no details relating to any assessments of compliance in the protocol. All unused capsules were returned to Scotia Pharmaceuticals at the end of the study"</P>
<P>Concommitant treatment of the children's eczema was permitted to continue as usual</P>
<P>The results were evaluated - by other individuals - 6 years after the study completed</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-04-02 11:37:57 +0100" MODIFIED_BY="Joel Bamford" STUDY_ID="STD-MacLeod-2001">
<CHAR_METHODS MODIFIED="2013-03-23 00:59:30 +0000" MODIFIED_BY="Joel Bamford">
<P>Design: randomised, double-blind, placebo-controlled</P>
<P>Duration: 16 weeks</P>
<P>Interval of assessment: 4 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-04-02 11:37:57 +0100" MODIFIED_BY="Joel Bamford">
<P>Number randomised: 19 (10 in the active group and 9 in the placebo group)</P>
<P>Sex (M/F): 4/4 in the active group, 3/5 in the EPO/Marine group, and 6/2 in the placebo group</P>
<P>Age of participants: EPO group = 29.1, EPO/Marine group = 25.3, placebo group = 26.4 years</P>
<P>Unit of allocation: whole person</P>
<P>Country and setting: Glasgow, UK; single dermatology centre</P>
<P>
<B>
<U>Inclusion criteria of the study</U>
</B>
</P>
<UL>
<LI>Participants of either sex</LI>
<LI>Participants 16 to 30; and, yet, the range of participants' ages was from 17 to 35</LI>
<LI>Participants with moderate to severe atopic eczema, as defined by extensive body involvement</LI>
<LI>Diagnosis: severity of the condition: moderate to severe atopic eczema, as defined by extensive body involvement with a regular need for moderately potent or potent steroid or frequent need for systemic steroids; cytotoxic therapy, combined with other measures, particularly antipruritic agents and antibiotics as required</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the study</U>
</B>
</P>
<UL>
<LI>Pruritis of any other cause</LI>
<LI>Any other inflammatory skin disorder or any systemic disorder</LI>
<LI>Any severe intercurrent illness, including liver failure, renal failure, malignancy</LI>
<LI>Participants pregnant or trying to conceive</LI>
<LI>Participants with epilepsy</LI>
<LI>Participants on phenothiazines</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-23 18:15:08 +0000" MODIFIED_BY="Joel Bamford">
<UL>
<LI>Treatment group - 2 groups:</LI>
</UL>
<UL>
<UL>
<LI>Efamol® - 12 capsules daily, each with 40 mg GLA and 11 mg vitamin E</LI>
<LI>Efamol® - marine, 12 capsules, each 500 mg, with 80% Efamol® and 20% fish oil</LI>
</UL>
</UL>
<UL>
<LI>Placebo: 12 capsules daily each with 500 mg paraffin oil</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-23 01:03:56 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Participant assessment of itching (method of assessment: VAS 0 to 100; none to worst ever)</LI>
<LI>Participant assessment of all other signs and symptoms of eczema except itch (method of assessment: VAS and diary)</LI>
<LI>Dermatologist assessment of all other signs and symptoms of eczema (method of assessment: VAS)</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-03-23 01:02:50 +0000" MODIFIED_BY="[Empty name]">
<P>Prior and concomitant treatment: allowed</P>
<P>Compliance assessment: undertaken by counting the returned capsules</P>
<P>The results were evaluated - by other individuals - 6 years after the study completed</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-04-02 11:27:18 +0100" MODIFIED_BY="Joel Bamford" STUDY_ID="STD-Schalin_x002d_Karrila-1987">
<CHAR_METHODS MODIFIED="2013-03-23 01:04:09 +0000" MODIFIED_BY="Joel Bamford">
<P>Design: double-blind, placebo-controlled, parallel</P>
<P>Duration: 12 weeks</P>
<P>Interval of assessment: 3 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-04-02 11:26:46 +0100" MODIFIED_BY="Joel Bamford">
<P>Number randomised: 25 (14 in the active group and 11 in the placebo group)</P>
<P>Sex (M/F): 9/16</P>
<P>Age of participants: 19 to 31 years</P>
<P>Unit of allocation: whole person</P>
<P>Country and setting: Finland, Turku Pediatrics single centre</P>
<P>
<B>
<U>Inclusion criteria of the study</U>
</B>
</P>
<UL>
<LI>Maintain normal diet</LI>
<LI>No other specifications</LI>
<LI>Diagnosis: clinical appearance. Many also had personal history of respiratory atopy with family history of atopy</LI>
<LI>Severity of condition: moderate to severe</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the study</U>
</B>
</P>
<UL>
<LI>Not specified</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-23 01:08:27 +0000" MODIFIED_BY="Joel Bamford">
<UL>
<LI>Treatment group: 8 capsules daily, each with 500 mg of EPO</LI>
<LI>Placebo group: 8 capsules daily, each with 500 mg paraffin oil</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-04-02 01:54:57 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Consumption of emollient cream and topical steroids</LI>
<LI>Overall severity and grade of inflammation</LI>
<LI>Response to treatment (method of assessment of above 3 by discussion between doctor and participant)</LI>
<LI>Fatty acid composition of plasma phospholipids (method of assessment was by laboratory testing)</LI>
<LI>Blood levels of prostaglandins and thromboxane (method of assessment was by laboratory testing)</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-04-02 11:27:18 +0100" MODIFIED_BY="[Empty name]">
<P>Prior treatment: 2 weeks off topical steroids and systemic medications</P>
<P>Concomitant treatment: permitted</P>
<P>Compliance undertaken by recording of mild topical cortisone, antihistamines, emollient, and blood assays</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-04-02 11:29:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Senapati-2008">
<CHAR_METHODS MODIFIED="2013-03-23 01:09:48 +0000" MODIFIED_BY="Joel Bamford">
<P>Design: randomised, double-blind, parallel</P>
<P>Duration: 5 months</P>
<P>Interval of assessment: 4 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-04-02 02:13:55 +0100" MODIFIED_BY="[Empty name]">
<P>Number randomised: 50 (25 each in the active and placebo groups)</P>
<P>Sex (M/F): 11/14 in the active group and 7/18 in the placebo group</P>
<P>Age of participants: detailed to decade, similar in the active and placebo groups</P>
<P>Unit of allocation: whole person</P>
<P>Country and setting: Kolkata, India; single centre, referral hospital's outpatient department</P>
<P>
<B>
<U>Inclusion criteria of the study</U>
</B>
</P>
<UL>
<LI>Diagnostic criteria: Hanifin and Rajka</LI>
<LI>Severiity: "all degrees from mild to severe using 'Intensity Item Score Aggregate (IISA)"</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the study</U>
</B>
</P>
<UL>
<LI>Pregnant and lactating women</LI>
<LI>Epilepsy patients</LI>
<LI>Those with history of peptic ulceration, intake of phenothiazines</LI>
<LI>Patients who received UVB phototherapy or photochemotherapy in the last month</LI>
<LI>Patients who received systemic steroid or other immunosuppressive drugs in the last 3 months</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-23 18:18:39 +0000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Treatment (active) group:</LI>
<UL>
<LI>1 to 4 capsules/day for participants up to 1 year of age;</LI>
<LI>5 to 6 capsules/day for those aged 2 to 5 years;</LI>
<LI>7 to 8 capsules/day for those aged 6 to 10 years;</LI>
<LI>9 to 10 capsules/day for those 11 to 16 years;</LI>
<LI>12 capsules/day for participants above 16 years of age (each capsule had 500 mg of EPO and vitamin E 10IU)</LI>
</UL>
<LI>Placebo: dose the same way according to age groups as the treatment arm (each capsule had 300 mg of sunflower oil and vitamin E 10IU)</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-04-02 11:29:26 +0100" MODIFIED_BY="Joel Bamford">
<OL>
<LI>Extent (method: extent of the disease: if only 1 area of predilection or less than 20% of body surface area (BSA) was involved, score was as follows: 1. If 2 to 3 areas or &lt; 40% of BSA was involved, the participant scored 2. For any involvement more than the aforementioned, the score was 3)</LI>
<LI>Intensity (method: individual scores from 6 separate clinical items - erythema, edema/papulation, vesiculation/oozing/crusting, excoriation, scaling, and lichenification (each graded as 0, 1, 2, and 3 for absence, mild, moderate, and severe degrees) - were summated to develop 'Intensity Item Score Aggregate (IISA)', which reflects the actual intensity of the disease. From this IISA, 'intensity score' was derived. For IISA 0, intensity score was 0. For IISA 1 to 6, score was 1. For IISA 7 to 12, score was 2)</LI>
<LI>Itching (method: Itching was also graded as 0, 1, 2, and 3 for absence, mild, moderate, and severe degrees, respectively)</LI>
<LI>Dryness (method: Dryness was evaluated only on uninvolved areas as follows: absence = score 0; mild = score 1; moderate = score 2; and, severe = score 3)</LI>
<LI>Total score (method: adding all 4 major parameter scores. The case was labelled as mild, moderate, or severe when the total score ranged from 1 to 4, 5 to 8, and 9 to 12, respectively)</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-03-23 01:12:29 +0000" MODIFIED_BY="Joel Bamford">
<P>Concomittent treatment: allowed continued emollients</P>
<P>Compliance to treatment: unsure</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-04-02 02:14:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Takwale-2003">
<CHAR_METHODS MODIFIED="2013-03-23 01:23:23 +0000" MODIFIED_BY="Joel Bamford">
<P>Design: double-blind, placebo-controlled, parallel</P>
<P>Participants stratified into 2 groups of equal size: those aged up to 12 and those aged over 12</P>
<P>Duration: 12-week</P>
<P>Interval of assessment: 2, 4, 8, and 12 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-04-02 02:14:02 +0100" MODIFIED_BY="[Empty name]">
<P>Number randomised: 140</P>
<P>Sex (M/F): not mentioned other than (page 1) "...evaluable population 140 (including 69 children)"</P>
<P>Age of participants: not listed</P>
<P>Unit of allocation: whole person</P>
<P>Country and setting: UK, acute district general hospital in Nuneaton, England; single centre</P>
<P>
<B>
<U>Inclusion criteria of the study</U>
</B>
</P>
<UL>
<LI>Participants of either sex aged over 2 years attending the hospital for treatment of atopic dermatitis</LI>
<LI>Diagnosis: Hanifin and Rajka criteria</LI>
<LI>Severity of condition: not specified</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the study</U>
</B>
</P>
<UL>
<LI>Pregant, lactating, and fertile women not using effective contraception</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-23 01:25:03 +0000" MODIFIED_BY="Joel Bamford">
<UL>
<LI>Treatment groups:</LI>
<UL>
<LI>4 capsules of 500 mg of BO each for adults</LI>
<LI>2 capsules of 500 mg of BO each for adults</LI>
</UL>
<LI>Placebo group: same dosage as above with liquid paraffin oil for adults and olive oil for children</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-23 18:20:37 +0000" MODIFIED_BY="Joel Bamford">
<OL>
<LI>Mean change in SASSAD score by physicians (method: SASSAD 6 signs (erythema, exudation, excoriation, dryness, cracking, and lichenification) at 6 sites (hands, feet, arms, legs, head and neck, and trunk). Each sign is graded at each site on a 4-point scale (0 to 3, representing grades of none, mild, moderate, and severe)</LI>
<LI>Overall assessment of treatment response by participant with 5-point visual analogue scale: worse, same, improved, much improved, or cleared</LI>
<LI>Assessment of tolerability by participant (4-point scale: very good, good, fair, or poor)</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-03-23 18:21:10 +0000" MODIFIED_BY="[Empty name]">
<P>Concomitant treatment: allowed participants to use conventional treatment for atopic eczema throughout the study</P>
<P>Prior treatment: previous treatment continued, except for "potent" topical steroids, which were prohibited for children. Systemic antihistamines were allowed, but no other systemic treatment or ultraviolet light treatment was permitted</P>
<P>A minimum 4-week wash-out period was needed for participants who had received systemic steroids, psoralen plus ultraviolet A (PUVA), or other oral immunosuppressive treatment</P>
<P>Assessment of compliance: not specified</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-04-02 11:32:10 +0100" MODIFIED_BY="Joel Bamford" STUDY_ID="STD-Valsecchi-2006">
<CHAR_METHODS MODIFIED="2013-04-02 11:31:32 +0100" MODIFIED_BY="[Empty name]">
<P>Design: randomised, placebo-controlled, parallel</P>
<P>Duration: 16-week</P>
<P>Interval of assessment: 4 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-03-23 01:29:04 +0000" MODIFIED_BY="Joel Bamford">
<P>Number randomised: 31 (15 in the active group and 16 in the placebo group)</P>
<P>Sex (M/F): not mentioned</P>
<P>Age of participants: 18 children = 2 to 14 years, 13 adults = 15 to 38</P>
<P>Unit of allocation: whole person</P>
<P>Country and setting: Bergamo, Italy; single clinic</P>
<P>
<U>
<B>Inclusion criteria of the study</B>
</U>
</P>
<UL>
<LI>"Having active lesions" (page 77)</LI>
<LI>Diagnosis: Hanifin and Rajka</LI>
<LI>Severity of condition: mild to severe</LI>
</UL>
<P>
<U>
<B>Exclusion criteria of the study</B>
</U>
</P>
<UL>
<LI>Not taken systemic corticosteroids for the past 3 weeks</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-23 01:29:30 +0000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Treatment group: 5 capsules daily, each with 500 mg EPO for adults, and 3 capsules daily each with 500 mg of borage for children</LI>
<LI>Placebo group: 5 capsules, each with 500 mg paraffin oil, number of capsules daily for adult and child same as treatment group</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-04-02 02:03:50 +0100" MODIFIED_BY="Joel Bamford">
<OL>
<LI>Quantitative measurement, which included both area involved and severity of signs and symptoms of eczema</LI>
</OL>
<P>The Atherton area and severity scoring system was used to measure eczema symptoms and signs. Laboratory investigations were performed</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-04-02 11:32:10 +0100" MODIFIED_BY="Joel Bamford">
<P>Previous treatment: if using systemic steroids, stopped at 3 weeks prior to inclusion in study. If using topical steroid, stopped at start Emollients continued</P>
<P>Compliance assessment: not specified</P>
<P>Concomitant treatment: only emollient</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-04-02 11:34:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wishart-1992">
<CHAR_METHODS MODIFIED="2013-03-23 01:31:31 +0000" MODIFIED_BY="[Empty name]">
<P>Design: randomised, double-blind, placebo-controlled</P>
<P>Duration: 16 weeks</P>
<P>Interval of assessment: 4 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-04-02 11:34:42 +0100" MODIFIED_BY="[Empty name]">
<P>Number randomised: 75 (38 in the active group and 37 in the placebo group)</P>
<P>Sex (M/F): 43/32 total (22/16 in the active group and 21/16 in the placebo group)</P>
<P>Age of participants: active group = 25.5 years, placebo group = 22.0 years</P>
<P>Unit of allocation: whole person</P>
<P>Country and setting: New Zealand, multicentre</P>
<P>
<B>
<U>Inclusion criteria of the study</U>
</B>
</P>
<UL>
<LI>Participants of either sex</LI>
<LI>Participants between the ages of 16 and 75 years</LI>
<LI>Treatment was only to be commenced on outpatients. Participants who needed hospitalisations for treatment of eczema were not permitted to enter the study during their stay in the hospital. They were permitted to be entered into the study immediately upon discharge from hospital. If they were in the study, they were to continue the study regimen in hospital</LI>
<LI>Diagnosis: severity of the condition 'moderate to severe atopic eczema, as defined by extensive body involvement with a regular need for high potency or equivalent steroid, frequent need for more potent steroid (Dermovate or equivalent) or for systemic steroids, or both; cytotoxic therapy, combined with other measures, particularly antipruritic agents and antibiotics as required</LI>
</UL>
<P>
<B>
<U>Exclusion criteria of the study</U>
</B>
</P>
<UL>
<LI>Participants with pruritus from any other cause other than atopic eczema</LI>
<LI>Participants with an inflammatory skin disorder, other than atopic eczema, or other systemic inflammatory disorders</LI>
<LI>Participants with severe intercurrent illnesses, including liver failure, renal failure, malignancy</LI>
<LI>Participants who were pregnant or actively trying to conceive</LI>
<LI>Participants with epilepsy</LI>
<LI>Participants on phenothiazines</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-23 01:33:17 +0000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Treatment group: 12 capsules of Efamol® daily, each with 40 mg GLA and 11 mg vitamin E</LI>
<LI>Placebo group: 12 capsules daily, each with 500 mg sunflower oil</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-23 01:35:42 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Dermatologist assessment of excoriation/itch (VAS)</LI>
<LI>Dermatologist assessment of other parameters of eczema except itch, individually and overall impression (VAS)</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-03-23 01:36:33 +0000" MODIFIED_BY="[Empty name]">
<P>Previous treatment not stopped</P>
<P>Concommitant treatment of eczema was permitted to continue as usual</P>
<P>The results were evaluated - by other individuals - 6 years after the study completed</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-04-02 11:39:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wright-1982">
<CHAR_METHODS MODIFIED="2013-03-23 01:36:59 +0000" MODIFIED_BY="[Empty name]">
<P>Design: randomised, double-blind, placebo-controlled, cross-over</P>
<P>Duration: 24 weeks (12 and 12)</P>
<P>Interval of assessment: 3 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-04-02 11:39:03 +0100" MODIFIED_BY="[Empty name]">
<P>Number randomised: 99 (60 in the active group and 39 in the placebo group)</P>
<P>Sex (M/F): not mentioned</P>
<P>Age of participants: 60 adults = 15 to 58 years, 39 children = 4 months to 14 years</P>
<P>Unit of allocation: whole person</P>
<P>Country and setting: UK, Bristol; single dermatology department</P>
<P>
<B>
<U>Inclusion criteria of the study</U>
</B>
</P>
<UL>
<LI>Diagnosis: clinical "atopic eczema" with personal or family history of atopic conditions and using mild topical steroid, emollients, and oral antihistamine</LI>
<LI>Severity: moderate or severe (no criteria)</LI>
</UL>
<P>"None was receiving potent topical steroids or systemic steroids" (page 1121)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-04-02 11:39:11 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Adults = 3 groups:</LI>
<UL>
<LI>4 Efamol® capsules</LI>
<LI>8 Efamol® capsules daily</LI>
<LI>12 Efamol® capsules daily</LI>
</UL>
<LI>Children = 2 groups:</LI>
<UL>
<LI>2 Efamol® capsules daily</LI>
<LI>4 Efamol® capsules daily</LI>
</UL>
</UL>
<P>Each Efamol® capsule had 500 mg of Efamol® (LA and GLA)</P>
<P>Each group had a corresponding placebo control taking the same number of capsules daily with 500 mg of liquid paraffin</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-23 01:39:50 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Doctor's assessment of degree of scaling, redness, and overall severity (method: 10 cm linear scale)</LI>
<LI>Participant's assessment of same as above, plus severity of itch (method: 10 cm linear scale)</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-04-02 11:39:33 +0100" MODIFIED_BY="[Empty name]">
<P>Previous treatment not stopped</P>
<P>Asessment of compliance: unsure</P>
<P>Concommitant treatment of eczema was permitted to continue as usual</P>
<P>Author S Wright did not respond to email. Dr Burton said he had did not have the records and was retired</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>N/A: not applicable</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2013-04-02 11:49:49 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2013-03-22 15:34:26 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Biagi-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-03-22 15:34:26 +0000" MODIFIED_BY="[Empty name]">
<P>This was an open study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-03-22 15:34:51 +0000" MODIFIED_BY="Joel Bamford" STUDY_ID="STD-Bordoni-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-03-22 15:34:51 +0000" MODIFIED_BY="Joel Bamford">
<P>The paper did not give mean data, and the lead author did not reply to inquiry</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-03-22 15:35:45 +0000" MODIFIED_BY="Joel Bamford" STUDY_ID="STD-Coskery-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-03-22 15:35:45 +0000" MODIFIED_BY="Joel Bamford">
<P>This was an abstract only (no detailed data). The corresponding author had no details about the clinical course. It was a double-blind, placebo-controlled study (EPO/placebo), but not randomised. It measured the texture of skin</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-03-22 15:34:25 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Courage-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-03-22 15:34:25 +0000" MODIFIED_BY="[Empty name]">
<P>This was not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-02 11:40:26 +0100" MODIFIED_BY="Joel Bamford" STUDY_ID="STD-Guenther-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-02 11:40:26 +0100" MODIFIED_BY="Joel Bamford" NOTES="&lt;p&gt;Bit more detail please, was it randomised.  If it was still available could you have included it?&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2013-04-02 11:40:26 +0100" NOTES_MODIFIED_BY="Joel Bamford">
<P>The results of the study were shredded (author, 2011). 17 children in a double-blind cross-over study of the sign of figiting in people with atopic dermatitis. There was no significant difference in atopic dermatitis between placebo and EPO using this measure</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-03-22 15:36:43 +0000" MODIFIED_BY="Joel Bamford" STUDY_ID="STD-Melnick-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-03-22 15:36:43 +0000" MODIFIED_BY="Joel Bamford">
<P>This had no placebo; both had the same amount of GLA/weight</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-02 11:49:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00878670">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-02 11:49:49 +0100" MODIFIED_BY="[Empty name]">
<P>This was initially found as an RCT on <A HREF="http://www.clinicaltrials.gov/">www.clinicaltrials.gov</A>. After contacting the author, we checked the web site again and learned that it was not an RCT but an open study. The study has now closed</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-03-22 15:36:19 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Swapan-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-03-22 15:36:19 +0000" MODIFIED_BY="[Empty name]">
<P>Even though randomisation was stated, consecutive participant selection was carried out</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2012-12-16 14:32:37 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2013-04-02 11:39:47 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2013-04-02 11:39:42 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 02:16:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bahmer-1992">
<DESCRIPTION>
<P>The trial mentioned randomisation, but did not give a specific method</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 02:18:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bamford-1985">
<DESCRIPTION>
<P>The trial used block randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 02:20:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Berth_x002d_Jones-1993">
<DESCRIPTION>
<P>Quote: "Randomization in blocks of three..."</P>
<P>Comment: The trial used block randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 02:21:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Biagi-1994">
<DESCRIPTION>
<P>Quote: "Children were randomised to receive either..."</P>
<P>Comment: The trial gave no method of generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 02:22:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Borrek-1997">
<DESCRIPTION>
<P>Randomisation was by draw (entrance to study)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 02:23:34 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Buslau-1996">
<DESCRIPTION>
<P>The trial did not specify the method of sequence generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 02:25:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Don-2003">
<DESCRIPTION>
<P>Quote (page 428): "Patients were assigned to two groups on the basis of a randomised list created by suitable statistical software"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 02:27:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Finlay-2001">
<DESCRIPTION>
<P>The trial used block randomisation (blocks of 4). Searle held the randomisation code, which was not identified to the investigators unless in an emergency</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 02:28:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-France-1988">
<DESCRIPTION>
<P>The trial used computer-generated block randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 02:30:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fraser-2001">
<DESCRIPTION>
<P>The trial was randomised, but did not mention a method of generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 02:32:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Harper-1990">
<DESCRIPTION>
<P>The trial used computer-generated randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 02:33:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Heddle-1990">
<DESCRIPTION>
<P>A randomisation table was given, but the method of sequence generation was not stated</P>
<P>Quote: "This was a single center, double-blind, randomised, placebo-controlled, crossover study of EPO versus safflower oil (SAFF, Placebo)"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 02:36:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hederos-1996">
<DESCRIPTION>
<P>Quote (page 484): "A randomisation list was provided that allocated patients in blocks of two"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 11:12:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Henz-1999">
<DESCRIPTION>
<P>This was provided from external sources, which were not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 11:14:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kenicer-2001">
<DESCRIPTION>
<P>Randomisation was by computer-generated sequence in blocks of 4, which was adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 11:16:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kiehl-1994">
<DESCRIPTION>
<P>The trial did not state the method of sequence generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 11:18:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kovar-1992">
<DESCRIPTION>
<P>Quote: "Computerized, block method for the 8 week double blind, parallel, placebo controlled study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-22 14:49:03 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lovell-1981">
<DESCRIPTION>
<P>Quote (page 278): "...received on a randomised, double-blind crossover basis..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 11:22:03 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-MacKie-Adult-1990">
<DESCRIPTION>
<P>Randomisation was computer-generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 11:23:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-MacKie-Child-1990">
<DESCRIPTION>
<P>Randomisation was computer-generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 11:25:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-MacLeod-2001">
<DESCRIPTION>
<P>A computer-generated sequence was used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 11:27:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schalin_x002d_Karrila-1987">
<DESCRIPTION>
<P>The trial was described as 'randomly divided', but the method was not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 11:29:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Senapati-2008">
<DESCRIPTION>
<P>Quote: "...using a random number table"</P>
<P>Comment: This trial did not specify the method of sequence generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 11:31:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Takwale-2003">
<DESCRIPTION>
<P>Quote: "...using computer generated random numbers"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 11:32:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Valsecchi-2006">
<DESCRIPTION>
<P>The paper stated 'randomly divided', but no details were given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 11:38:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wishart-1992">
<DESCRIPTION>
<P>Randomisation was computer-generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 11:39:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wright-1982">
<DESCRIPTION>
<P>The trial used block randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2013-04-02 11:39:43 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 02:16:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bahmer-1992">
<DESCRIPTION>
<P>The trial did not give a method for allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 02:18:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bamford-1985">
<DESCRIPTION>
<P>Specific study numbers were used on labels, which did not contain medication/placebo name. (The trial investigator provided this further information)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 02:20:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Berth_x002d_Jones-1993">
<DESCRIPTION>
<P>The trial did not state the method by which it concealed allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 02:21:24 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Biagi-1994">
<DESCRIPTION>
<P>The trial gave no details</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 02:22:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Borrek-1997">
<DESCRIPTION>
<P>The trial did not specify this</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 02:23:36 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Buslau-1996">
<DESCRIPTION>
<P>The trial did not specify the method of allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 02:26:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Don-2003">
<DESCRIPTION>
<P>The BO group was identified by letter A; the olive oil (placebo) group, by letter B. Investigators were unaware of this classification before and during the study. Comment: It is unclear if allocation was adequately concealed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 02:27:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Finlay-2001">
<DESCRIPTION>
<P>The trial used sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 02:28:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-France-1988">
<DESCRIPTION>
<P>A Securitainer® was used for each participant and at each visit</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 02:30:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fraser-2001">
<DESCRIPTION>
<P>There was no statement about allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 02:31:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Harper-1990">
<DESCRIPTION>
<P>Quote (page 15): "A listing of the randomization schedule and code is not available. Appendix 4 contains a listing of children with their randomised assigned treatment"</P>
<P>Comment: This was adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 02:33:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Heddle-1990">
<DESCRIPTION>
<P>The trial did not mention a method of concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 02:36:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hederos-1996">
<DESCRIPTION>
<P>No details of concealment given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 11:12:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Henz-1999">
<DESCRIPTION>
<P>This was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 11:14:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kenicer-2001">
<DESCRIPTION>
<P>This was adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 11:16:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kiehl-1994">
<DESCRIPTION>
<P>The paper stated "double-blind", but did not specify the method</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 11:18:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kovar-1992">
<DESCRIPTION>
<P>Codes were kept in sealed envelopes, which were only to be opened if needed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 11:20:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lovell-1981">
<DESCRIPTION>
<P>The paper did not state this (a short 5-paragraph report)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 11:22:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-MacKie-Adult-1990">
<DESCRIPTION>
<P>Allocation concealment was done through sealed coded envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 11:23:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-MacKie-Child-1990">
<DESCRIPTION>
<P>The trial used sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 11:25:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-MacLeod-2001">
<DESCRIPTION>
<P>The trial used sealed opaque envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 11:27:26 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Schalin_x002d_Karrila-1987">
<DESCRIPTION>
<P>The method was not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 11:29:53 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Senapati-2008">
<DESCRIPTION>
<P>The paper did not specify this</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 11:31:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Takwale-2003">
<DESCRIPTION>
<P>The study used sealed containers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 11:32:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Valsecchi-2006">
<DESCRIPTION>
<P>The paper did not state the method of allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 11:38:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wishart-1992">
<DESCRIPTION>
<P>The trial used sealed opaque envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 11:39:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wright-1982">
<DESCRIPTION>
<P>The paper did not describe allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2012-01-19 19:59:10 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2013-04-02 11:39:44 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-04-02 02:17:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bahmer-1992">
<DESCRIPTION>
<P>There were no dropouts or losses to follow up (7/7 glandol and 5/5 placebo completed)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-04-02 02:18:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bamford-1985">
<DESCRIPTION>
<P>14/77 participants in the EPO group dropped out; 17/77 participants in the placebo group dropped out. They gave reasons</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-04-02 02:20:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Berth_x002d_Jones-1993">
<DESCRIPTION>
<P>The trial reported all outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-04-02 02:21:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Biagi-1994">
<DESCRIPTION>
<P>3/48 participants did not attend for follow up. The dropouts or losses to follow up by assignment group were unclear, as were the reasons</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-04-02 02:22:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Borrek-1997">
<DESCRIPTION>
<P>2 participants from each group withdrew due to non-compliance</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-04-02 02:23:37 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Buslau-1996">
<DESCRIPTION>
<P>7/25 participants in the active group withdrew, and 11/25 in the placebo group withdrew. The trial undertook ITT analysis, but dropouts were not balanced between the groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-04-02 02:25:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Don-2003">
<DESCRIPTION>
<P>9/10 participants in the borage oil group completed the study, and 9/10 in the olive oil group completed the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-04-02 02:27:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Finlay-2001">
<DESCRIPTION>
<P>2/30 participants in the EPO group withdrew due to adverse events, as did 2/30 in the placebo group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-04-02 02:28:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-France-1988">
<DESCRIPTION>
<P>Of 25 participants in the active group, 4 withdrew and 3 were lost to follow up. Of 20 participants in the placebo group, 2 withdrew and 2 were lost to follow up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-04-02 02:30:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fraser-2001">
<DESCRIPTION>
<P>No participants dropped out in the EPO group. 4 participants dropped out in the placebo group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-04-02 02:31:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Harper-1990">
<DESCRIPTION>
<P>The trial undertook ITT analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-04-02 02:33:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Heddle-1990">
<DESCRIPTION>
<P>All (25/25) participants completed, and an ITT model was used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-04-02 02:36:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hederos-1996">
<DESCRIPTION>
<P>2/30 participants in the EPO group withdrew before the end of therapy, as did 0/30 in the placebo group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-04-02 11:12:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Henz-1999">
<DESCRIPTION>
<P>This was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-04-02 11:14:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kenicer-2001">
<DESCRIPTION>
<P>The trial undertook ITT analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-04-02 11:16:05 +0100" MODIFIED_BY="Cathy Bennett" RESULT="YES" STUDY_ID="STD-Kiehl-1994">
<DESCRIPTION>
<P>There were no dropouts (39/39 in the glandol group; 23/23 in the EPO group)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-04-02 11:18:25 +0100" MODIFIED_BY="Cathy Bennett" RESULT="YES" STUDY_ID="STD-Kovar-1992">
<DESCRIPTION>
<P>There were no withdrawals. 3/24 participants in the active group were lost to follow up, as were 2/24 in the placebo group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-04-02 11:19:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lovell-1981">
<DESCRIPTION>
<P>All randomised participants were included in the results</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-04-02 11:22:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-MacKie-Adult-1990">
<DESCRIPTION>
<P>This was low risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-04-02 11:23:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-MacKie-Child-1990">
<DESCRIPTION>
<P>There were no withdrawals, but defaults: 4/10 in the active group and 2/9 in the placebo group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-04-02 11:25:40 +0100" MODIFIED_BY="Cathy Bennett" RESULT="NO" STUDY_ID="STD-MacLeod-2001">
<DESCRIPTION>
<P>There were 3/8 withdrawals in the active group, and there were 4/8 withdrawals in the placebo group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-04-02 11:27:27 +0100" MODIFIED_BY="Cathy Bennett" RESULT="YES" STUDY_ID="STD-Schalin_x002d_Karrila-1987">
<DESCRIPTION>
<P>1 participant out of 14 in the EPO group dropped out due to allergy to concomitant medication (unrelated to EPO); there were no dropouts (out of 11 participants) in the placebo group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-04-02 11:29:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Senapati-2008">
<DESCRIPTION>
<P>This was low risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-04-02 11:31:19 +0100" MODIFIED_BY="Cathy Bennett" RESULT="YES" STUDY_ID="STD-Takwale-2003">
<DESCRIPTION>
<P>1 participant withdrew, out of 14, in the active group due to severe allergic reaction; there were 0 dropouts in the placebo group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-04-02 11:32:14 +0100" MODIFIED_BY="Cathy Bennett" RESULT="UNKNOWN" STUDY_ID="STD-Valsecchi-2006">
<DESCRIPTION>
<P>2/15 participants in the GLA group dropped out, and 1 participant, out of 16, dropped out in the placebo group; the reasons were unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-04-02 11:38:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wishart-1992">
<DESCRIPTION>
<P>This was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-04-02 11:39:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wright-1982">
<DESCRIPTION>
<P>8/60 participants in the active group dropped out, as did 8/39 in the placebo group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2013-04-02 11:39:45 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 02:17:03 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bahmer-1992">
<DESCRIPTION>
<P>The trial reported all outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 02:18:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bamford-1985">
<DESCRIPTION>
<P>The trial reported all prespecified outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 02:20:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Berth_x002d_Jones-1993">
<DESCRIPTION>
<P>There was no selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 02:21:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Biagi-1994">
<DESCRIPTION>
<P>The trial reported all prespecified outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 02:22:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Borrek-1997">
<DESCRIPTION>
<P>The trial reported all prespecified outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 02:23:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Buslau-1996">
<DESCRIPTION>
<P>The trial reported all prespecified outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 02:25:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Don-2003">
<DESCRIPTION>
<P>The trial reported all prespecified outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 02:27:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Finlay-2001">
<DESCRIPTION>
<P>The trial reported all prespecified outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-22 14:15:21 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-France-1988">
<DESCRIPTION>
<P>Quote: "Primary and secondary efficacy variables not stated in the study..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 02:30:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fraser-2001">
<DESCRIPTION>
<P>There was no selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 02:31:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Harper-1990">
<DESCRIPTION>
<P>There was no selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 02:33:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Heddle-1990">
<DESCRIPTION>
<P>The trial reported all prespecified outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 02:36:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hederos-1996">
<DESCRIPTION>
<P>The trial reported all prespecified outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 11:12:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Henz-1999">
<DESCRIPTION>
<P>This was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 11:14:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kenicer-2001">
<DESCRIPTION>
<P>There was no selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 11:16:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kiehl-1994">
<DESCRIPTION>
<P>The trial reported all prespecified outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 11:18:25 +0100" MODIFIED_BY="Cathy Bennett" RESULT="UNKNOWN" STUDY_ID="STD-Kovar-1992">
<DESCRIPTION>
<P>This was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 11:19:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lovell-1981">
<DESCRIPTION>
<P>This was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 11:22:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-MacKie-Adult-1990">
<DESCRIPTION>
<P>This was low risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 11:23:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-MacKie-Child-1990">
<DESCRIPTION>
<P>This was low risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 11:25:42 +0100" MODIFIED_BY="Cathy Bennett" RESULT="UNKNOWN" STUDY_ID="STD-MacLeod-2001">
<DESCRIPTION>
<P>This was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 11:27:28 +0100" MODIFIED_BY="Cathy Bennett" RESULT="YES" STUDY_ID="STD-Schalin_x002d_Karrila-1987">
<DESCRIPTION>
<P>The trial reported all prespecified outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 11:29:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Senapati-2008">
<DESCRIPTION>
<P>This was low risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-22 15:14:53 +0000" MODIFIED_BY="Cathy Bennett" RESULT="UNKNOWN" STUDY_ID="STD-Takwale-2003">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 11:32:14 +0100" MODIFIED_BY="Cathy Bennett" RESULT="YES" STUDY_ID="STD-Valsecchi-2006">
<DESCRIPTION>
<P>The trial reported all prespecified outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 11:38:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wishart-1992">
<DESCRIPTION>
<P>This was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 11:39:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wright-1982">
<DESCRIPTION>
<P>This was unclear there was no ITT statement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2013-04-02 11:39:46 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 02:17:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bahmer-1992">
<DESCRIPTION>
<P>All randomised participants were included in the analysis in the groups to which they were randomised. We contacted the author</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 02:18:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bamford-1985">
<DESCRIPTION>
<P>We were unsure whether all participants were included in the analysis in the groups to which they were randomised. We contacted the biostatistician author. A non-profit foundation funded the trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 02:20:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Berth_x002d_Jones-1993">
<DESCRIPTION>
<P>We were unsure whether all participants were included in the analysis in the groups to which they were randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 02:21:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Biagi-1994">
<DESCRIPTION>
<P>We contacted the author; there was no other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 02:22:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Borrek-1997">
<DESCRIPTION>
<P>Quote (page 101): "No difference between the two groups in the most important variables"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 02:23:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Buslau-1996">
<DESCRIPTION>
<P>No detail of funding or support was listed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 02:25:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Don-2003">
<DESCRIPTION>
<P>We contacted the author; there was no other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 02:27:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Finlay-2001">
<DESCRIPTION>
<P>There was no other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 02:29:01 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-France-1988">
<DESCRIPTION>
<P>Case report forms (CRFs) varied at different sites. Ages were not recorded (page 24)</P>
<P>The results were evaluated 6 years after study completion and evaluated by other individuals</P>
<P>Quote (page 4): "Efficacy variables were not stated in the protocol...for the purpose of this report the patient assessment of itching was the primary efficacy variable"</P>
<P>3 participants were included in analyses that were not accounted for in the randomisation schedule (page 14)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 02:30:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fraser-2001">
<DESCRIPTION>
<P>There was no other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 02:31:59 +0100" MODIFIED_BY="Joel Bamford" RESULT="NO" STUDY_ID="STD-Harper-1990">
<DESCRIPTION>
<P>Pharmacia sponsored the trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 02:33:58 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Heddle-1990">
<DESCRIPTION>
<P>The final write-up and statistical evaluation was done at least 6 years after the last participant was in the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 02:36:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hederos-1996">
<DESCRIPTION>
<P>There was no other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 11:12:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Henz-1999">
<DESCRIPTION>
<P>This was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 11:14:48 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kenicer-2001">
<DESCRIPTION>
<P>Quote (page 29): "34% of Active and 32% of placebo participants did not satisfy the inclusion criterion"</P>
<P>Quote (page 3): "For the purpose of this report the primary and secondary objectives have been re-defined"</P>
<P>The results were evaluated 6 years after the completion of the study; other individuals evaluated the results</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 11:16:06 +0100" MODIFIED_BY="Cathy Bennett" RESULT="YES" STUDY_ID="STD-Kiehl-1994">
<DESCRIPTION>
<P>There was no other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 11:18:28 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kovar-1992">
<DESCRIPTION>
<P>Quote (page 22): "No statistical methodology was planned in the protocol..."</P>
<P>Comment: A statistical analysis plan was developed in June 2001 (some years after the study was completed)</P>
<P>Quote (page 23): "A primary objective for this study was not stated within the protocol"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 11:19:51 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lovell-1981">
<DESCRIPTION>
<P>1 author (DFH) worked full time for the company. We contacted the author</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 11:22:06 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-MacKie-Adult-1990">
<DESCRIPTION>
<P>The results were evaluated 6 years after the completion of the study; other individuals evaluated the results</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 11:23:49 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-MacKie-Child-1990">
<DESCRIPTION>
<P>The results were evaluated 6 years after the completion of the study; other individuals evaluated the results. 1 child was included against protocol (age 12)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 11:26:26 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-MacLeod-2001">
<DESCRIPTION>
<P>The results were evaluated 6 years after completion of the study; other individuals evaluated the results</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 11:27:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schalin_x002d_Karrila-1987">
<DESCRIPTION>
<P>There was no other bias. A non-profit foundation provided funding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 11:29:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Senapati-2008">
<DESCRIPTION>
<P>This was low risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-22 15:14:54 +0000" MODIFIED_BY="Cathy Bennett" RESULT="UNKNOWN" STUDY_ID="STD-Takwale-2003">
<DESCRIPTION>
<P>-</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 11:32:15 +0100" MODIFIED_BY="Cathy Bennett" RESULT="UNKNOWN" STUDY_ID="STD-Valsecchi-2006">
<DESCRIPTION>
<P>There was no other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 11:38:40 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wishart-1992">
<DESCRIPTION>
<P>The results were evaluated 6 years after the completion of the study; other individuals evaluated the results</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-02 11:39:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wright-1982">
<DESCRIPTION>
<P>This was unclear. We contacted the second author, who replied: "...retired, I do not know how to contact first author or [know the] whereabouts of records"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2013-04-02 11:39:47 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-04-02 02:17:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bahmer-1992">
<DESCRIPTION>
<P>This was adequate as both the participant and assessor were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-04-02 02:18:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bamford-1985">
<DESCRIPTION>
<P>This was adequate as both the participant and assessor were blinded. The placebo capsules were identical</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-04-02 02:20:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Berth_x002d_Jones-1993">
<DESCRIPTION>
<P>Quote: "The study had a double-blind design"</P>
<P>Comment: The trial stated blinding, but did not specify the method</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-04-02 02:21:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Biagi-1994">
<DESCRIPTION>
<P>Quote: "...all assessments were made double blind"</P>
<P>Comment: This was adequate, but details were not given of who was blinded and how. This was probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-04-02 02:23:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Borrek-1997">
<DESCRIPTION>
<P>Quote (page 101): "Patient and examiner were blinded with respect to after completion of the capsule contents"</P>
<P>Comment: This was adequate (both blinded)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-04-02 02:23:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Buslau-1996">
<DESCRIPTION>
<P>This was adequate for participants, but it was unclear if they blinded the clinician outcome assessor</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-04-02 02:25:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Don-2003">
<DESCRIPTION>
<P>Oils were dispensed in dark unlabelled bottles. Interventions had a different taste, smell, and colour</P>
<P>Quote: "None of the investigators was aware of (...the A vs B...) classification before or during the study." (Methods section)</P>
<P>Comment: Attempts were made to blind both participants and personnel, but it was unclear if this was adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-04-02 02:27:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Finlay-2001">
<DESCRIPTION>
<P>There was adequate blinding of both investigators and participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-04-02 02:29:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-France-1988">
<DESCRIPTION>
<P>This was adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-04-02 02:30:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fraser-2001">
<DESCRIPTION>
<P>This was stated, but details were not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-04-02 02:32:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Harper-1990">
<DESCRIPTION>
<P>Quote (page 15): "Securicontainer #1 was given out by physician or pharmacist to the first patient entered in the trial"</P>
<P>Comment: This was adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-04-02 02:33:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Heddle-1990">
<DESCRIPTION>
<P>The study did not state the method, but it was performed under double-blind conditions</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-04-02 02:36:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hederos-1996">
<DESCRIPTION>
<P>Quote (page 494): "The study was a double blind, randomised, placebo controlled trial"</P>
<P>Comment: Participants were blinded as "identical" capsules were given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-04-02 11:12:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Henz-1999">
<DESCRIPTION>
<P>This was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-04-02 11:14:41 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kenicer-2001">
<DESCRIPTION>
<P>Quote (page 19): "There was no evidence in the protocol that the study was performed under blind conditions"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-04-02 11:16:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kiehl-1994">
<DESCRIPTION>
<P>Both participants and personnel were blinded; it is unclear if the outcome assessors were blinded</P>
<P>Comment: This was probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-04-02 11:18:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kovar-1992">
<DESCRIPTION>
<P>This was adequate: Pill appearance was the same, and the medication was dispensed in a blind fashion</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-04-02 11:19:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lovell-1981">
<DESCRIPTION>
<P>The first phase was double-blind</P>
<P>The second phase was only participant-blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-04-02 11:22:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-MacKie-Adult-1990">
<DESCRIPTION>
<P>Blinding was adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-04-02 11:23:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-MacKie-Child-1990">
<DESCRIPTION>
<P>This was adequately blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-04-02 11:25:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-MacLeod-2001">
<DESCRIPTION>
<P>This was adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-04-02 11:27:36 +0100" MODIFIED_BY="Cathy Bennett" RESULT="UNKNOWN" STUDY_ID="STD-Schalin_x002d_Karrila-1987">
<DESCRIPTION>
<P>Quote (page 12): "...14 patients receiving evening primrose oil (EPO) and 11 patients receiving placebo, in a double-blind trial. EPO was provided in capsules containing 360 mg linoleic acid, 50 mg oleic acid and 45 mg GLA (Efamol®). The placebo capsules contained 500 mg of liquid paraffin"</P>
<P>Comment: This was probably identical and adequate, but it was unclear if assessors were blinded (described as 'double blind')</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-04-02 11:29:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Senapati-2008">
<DESCRIPTION>
<P>The study title did not state this: "Evening primrose oil is effective in atopic dermatitis: A randomised placebo-controlled trial". The study did not mention blinding<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-04-02 11:31:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Takwale-2003">
<DESCRIPTION>
<P>The study stated "blinded", with no details</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-04-02 11:32:15 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Valsecchi-2006">
<DESCRIPTION>
<P>The trial report did not mention blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-04-02 11:38:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wishart-1992">
<DESCRIPTION>
<P>The trial used Securitainers® for medication handling</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-04-02 11:39:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wright-1982">
<DESCRIPTION>
<P>This was adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2012-01-19 19:59:10 +0000" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2013-03-22 12:16:47 +0000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2013-03-22 12:15:23 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>EPO versus placebo</NAME>
<CONT_OUTCOME CHI2="12.075403994021167" CI_END="6.044868747044661" CI_START="-10.483253480444535" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.2191923666999367" ESTIMABLE="YES" I2="50.31222141328978" I2_Q="0.0" ID="CMP-001.01" MODIFIED="2013-03-22 12:11:56 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.06030773217831753" P_Q="0.3692675989377753" P_Z="0.5986661883260423" Q="0.8061278195339175" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="60.51757907990973" TOTALS="YES" TOTAL_1="91" TOTAL_2="85" UNITS="" WEIGHT="100.00000000000001" Z="0.5263195726207821">
<NAME>Participant-reported global improvement in symptoms (0 to 100 VAS reduction)</NAME>
<GROUP_LABEL_1>EPO</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours EPO</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.9498962711392185" CI_END="15.489601143587365" CI_START="-39.33507257215879" DF="1" EFFECT_SIZE="-11.922735714285714" ESTIMABLE="YES" I2="74.68287946428572" ID="CMP-001.01.01" MODIFIED="2013-01-08 18:27:52 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.04687432499046329" P_Z="0.39395455043997274" STUDIES="2" TAU2="292.75688749999995" TOTAL_1="13" TOTAL_2="17" WEIGHT="22.524506565078052" Z="0.8524677308012101">
<NAME>Children only</NAME>
<CONT_DATA CI_END="23.8712142018161" CI_START="-18.471214201816103" EFFECT_SIZE="2.7" ESTIMABLE="YES" MEAN_1="7.3" MEAN_2="4.6" MODIFIED="2013-01-08 18:27:23 +0000" MODIFIED_BY="[Empty name]" ORDER="52" SD_1="22.23" SD_2="22.23" SE="10.80183838520092" STUDY_ID="STD-Harper-1990" TOTAL_1="8" TOTAL_2="9" WEIGHT="10.0330685334977"/>
<CONT_DATA CI_END="-7.572723022603011" CI_START="-43.02727697739698" EFFECT_SIZE="-25.299999999999997" ESTIMABLE="YES" MEAN_1="2.6" MEAN_2="27.9" MODIFIED="2013-01-08 18:27:52 +0000" MODIFIED_BY="[Empty name]" ORDER="53" SD_1="15.9" SD_2="15.81" SE="9.044695268498547" STUDY_ID="STD-MacKie-Child-1990" TOTAL_1="5" TOTAL_2="8" WEIGHT="12.491438031580353"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.352584142960766" CI_END="7.419698371891382" CI_START="-5.465995896613681" DF="4" EFFECT_SIZE="0.9768512376388505" ESTIMABLE="YES" I2="8.10057040553677" ID="CMP-001.01.02" MODIFIED="2013-01-08 18:30:48 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.36038681263649663" P_Z="0.7663399997457057" STUDIES="5" TAU2="4.5819759753390725" TOTAL_1="78" TOTAL_2="68" WEIGHT="77.47549343492196" Z="0.2971657101480566">
<NAME>Other (adults only or adults and children)</NAME>
<CONT_DATA CI_END="7.032021439170876" CI_START="-24.832021439170873" EFFECT_SIZE="-8.899999999999999" ESTIMABLE="YES" MEAN_1="9.8" MEAN_2="18.7" MODIFIED="2013-01-08 18:29:04 +0000" MODIFIED_BY="[Empty name]" ORDER="54" SD_1="22.92" SD_2="22.97" SE="8.128731734277071" STUDY_ID="STD-France-1988" TOTAL_1="17" TOTAL_2="15" WEIGHT="14.043592547064081"/>
<CONT_DATA CI_END="10.989110430371966" CI_START="-7.989110430371966" EFFECT_SIZE="1.5" ESTIMABLE="YES" MEAN_1="3.4" MEAN_2="1.9" MODIFIED="2013-01-08 18:29:34 +0000" MODIFIED_BY="[Empty name]" ORDER="55" SD_1="18.5" SD_2="18.55" SE="4.841471835819871" STUDY_ID="STD-Fraser-2001" TOTAL_1="32" TOTAL_2="27" WEIGHT="21.175405198302542"/>
<CONT_DATA CI_END="9.877449265523499" CI_START="-22.277449265523497" EFFECT_SIZE="-6.2" ESTIMABLE="YES" MEAN_1="0.3" MEAN_2="6.5" MODIFIED="2013-01-08 18:30:02 +0000" MODIFIED_BY="[Empty name]" ORDER="56" SD_1="23.56" SD_2="23.54" SE="8.202930968293481" STUDY_ID="STD-Kenicer-2001" TOTAL_1="16" TOTAL_2="17" WEIGHT="13.910437395854995"/>
<CONT_DATA CI_END="21.223840165408532" CI_START="-9.823840165408528" EFFECT_SIZE="5.700000000000001" ESTIMABLE="YES" MEAN_1="15.4" MEAN_2="9.7" MODIFIED="2013-01-08 18:30:25 +0000" MODIFIED_BY="[Empty name]" ORDER="57" SD_1="13.35" SD_2="15.58" SE="7.920472155538877" STUDY_ID="STD-MacKie-Adult-1990" TOTAL_1="8" TOTAL_2="6" WEIGHT="14.424434369082144"/>
<CONT_DATA CI_END="27.86517571091853" CI_START="-4.265175710918532" EFFECT_SIZE="11.799999999999999" ESTIMABLE="YES" MEAN_1="14.2" MEAN_2="2.4" MODIFIED="2013-01-08 18:30:48 +0000" MODIFIED_BY="[Empty name]" ORDER="58" SD_1="11.23" SD_2="11.22" SE="8.196668835569728" STUDY_ID="STD-MacLeod-2001" TOTAL_1="5" TOTAL_2="3" WEIGHT="13.921623924618194"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_DATA="NO" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-02-19 12:16:46 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="20.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Parent assessment at end of treatment (VAS)</NAME>
<GROUP_LABEL_1>EPO</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours EPO</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_DATA CI_END="14.600984987704123" CI_START="-8.800984987704123" EFFECT_SIZE="2.9" ESTIMABLE="YES" ESTIMATE="2.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-10-27 10:03:31 +0100" MODIFIED_BY="[Empty name]" ORDER="11" SE="5.97" STUDY_ID="STD-Hederos-1996" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0"/>
</IV_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.03" MODIFIED="2013-02-19 12:16:56 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="30.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="16" TOTAL_2="16" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Parents global improvent in eczema symptoms at 8 weeks</NAME>
<GROUP_LABEL_1>EPO</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours EPO</GRAPH_LABEL_2>
<CONT_DATA CI_END="16.16346281004006" CI_START="-17.76346281004006" EFFECT_SIZE="-0.7999999999999989" ESTIMABLE="YES" MEAN_1="8.4" MEAN_2="9.2" MODIFIED="2012-04-29 14:39:20 +0100" MODIFIED_BY="[Empty name]" ORDER="45" SD_1="24.48" SD_2="24.48" SE="8.654987001723342" STUDY_ID="STD-Kovar-1992" TOTAL_1="16" TOTAL_2="16" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.4461356155231115" CI_END="0.4480174200044318" CI_START="-6.959470867449543" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.2557267237225553" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.04" MODIFIED="2013-03-22 12:12:06 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.7271934135865022" P_Q="0.9098373483083176" P_Z="0.08491020768915168" Q="0.01282413684181066" RANDOM="YES" SCALE="30.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="155" TOTAL_2="134" UNITS="" WEIGHT="99.99999999999999" Z="1.7228801111460263">
<NAME>Physician-reported global improvement in symptoms (0 to 100 VAS reduction)</NAME>
<GROUP_LABEL_1>EPO</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours EPO</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.141105325224743" CI_END="3.3036915931348263" CI_START="-9.181022533863757" DF="2" EFFECT_SIZE="-2.938665470364466" ESTIMABLE="YES" I2="6.590302847896187" ID="CMP-001.04.01" MODIFIED="2013-01-08 18:37:56 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3428192085582348" P_Z="0.3561756331582444" STUDIES="3" TAU2="2.193744407556246" TOTAL_1="51" TOTAL_2="50" WEIGHT="38.53407506428243" Z="0.9226768712421418">
<NAME>Children only</NAME>
<CONT_DATA CI_END="1.136164775728055" CI_START="-15.336164775728054" EFFECT_SIZE="-7.1" ESTIMABLE="YES" MEAN_1="5.0" MEAN_2="12.1" MODIFIED="2013-01-08 18:37:10 +0000" MODIFIED_BY="[Empty name]" ORDER="59" SD_1="13.34" SD_2="13.21" SE="4.202202102025278" STUDY_ID="STD-Finlay-2001" TOTAL_1="21" TOTAL_2="19" WEIGHT="20.222363014773375"/>
<CONT_DATA CI_END="14.143761117450289" CI_START="-16.74376111745029" EFFECT_SIZE="-1.2999999999999998" ESTIMABLE="YES" MEAN_1="3.2" MEAN_2="4.5" MODIFIED="2013-01-08 18:37:31 +0000" MODIFIED_BY="[Empty name]" ORDER="60" SD_1="15.64" SD_2="15.63" SE="7.879614747652869" STUDY_ID="STD-Harper-1990" TOTAL_1="7" TOTAL_2="9" WEIGHT="5.7514295552049415"/>
<CONT_DATA CI_END="13.15060117577671" CI_START="-7.750601175776708" EFFECT_SIZE="2.700000000000001" ESTIMABLE="YES" MEAN_1="9.8" MEAN_2="7.1" MODIFIED="2013-01-08 18:37:56 +0000" MODIFIED_BY="[Empty name]" ORDER="61" SD_1="17.89" SD_2="17.87" SE="5.332037352833887" STUDY_ID="STD-Kovar-1992" TOTAL_1="23" TOTAL_2="22" WEIGHT="12.560282494304113"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.296858685472424" CI_END="1.3331697065875385" CI_START="-8.11513221665144" DF="4" EFFECT_SIZE="-3.390981255031951" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.02" MODIFIED="2013-01-08 18:40:50 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6813410798249506" P_Z="0.15947002982990816" STUDIES="5" TAU2="0.0" TOTAL_1="104" TOTAL_2="84" WEIGHT="61.46592493571755" Z="1.4068562131288598">
<NAME>Other (adults only or adults and children)</NAME>
<CONT_DATA CI_END="6.07872026444365" CI_START="-24.278720264443653" EFFECT_SIZE="-9.100000000000001" ESTIMABLE="YES" MEAN_1="16.7" MEAN_2="25.8" MODIFIED="2013-01-08 18:38:26 +0000" MODIFIED_BY="[Empty name]" ORDER="62" SD_1="20.84" SD_2="20.84" SE="7.744387337814092" STUDY_ID="STD-France-1988" TOTAL_1="14" TOTAL_2="15" WEIGHT="5.954038535235435"/>
<CONT_DATA CI_END="5.323545657157346" CI_START="-8.923545657157344" EFFECT_SIZE="-1.799999999999999" ESTIMABLE="YES" MEAN_1="10.8" MEAN_2="12.6" MODIFIED="2013-01-08 18:38:46 +0000" MODIFIED_BY="[Empty name]" ORDER="63" SD_1="15.42" SD_2="15.42" SE="3.6345288552988544" STUDY_ID="STD-Fraser-2001" TOTAL_1="36" TOTAL_2="36" WEIGHT="27.032706625307704"/>
<CONT_DATA CI_END="9.784493291280175" CI_START="-10.984493291280174" EFFECT_SIZE="-0.5999999999999999" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="1.4" MODIFIED="2013-01-08 18:39:17 +0000" MODIFIED_BY="[Empty name]" ORDER="64" SD_1="5.01" SD_2="6.79" SE="5.298308220554935" STUDY_ID="STD-Kenicer-2001" TOTAL_1="5" TOTAL_2="2" WEIGHT="12.720709515863623"/>
<CONT_DATA CI_END="2.938918077907797" CI_START="-26.738918077907798" EFFECT_SIZE="-11.9" ESTIMABLE="YES" MEAN_1="10.6" MEAN_2="22.5" MODIFIED="2013-01-08 18:39:42 +0000" MODIFIED_BY="[Empty name]" ORDER="65" SD_1="12.83" SD_2="13.5" SE="7.571015689551078" STUDY_ID="STD-MacLeod-2001" TOTAL_1="14" TOTAL_2="4" WEIGHT="6.229848438960403"/>
<CONT_DATA CI_END="9.498471726494625" CI_START="-14.498471726494625" EFFECT_SIZE="-2.5" ESTIMABLE="YES" MEAN_1="20.0" MEAN_2="22.5" MODIFIED="2013-01-08 18:40:50 +0000" MODIFIED_BY="[Empty name]" ORDER="66" SD_1="23.9" SD_2="23.9" SE="6.1217817373875425" STUDY_ID="STD-Wishart-1992" TOTAL_1="35" TOTAL_2="27" WEIGHT="9.528621820350386"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="8.900984987704124" CI_START="-14.500984987704122" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="-2.8" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.9494380685611916" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2013-03-22 12:12:28 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.6390612565120649" Q="0.0" RANDOM="YES" SCALE="20.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.46901172529313234">
<NAME>Physician assessment at the end of treatment (VAS - MD)</NAME>
<GROUP_LABEL_1>EPO</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours EPO</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_DATA CI_END="8.900984987704124" CI_START="-14.500984987704122" EFFECT_SIZE="-2.8" ESTIMABLE="YES" ESTIMATE="-2.8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-10-27 11:23:44 +0100" MODIFIED_BY="[Empty name]" ORDER="21" SE="5.97" STUDY_ID="STD-Hederos-1996" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0"/>
</IV_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.06" MODIFIED="2013-03-22 12:12:40 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="12" TOTAL_2="13" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Physician-reported improvement in symptoms (VAS 0 to 50)</NAME>
<GROUP_LABEL_1>EPO</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours EPO</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.7939971160385587" CI_START="-1.6539971160385587" EFFECT_SIZE="-0.43000000000000005" ESTIMABLE="YES" MEAN_1="0.25" MEAN_2="0.68" MODIFIED="2011-10-27 11:33:38 +0100" MODIFIED_BY="[Empty name]" ORDER="22" SD_1="1.56" SD_2="1.56" SE="0.6244997998398398" STUDY_ID="STD-Heddle-1990" TOTAL_1="12" TOTAL_2="13" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.07" MODIFIED="2013-03-22 12:14:10 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="16" TOTAL_2="16" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Physician-reported assessment at end of treatment (0 to 3 scale): high-dose</NAME>
<GROUP_LABEL_1>EPO</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EPO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.033356546747122295" CI_START="-1.0866434532528775" EFFECT_SIZE="-0.5599999999999999" ESTIMABLE="YES" MEAN_1="0.61" MEAN_2="1.17" MODIFIED="2012-04-27 16:36:23 +0100" MODIFIED_BY="[Empty name]" ORDER="23" SD_1="0.76" SD_2="0.76" SE="0.26870057685088805" STUDY_ID="STD-Biagi-1994" TOTAL_1="16" TOTAL_2="16" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.08" MODIFIED="2013-03-22 12:14:16 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="16" TOTAL_2="16" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Physician-reported assessment at end of treatment (0 to 3 scale): low-dose</NAME>
<GROUP_LABEL_1>EPO</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EPO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.030680142278984635" CI_START="-1.0506801422789844" EFFECT_SIZE="-0.5099999999999999" ESTIMABLE="YES" MEAN_1="0.66" MEAN_2="1.17" MODIFIED="2013-01-08 08:58:50 +0000" MODIFIED_BY="[Empty name]" ORDER="44" SD_1="0.8" SD_2="0.76" SE="0.2758622844826744" STUDY_ID="STD-Biagi-1994" TOTAL_1="16" TOTAL_2="16" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.09" MODIFIED="2013-03-22 12:13:15 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="25" TOTAL_2="25" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Physician-reported assessment at end of treatment (total disease scores)</NAME>
<GROUP_LABEL_1>EPO</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EPO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-2.620045661202821" CI_START="-4.4199543387971785" EFFECT_SIZE="-3.5199999999999996" ESTIMABLE="YES" MEAN_1="2.24" MEAN_2="5.76" MODIFIED="2011-10-27 12:02:53 +0100" MODIFIED_BY="[Empty name]" ORDER="25" SD_1="1.45" SD_2="1.78" SE="0.45916881427204964" STUDY_ID="STD-Senapati-2008" TOTAL_1="25" TOTAL_2="25" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.10" MODIFIED="2013-03-22 12:13:23 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="30.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="33" TOTAL_2="34" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Physician-reported improvement in Leicester scores</NAME>
<GROUP_LABEL_1>EPO</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours EPO</GRAPH_LABEL_2>
<CONT_DATA CI_END="9.270106368191598" CI_START="-6.610106368191599" EFFECT_SIZE="1.33" ESTIMABLE="YES" MEAN_1="8.48" MEAN_2="7.15" MODIFIED="2012-04-27 16:29:52 +0100" MODIFIED_BY="[Empty name]" ORDER="37" SD_1="16.37" SD_2="16.79" SE="4.051149118464495" STUDY_ID="STD-Berth_x002d_Jones-1993" TOTAL_1="33" TOTAL_2="34" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.11" MODIFIED="2013-03-22 12:13:34 +0000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="20.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="14" TOTAL_2="11" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Physician-reported assessment at end of treatment (VAS 0 to 100)</NAME>
<GROUP_LABEL_1>EPO</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EPO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="16.24292575392434" CI_START="-13.642925753924336" EFFECT_SIZE="1.3000000000000007" ESTIMABLE="YES" MEAN_1="25.3" MEAN_2="24.0" MODIFIED="2011-11-25 06:39:00 +0000" MODIFIED_BY="[Empty name]" ORDER="44" SD_1="17.6" SD_2="19.9" SE="7.624081805478176" STUDY_ID="STD-Schalin_x002d_Karrila-1987" TOTAL_1="14" TOTAL_2="11" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.12" MODIFIED="2013-02-19 12:13:33 +0000" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="19" TOTAL_2="17" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Dermatology Life Quality Index (DLQI) at the end of treatment</NAME>
<GROUP_LABEL_1>EPO</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours EPO</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.417299645224197" CI_START="-1.257299645224197" EFFECT_SIZE="0.08000000000000007" ESTIMABLE="YES" MEAN_1="3.56" MEAN_2="3.48" MODIFIED="2011-10-27 13:32:32 +0100" MODIFIED_BY="[Empty name]" ORDER="25" SD_1="2.07" SD_2="2.02" SE="0.6823082749339507" STUDY_ID="STD-Finlay-2001" TOTAL_1="19" TOTAL_2="17" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="1.9700991881485752" CI_END="1.3279072675526025" CI_START="0.7078971915763304" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9695472269953052" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="37" I2="0.0" I2_Q="0.0" ID="CMP-001.13" LOG_CI_END="0.12316774777569232" LOG_CI_START="-0.15002981063388754" LOG_EFFECT_SIZE="-0.013431031429097653" METHOD="MH" MODIFIED="2013-01-09 08:42:20 +0000" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.5786358957765328" P_Q="1.0" P_Z="0.847183871803067" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="142" TOTAL_2="122" WEIGHT="100.0" Z="0.1927128341080652">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>EPO</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EPO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.497752862895401" CI_START="0.16691672317468262" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.17544015839993335" LOG_CI_START="-0.7775001497278957" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2011-10-27 14:01:43 +0100" MODIFIED_BY="[Empty name]" ORDER="26" O_E="0.0" SE="0.5597618541248889" STUDY_ID="STD-Hederos-1996" TOTAL_1="50" TOTAL_2="30" VAR="0.31333333333333335" WEIGHT="8.219061546078425"/>
<DICH_DATA CI_END="1.8814148260880237" CI_START="0.38401951020141323" EFFECT_SIZE="0.85" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.27448456206738225" LOG_CI_START="-0.4156467106387969" LOG_EFFECT_SIZE="-0.07058107428570728" MODIFIED="2011-10-27 14:02:14 +0100" MODIFIED_BY="[Empty name]" ORDER="27" O_E="0.0" SE="0.4053865257925054" STUDY_ID="STD-Kenicer-2001" TOTAL_1="32" TOTAL_2="34" VAR="0.16433823529411765" WEIGHT="15.670765519025593"/>
<DICH_DATA CI_END="1.556815906698783" CI_START="0.7251379210235831" EFFECT_SIZE="1.0625" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="16" LOG_CI_END="0.19223726033191707" LOG_CI_START="-0.13957938288721877" LOG_EFFECT_SIZE="0.02632893872234915" MODIFIED="2011-10-27 14:04:07 +0100" MODIFIED_BY="[Empty name]" ORDER="28" O_E="0.0" SE="0.19491073874579454" STUDY_ID="STD-Kovar-1992" TOTAL_1="24" TOTAL_2="24" VAR="0.03799019607843137" WEIGHT="67.78869858391394"/>
<DICH_DATA CI_END="3.3719938071403606" CI_START="0.38091542212342466" EFFECT_SIZE="1.1333333333333333" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5278867683467622" LOG_CI_START="-0.41917144370157683" LOG_EFFECT_SIZE="0.054357662322592676" MODIFIED="2011-10-27 14:03:41 +0100" MODIFIED_BY="[Empty name]" ORDER="29" O_E="0.0" SE="0.5563066817709513" STUDY_ID="STD-Wishart-1992" TOTAL_1="36" TOTAL_2="34" VAR="0.30947712418300655" WEIGHT="8.321474350982044"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.8452995485099768" CI_END="1.5722455099289432" CI_START="0.6376969259769674" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0013072098825497" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-001.14" LOG_CI_END="0.19652036312972013" LOG_CI_START="-0.19538567652765487" LOG_EFFECT_SIZE="5.673433010326076E-4" METHOD="MH" MODIFIED="2013-01-09 08:42:16 +0000" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.65530811605441" P_Q="1.0" P_Z="0.9954722775970752" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="90" TOTAL_2="82" WEIGHT="100.00000000000001" Z="0.005674688952822232">
<NAME>Adverse event (minor signs or symptoms)</NAME>
<GROUP_LABEL_1>EPO</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EPO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8290322075312746" CI_START="0.6657062092670409" EFFECT_SIZE="1.103448275862069" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="13" LOG_CI_END="0.26222135305977046" LOG_CI_START="-0.17671739221787075" LOG_EFFECT_SIZE="0.04275198042094988" MODIFIED="2011-10-27 14:11:01 +0100" MODIFIED_BY="[Empty name]" ORDER="30" O_E="0.0" SE="0.25783479175791774" STUDY_ID="STD-Finlay-2001" TOTAL_1="29" TOTAL_2="26" VAR="0.06647877984084881" WEIGHT="79.71794176567236"/>
<DICH_DATA CI_END="3.5438903892126863" CI_START="0.18059249291346818" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.5494802809079438" LOG_CI_START="-0.7433003069240565" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2011-10-27 14:11:39 +0100" MODIFIED_BY="[Empty name]" ORDER="31" O_E="0.0" SE="0.7593857166596344" STUDY_ID="STD-France-1988" TOTAL_1="25" TOTAL_2="20" VAR="0.5766666666666665" WEIGHT="9.189973699431919"/>
<DICH_DATA CI_END="2.3254889474370875" CI_START="0.15480615394743313" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.3665142797415406" LOG_CI_START="-0.8102117789742533" LOG_EFFECT_SIZE="-0.2218487496163564" MODIFIED="2011-10-27 14:12:05 +0100" MODIFIED_BY="[Empty name]" ORDER="32" O_E="0.0" SE="0.6912147117775906" STUDY_ID="STD-Fraser-2001" TOTAL_1="36" TOTAL_2="36" VAR="0.47777777777777775" WEIGHT="11.092084534895735"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.15" MODIFIED="2013-03-22 12:15:02 +0000" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="13" TOTAL_2="11" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Concurrent treatment (emollient cream) (kg)</NAME>
<GROUP_LABEL_1>EPO</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EPO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.3800782112106103" CI_START="-0.42007821121061034" EFFECT_SIZE="-0.020000000000000018" ESTIMABLE="YES" MEAN_1="0.87" MEAN_2="0.89" MODIFIED="2011-10-27 14:43:31 +0100" MODIFIED_BY="[Empty name]" ORDER="33" SD_1="0.54" SD_2="0.46" SE="0.20412528718199732" STUDY_ID="STD-Schalin_x002d_Karrila-1987" TOTAL_1="13" TOTAL_2="11" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.16" MODIFIED="2013-03-22 12:15:23 +0000" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="13" TOTAL_2="11" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Concurrent treatment (topical steroid) (kg)</NAME>
<GROUP_LABEL_1>EPO</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EPO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.020689948808637934" CI_START="-0.2593100511913621" EFFECT_SIZE="-0.14" ESTIMABLE="YES" MEAN_1="0.06" MEAN_2="0.2" MODIFIED="2011-10-27 14:49:57 +0100" MODIFIED_BY="[Empty name]" ORDER="34" SD_1="0.03" SD_2="0.2" SE="0.060873593664202266" STUDY_ID="STD-Schalin_x002d_Karrila-1987" TOTAL_1="13" TOTAL_2="11" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2013-03-22 12:16:47 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Borage oil versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-03-22 12:15:43 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="30.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="7" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>Participant-reported improvement in symptoms</NAME>
<GROUP_LABEL_1>Borage oil</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours borage oil</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="21.923074834317596" CI_START="0.5818117274703614" EFFECT_SIZE="3.5714285714285716" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.3409014663235086" LOG_CI_START="-0.23521752900794693" LOG_EFFECT_SIZE="0.5528419686577808" MODIFIED="2011-10-27 17:12:31 +0100" MODIFIED_BY="[Empty name]" ORDER="35" O_E="0.0" SE="0.9258200997725515" STUDY_ID="STD-Bahmer-1992" TOTAL_1="7" TOTAL_2="5" VAR="0.8571428571428572" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.02" MODIFIED="2013-03-22 12:15:51 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="11" TOTAL_2="11" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Participant-reported complaints at end of treatment</NAME>
<GROUP_LABEL_1>Borage oil</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours borage oil</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.7714629021405452" CI_START="-1.5714629021405442" EFFECT_SIZE="0.10000000000000053" ESTIMABLE="YES" MEAN_1="5.4" MEAN_2="5.3" MODIFIED="2011-10-27 17:20:27 +0100" MODIFIED_BY="[Empty name]" ORDER="36" SD_1="2.0" SD_2="2.0" SE="0.8528028654224418" STUDY_ID="STD-Borrek-1997" TOTAL_1="11" TOTAL_2="11" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.03" MODIFIED="2013-03-22 12:16:01 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="20.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="11" TOTAL_2="11" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Physician-reported Costa scores at end of treatment</NAME>
<GROUP_LABEL_1>Borage oil</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours borage oil</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="11.182774720500042" CI_START="-13.182774720500042" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="37.0" MEAN_2="38.0" MODIFIED="2011-10-27 17:45:14 +0100" MODIFIED_BY="[Empty name]" ORDER="39" SD_1="13.0" SD_2="16.0" SE="6.215815605080611" STUDY_ID="STD-Borrek-1997" TOTAL_1="11" TOTAL_2="11" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="14" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-03-22 12:16:13 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="18" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Physician-reported number showing improvement (ADASI score)</NAME>
<GROUP_LABEL_1>Borage oil</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours borage oil</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.4879171757710297" CI_START="0.9442749486570784" EFFECT_SIZE="1.8148148148148149" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="6" LOG_CI_END="0.5425661636078116" LOG_CI_START="-0.024901531868758934" LOG_EFFECT_SIZE="0.2588323158695264" MODIFIED="2011-10-27 17:51:46 +0100" MODIFIED_BY="[Empty name]" ORDER="40" O_E="0.0" SE="0.3333333333333333" STUDY_ID="STD-Buslau-1996" TOTAL_1="18" TOTAL_2="14" VAR="0.1111111111111111" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.05" MODIFIED="2013-03-22 12:16:31 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="20.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="9" TOTAL_2="9" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Physician-reported severity of eczema at end of treatment (SCORAD Index)</NAME>
<GROUP_LABEL_1>Borage oil</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours borage oil</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="19.4021551124326" CI_START="-10.342155112432597" EFFECT_SIZE="4.530000000000001" ESTIMABLE="YES" MEAN_1="22.46" MEAN_2="17.93" MODIFIED="2011-10-27 18:02:27 +0100" MODIFIED_BY="[Empty name]" ORDER="41" SD_1="17.8" SD_2="14.19" SE="7.5879736718339" STUDY_ID="STD-Don-2003" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.06" MODIFIED="2013-03-22 12:16:24 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="85" TOTAL_2="55" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Physician-reported SASSAD score at end of treatment</NAME>
<GROUP_LABEL_1>Borage oil</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours borage oil</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="9.562481881592552" CI_START="-1.5624818815925519" EFFECT_SIZE="4.0" ESTIMABLE="YES" MEAN_1="27.0" MEAN_2="23.0" MODIFIED="2011-10-27 18:11:32 +0100" MODIFIED_BY="[Empty name]" ORDER="42" SD_1="17.0" SD_2="16.0" SE="2.8380531098880892" STUDY_ID="STD-Takwale-2003" TOTAL_1="85" TOTAL_2="55" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.07" MODIFIED="2013-03-22 12:16:47 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="13" TOTAL_2="15" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Physician-reported clinical score improvement from baseline</NAME>
<GROUP_LABEL_1>Borage oil</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours borage oil</GRAPH_LABEL_2>
<CONT_DATA CI_END="53.5936131807952" CI_START="-8.973613180795212" EFFECT_SIZE="22.309999999999995" ESTIMABLE="YES" MEAN_1="70.85" MEAN_2="48.54" MODIFIED="2011-10-27 18:16:24 +0100" MODIFIED_BY="[Empty name]" ORDER="43" SD_1="47.36" SD_2="35.12" SE="15.961320426067191" STUDY_ID="STD-Valsecchi-2006" TOTAL_1="13" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="29" EVENTS_2="27" I2="0.0" I2_Q="0.0" ID="CMP-002.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-02-19 12:15:22 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="79" TOTAL_2="79" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Borage oil</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours borage oil</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6368153290497685" CI_START="0.7048046875683939" EFFECT_SIZE="1.0740740740740742" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="27" LOG_CI_END="0.21399968362770963" LOG_CI_START="-0.15193121614777197" LOG_EFFECT_SIZE="0.03103423373996882" MODIFIED="2011-10-27 18:31:21 +0100" MODIFIED_BY="[Empty name]" ORDER="44" O_E="0.0" SE="0.21494962191528544" STUDY_ID="STD-Henz-1999" TOTAL_1="79" TOTAL_2="79" VAR="0.04620333996152416" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-002.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-02-19 12:15:33 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="79" TOTAL_2="79" WEIGHT="0.0" Z="0.0">
<NAME>Adverse event (flu-like symptoms)</NAME>
<GROUP_LABEL_1>Borage oil</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours borage oil</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.586179042338402" CI_START="0.47737139657518907" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.4126585879875127" LOG_CI_START="-0.3211436068661624" LOG_EFFECT_SIZE="0.04575749056067514" MODIFIED="2011-10-27 18:36:05 +0100" MODIFIED_BY="[Empty name]" ORDER="45" O_E="0.0" SE="0.43103904163649553" STUDY_ID="STD-Henz-1999" TOTAL_1="79" TOTAL_2="79" VAR="0.18579465541490855" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="22" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-002.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-02-19 12:17:15 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="85" TOTAL_2="55" WEIGHT="0.0" Z="0.0">
<NAME>Adverse event (upper respiratory tract infection)</NAME>
<GROUP_LABEL_1>Borage oil</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours borage oil</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1092064736780403" CI_START="0.41426849267291754" EFFECT_SIZE="0.6778711484593838" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="21" LOG_CI_END="0.04501239559248663" LOG_CI_START="-0.3827180958560104" LOG_EFFECT_SIZE="-0.1688528501317619" MODIFIED="2011-10-27 18:41:02 +0100" MODIFIED_BY="[Empty name]" ORDER="46" O_E="0.0" SE="0.25125100797692723" STUDY_ID="STD-Takwale-2003" TOTAL_1="85" TOTAL_2="55" VAR="0.06312706900942194" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2013-04-02 11:39:48 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2013-04-02 11:39:48 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAADnCAMAAAD4paggAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2013-04-02 11:39:48 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAT0AAAR/CAIAAADmUaYKAAA6L0lEQVR42u3dvW4lxfr+/SUhIQIH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</FILE>
</FIGURE>
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2013-04-02 00:56:41 +0100" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAaYAAAJhCAYAAAAKdBSSAABE9UlEQVR42u2dDYRVW9z/L0mSJJJr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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2013-03-22 12:11:57 +0000" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-001.01" SETTINGS="SHOW_ROB_TABLE:NO;SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 EPO versus placebo, outcome: 1.1 Participant-reported global improvement in symptoms (0 to 100 VAS reduction).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAz4AAAFwCAMAAABO2F7fAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2013-03-22 12:12:07 +0000" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-001.04" SETTINGS="SHOW_ROB_TABLE:NO;SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 EPO versus placebo, outcome: 1.4 Physician-reported global improvement in symptoms (0 to 100 VAS reduction).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAzUAAAGACAMAAACjqrwxAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2013-03-23 17:19:33 +0000" MODIFIED_BY="Joel Bamford">
<APPENDIX ID="APP-01" MODIFIED="2012-08-29 10:06:33 +0100" MODIFIED_BY="Liz Doney" NO="1">
<TITLE MODIFIED="2012-08-28 11:53:08 +0100" MODIFIED_BY="Liz Doney">CENTRAL (Cochrane Library) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-08-29 10:06:33 +0100" MODIFIED_BY="Liz Doney">
<P>#1 (atopic dermatitis) or (atopic eczema)<BR/>#2 (neurodermatitis or (atopic ekzema))<BR/>#3 MeSH descriptor Dermatitis, Atopic explode all trees<BR/>#4 MeSH descriptor Neurodermatitis explode all trees<BR/>#5 MeSH descriptor Eczema explode all trees<BR/>#6 (#1 OR #2 OR #3 OR #4 OR #5)<BR/>#7 MeSH descriptor Borago explode all trees<BR/>#8 MeSH descriptor Oenothera biennis explode all trees<BR/>#9 (evening next primrose)<BR/>#10 (borag* or efamol or epogam or epo)<BR/>#11 (oenothera biennis)<BR/>#12 (#7 OR #8 OR #9 OR #10 OR #11)<BR/>#13 (#6 AND #12)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2012-12-16 12:28:04 +0000" MODIFIED_BY="Liz Doney" NO="2">
<TITLE MODIFIED="2012-08-28 11:53:18 +0100" MODIFIED_BY="Liz Doney">Medline (OVID) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-12-16 12:28:04 +0000" MODIFIED_BY="Liz Doney">
<P>1. randomised controlled trial.pt.<BR/>2. controlled clinical trial.pt.<BR/>3. randomized.ab.<BR/>4. placebo.ab.<BR/>5. clinical trials as topic.sh.<BR/>6. randomly.ab.<BR/>7. trial.ti.<BR/>8. 1 or 2 or 3 or 4 or 5 or 6 or 7<BR/>9. (animals not (human and animals)).sh.<BR/>10. 8 not 9<BR/>11. exp Eczema/ or eczema.mp.<BR/>12. atopic dermatitis.mp. or exp Dermatitis, Atopic/<BR/>13. atopic eczema.mp.<BR/>14. neurodermatitis.mp. or exp Neurodermatitis/<BR/>15. exp Dermatitis/ or dermatitis.mp.<BR/>16. 11 or 12 or 13 or 14 or 15<BR/>17. 10 and 16<BR/>18. borage.mp. or exp Borago/<BR/>19. primrose.mp.<BR/>20. epo.mp.<BR/>21. exp Oenothera biennis/<BR/>22. exp Plant Oils/<BR/>23. epogam.mp.<BR/>24. efamol.mp.<BR/>25. 18 or 19 or 20 or 21 or 22 or 23 or 24<BR/>26. 17 and 25</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2012-08-28 11:55:04 +0100" MODIFIED_BY="Liz Doney" NO="3">
<TITLE MODIFIED="2011-03-02 11:12:53 +0000" MODIFIED_BY="Liz Doney">EMBASE (OVID) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-08-28 11:55:04 +0100" MODIFIED_BY="Liz Doney">
<P>1. random$.mp.<BR/>2. factorial$.mp.<BR/>3. (crossover$ or cross-over$).mp.<BR/>4. placebo$.mp. or PLACEBO/<BR/>5. (doubl$ adj blind$).mp. <BR/>6. (singl$ adj blind$).mp. <BR/>7. (assign$ or allocat$).mp.<BR/>8. volunteer$.mp. or VOLUNTEER/<BR/>9. Crossover Procedure/<BR/>10. Double Blind Procedure/<BR/>11. Randomized Controlled Trial/<BR/>12. Single Blind Procedure/<BR/>13. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12<BR/>14. eczema.mp. or ECZEMA/<BR/>15. atopic dermatitis.mp. or exp atopic dermatitis/<BR/>16. atopic eczema.mp.<BR/>17. neurodermatitis.mp. or exp NEURODERMATITIS/<BR/>18. exp DERMATITIS/ or dermatitis.mp.<BR/>19. borage.mp. or exp Borago/<BR/>20. exp PRIMROSE OIL/ or exp EVENING PRIMROSE/ or primrose.mp.<BR/>21. epo.mp.<BR/>22. efamol.mp.<BR/>23. oenothera biennis.mp<BR/>24. epogam.mp<BR/>25. 14 or 15 or 16 or 17 or 18<BR/>26. 19 or 20 or 21 or 22 or 23 or 24<BR/>27. 13 and 25 and 26</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2012-12-16 12:28:09 +0000" MODIFIED_BY="Liz Doney" NO="4">
<TITLE MODIFIED="2011-03-02 11:13:02 +0000" MODIFIED_BY="Liz Doney">AMED (OVID) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-12-16 12:28:09 +0000" MODIFIED_BY="Liz Doney">
<P>1. randomised controlled trial.pt.<BR/>2. controlled clinical trial.pt.<BR/>3. randomized.ab.<BR/>4. placebo.ab.<BR/>5. clinical trials as topic.sh.<BR/>6. randomly.ab.<BR/>7. trial.ti.<BR/>8. 1 or 2 or 3 or 4 or 5 or 6 or 7<BR/>9. (animals not (human and animals)).sh.<BR/>10. 8 not 9<BR/>11. exp Plant extracts/ or exp Plant oils/ or borage.mp. or exp Plants medicinal/<BR/>12. primrose.mp.<BR/>13. exp Efamol/ or efamol.mp.<BR/>14. epo.mp.<BR/>15. oenothera biennis.mp.<BR/>16. epogam.mp.<BR/>17. 11 or 13 or 14 or 16<BR/>18. exp Eczema/ or eczema.mp.<BR/>19. exp Dermatitis atopic/ or atopic dermatitis.mp.<BR/>20. atopic eczema.mp.<BR/>21. neurodermatitis.mp. or exp Neurodermatitis/<BR/>22. dermatitis.mp. or exp Dermatitis/<BR/>23. 18 or 19 or 20 or 21 or 22<BR/>24. 10 and 17 and 23</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2010-09-29 15:06:48 +0100" MODIFIED_BY="Liz Doney" NO="5">
<TITLE MODIFIED="2010-09-29 15:06:33 +0100" MODIFIED_BY="Liz Doney">LILACS search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2010-09-29 15:06:48 +0100" MODIFIED_BY="Liz Doney">
<P>((Pt RANDOMIZED CONTROLLED TRIAL OR Pt CONTROLLED CLINICAL TRIAL OR Mh RANDOMIZED CONTROLLED TRIALS OR Mh RANDOM ALLOCATION OR Mh DOUBLE-BLIND METHOD OR Mh SINGLE-BLIND METHOD OR Pt MULTICENTER STUDY) OR ((tw ensaio or tw ensayo or tw trial) and (tw azar or tw acaso or tw placebo or tw control$ or tw aleat$ or tw random$ or (tw duplo and tw cego) or (tw doble and tw ciego) or (tw double and tw blind)) and tw clinic$)) AND NOT ((CT ANIMALS OR MH ANIMALS OR CT RABBITS OR CT MICE OR MH RATS OR MH PRIMATES OR MH DOGS OR MH RABBITS OR MH SWINE) AND NOT (CT HUMAN AND CT ANIMALS)) [Palavras] and ((atopic and dermatitis) or (atopic and eczema) or ((atopic and ekzema) or neurodermatitis) or ((atopica or atopia) and eccema)) [Palavras]</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2013-03-23 17:19:33 +0000" MODIFIED_BY="Joel Bamford" NO="6">
<TITLE MODIFIED="2013-03-22 12:28:10 +0000" MODIFIED_BY="Joel Bamford">Abbreviations used</TITLE>
<APPENDIX_BODY MODIFIED="2013-03-23 17:19:33 +0000" MODIFIED_BY="Joel Bamford">
<TABLE COLS="2" ROWS="11">
<TR>
<TD ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Abbreviation</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Full term</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ADRsMHRA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>adverse drug reaction noted by the World Health Organization</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>AEDS</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>atopic eczema/dermatitis syndrome</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>BO</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>borage oil</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CAM</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>complementary and alternative medicine</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>E-BM</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>evidence-based medicine</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EFA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>essential fatty acid</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EPO</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>evening primrose oil</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>GLA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>gamma-linoleic acid</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>MIMS</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Monthly Index of Medical Specialties severity classificaton</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Costa, ADASI, SASSAD, and SCORAD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>these are scales for measuring eczema severity</P>
</TD>
</TR>
</TABLE>
<P/>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_3" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="3">
<FLOWCHARTBOX TEXT="&lt;p&gt;27 contributed to the main outcome evaluation&lt;/p&gt;&lt;p&gt;&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;34 records assessed in full text&lt;/p&gt;" WIDTH="150">
<FLOWCHARTBOX TEXT="&lt;p&gt;176 assessed for eligibility&lt;/p&gt;" WIDTH="200">
<FLOWCHARTBOX TEXT="&lt;p&gt;179 citations were screened (167 from database searches, 11 from unpublished studies, 1 from a trials register)&lt;/p&gt;" WIDTH="220">
<OUT TEXT="&lt;p&gt;3 duplicates removed&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;142 studies excluded based on titles and abstracts&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;7 studies excluded and reasons given for exclusion. &lt;/p&gt;&lt;p&gt;A further study which was an ongoing study was excluded when it was made clear it was not an RCT&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>